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OBJECTIVES 
 
 
 
Serotonin is involved as a neurotransmitter in the pathophysiology of different psychiatric 
disorders such as depression, anxiety and anorexia nervosa. The serotonergic 
neurotransmission in the frontal cortex can be investigated by using the single photon 
emission computed tomography (SPECT) radiopharmaceutical 123I-labelled 4-amino-N-[1-[3-
(4-fluorophenoxy)propyl]-4-methyl-4-piperidinyl]-5-iodo-2-methoxybenzamide ([123I]-5-I-
R91150, figure 1, 2) that binds selectively to the serotonin 5-HT2A receptor in the human 
brain. 
 
P-glycoprotein (Pgp) is an ATP-dependent 170 kDa drug efflux pump, responsible a.o. for 
clearance of toxic compounds from the brain. It was shown previously by other authors that 
the tissue distribution of P-glycoprotein can be a major determinant for the pharmacokinetics 
of different Pgp substrates, especially in the blood-brain barrier. Modulation of P-glycoprotein 
activity with certain compounds (for example cyclosporin A and verapamil) might increase 
the pharmacological effects of Pgp substrates and is therefore potentially of clinical 
importance. 
 
In this thesis, the influence of P-glycoprotein modulation on the pharmacokinetics and brain 
uptake of the 5-HT2A radioligand [123I]-R91150 will be evaluated. We will investigate 
whether [123I]-R91150 is a possible substrate for in vivo P-glycoprotein modulation by 
cyclosporin A in rodents. Also, the influence of Pgp modulation on the brain uptake and 
SPECT imaging with [123I]-R91150 will be studied in rodents. 
 
 
Figure 1: Structure of [123I]-3-I-CO (1) and [123I]-R91150 (2) 
 vi
The second goal of this project was to synthesize a new selective ligand for the serotonin 5-
HT2A receptor, label this molecule with 123I and perform an in vivo evaluation to asses the 
potential of the radioligand for in vivo imaging of the serotonin 5-HT2A receptor with SPECT. 
[123I]-3-I-CO ([123I]-(4-fluorophenyl)[(3-iodophenetyl)piperidin-4-yl] methanone was selected 
as potential radioligand (figure 1, 1). We will also investigate whether the brain uptake of 
[123I]-3-I-CO is influenced by modulation of P-glycoprotein with cyclosporin A. 
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1. INTRODUCTION 
 
1.1. Medical imaging 
 
Medical imaging was initiated in the 19th century with the discovery of X-rays by Roentgen. 
Nowadays, different techniques and modalities are employed to visualize parts of the body or 
specific organs, for example the brain. In this chapter, X-ray/CT-imaging, MRI imaging and 
imaging with PET/SPECT will be discussed briefly. X-ray and CT-imaging provide images of 
the body and internal structures (= anatomical information), whereas PET and SPECT provide 
functional information. MRI provides both anatomical and functional information. 
X-ray imaging was used in human medicine immediately after its discovery because of its 
enormous potential to visualize the human body. X-rays penetrate through most biological 
tissues and are ‘recorded’ on a film, providing a projection image of the human body. 
Penetration and absorption of X-rays depends on the density of the penetrated tissue. 
Computed tomography imaging (CT-imaging) was developed to deal with the fact that normal 
X-ray imaging only provides a projection image, without three-dimensional information. In 
CT-imaging, the X-ray source turns around the patient, along with the X-ray detector. This 
way, X-ray CT-imaging produces thin slices of the whole body, approximately 1 mm thick. 
Modern CT-cameras are equipped with a ring of detectors. Acquisition time is limited to a 
few minutes for total body scans. The different projections are stitched together with software 
to yield a three-dimensional image of the human body. 
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1.1.1. Magnetic Resonance Imaging 
 
Medical magnetic resonance imaging (MRI) is a technique for obtaining high-resolution 
images of various organs within the human body by mapping the distribution of hydrogen 
nuclei in the body. In MRI imaging, the patient is placed in a strong magnetic field generated 
by a superconducting magnet. The principles of NMR (nuclear magnetic resonance) are used 
in MRI. As atomic nuclei with an odd number of protons (for example 1H) spin, they create 
micro-magnetic fields around themselves, causing a small magnetic moment. Atoms with an 
even proton number show no spin. When these atoms are placed in an external magnetic field, 
they will align themselves according to this field. By applying radio waves with a certain 
frequency, the nuclei disalign from the external magnetic field. When the radio wave 
application is halted, the nuclei will realign themselves with the magnetic field (= relaxation), 
while emitting a radio signal which can be detected externally. The relaxation time is also 
measured. The obtained data are then processed in a computer to yield three-dimensional 
images of organs and tissues. 
There are different types of MRI imaging, amongst others diffusion MRI (measuring the 
diffusion pattern of water in biological tissues) and functional MRI (specific signals for 
certain molecules). Originally, nuclear magnetic imaging (NMR) techniques were used to 
elucidate the structure of chemical compounds 
Disadvantages of MRI are inherent to the technique used: high costs, high magnetic fields and 
large space requirements for the equipment[1]. Characteristic is the loud noise of the MRI 
camera equipment. 
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1.1.2. Single Photon Emission Computed Tomography (SPECT) 
 
1.1.2.1. SPECT 
 
SPECT is the most used modality in nuclear medicine imaging. The first SPECT scanner was 
developed in 1957. Gamma-emitting radio-isotopes, coupled to a molecule with known 
pharmacological properties are used in SPECT imaging. The SPECT-tracer is injected, and 
the single photons emitted by the isotope are detected by a gamma-camera. 
The camera consists of a collimator, a scintillation crystal and photomultiplier tubes, with 
associated electronics and computer equipment to perform the necessary manipulations and 
calculations (figure 1.1). 
 
 
Figure 1.1: Operation principle of a SPECT-camera 
 
The use of a collimator ensures that only photons reaching the detector in a ninety degree 
angle are detected. A scintillation crystal is used to convert the high-energy photons into light 
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photons. A sodium iodide crystal, doped with thallium is commonly used as the scintillator in 
SPECT imaging.  
The photons are converted into an electrical signal (photo-electrical effect), which is 
amplified to a detectable level with photomultiplier tubes. The result is a radioactivity 
distribution image of the scanned object.  
The most commonly used isotopes in SPECT imaging are 123I (half-life: 13.2 h, E: 159 keV 
and 99mTc (half-life: 6,07 h, E: 143 keV). These isotopes are not commonly found in nature 
(or in many pharmaceutically active compounds), so incorporating them into biologically 
active molecules without changing the desired characteristics of the drug presents a difficult 
challenge. 
Originally, only planar imaging with gamma cameras was possible. The obtained images are 
projection images, and the organ-of interest can be blocked by other organs lying in front of 
it. More recently, tomographic imaging techniques were developed – comparable to the 
principle of CT-scanning. This technique yields different ‘slices’ from the scanned object 
with a rotating gamma camera. Reconstruction takes place with a computer after the scan, and 
provides a three-dimensional image of the object (= SPECT, or Single Photon Emission 
Computed Tomography). 
A major factor contributing to the relatively low resolution obtained with SPECT are the 
collimators. More recently, two-headed and triple-head rotating cameras have been 
developed, resulting in improved sensitivity and higher spatial resolution. Workable 
resolutions are 3-6 mm, a much lower resolution than those obtained with PET imaging. 
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1.1.2.2. Pinhole SPECT 
 
Human SPECT cameras are not suited for imaging small animals with high resolution, for 
example the brain of a rat, or a whole mouse. High spatial resolution is required for small-
animal imaging. The pinhole collimator is based on the camera obscura principle, where an 
image is magnified through a small hole (figure 1.2). 
 
 
Figure 1.2: HiSPECT high resolution multi-pinhole SPECT imaging system[2] 
 
By using pinhole apertures with a sufficiently small diameter, sub-millimetre spatial 
resolutions can be obtained[3].  
By using multiple pinhole apertures and focussing them on different regions in the field-of-
view (see figure 1.2), it is possible to increase the size of the field-of-view[4], and to image 
larger objects or animals. 
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During reconstruction of the scan, the different regions (one regions per pinhole-aperture) are 
‘stitched’ together with software after recording the scan. Recently, clinically used SPECT 
cameras have been adapted to enable imaging of small animals, such as rats and mice. By 
using pinhole collimators, we were able to ‘magnify’ a small area, resulting in an image with 
higher resolution.  
The system we used is called HiSPECT (Bioscan Inc, Germany)[5]. HiSPECT is a high 
resolution high sensitivity imaging module compatible with all commercial gamma cameras. 
The module consists of upgrading clinical gamma cameras with pyramidal collimators and 
task-based multi-pinhole apertures (figure 1.2). 9 Pinholes were used per camera head.  
The camera used was a triple-headed clinical SPECT camera (Trionix Triad). Pinhole 
diameter was 1.0 mm for rat brain imaging. Resolution capabilities of this system were 
assessed with phantom images, and the smallest resolution attained was 0.8 mm. 
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1.1.3. Positron Emission Tomography (PET) 
 
Positron emission tomography or PET is an important tool in nuclear medicine imaging and 
was developed in the early 1970’s. Positron emission tomography employs radio-isotopes 
coupled to biologically active molecules with known pharmacological and physiological 
properties. The isotopes used in PET are positron-emitting isotopes. Decay of these isotopes 
results in the emission of positrons. When a positron at rest comes into contact with an 
electron, a process called annihilation takes place. Two anti-parallel photons with an energy 
of 511 keV each are emitted in opposite directions (figure 1.3). 
 
 
Figure 1.3: Principle of Positron Emission Tomography 
 
A PET camera consists of a ring of detectors, coupled to photomultiplier tubes. Contrary to 
SPECT, no collimators are used, but imaging with PET is based on coincidence. As two anti-
parallel photons are emitted in opposite directions after annihilation of a proton, they will be 
detected by two detectors at opposite sides of the PET-camera (figure 1.4). This coincidence 
detection of two photons defines a ‘line’ through the scanned object along which the 
annihilation event occurred.  
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Only these coincidence events are detected by the camera, eliminating the need for a 
collimator. As a result the sensitivity of a PET camera is much higher compared to the 
sensitivity of a collimated SPECT camera. 
 
 
Figure 1.4: Structure of a positron emission tomography camera[6] 
 
The isotopes most used for PET imaging include 18F (half-life: 109.8 min), 13N (half-life: 10 
min), 15O (half-life: 2.4 min) and 11C (half-life: 20 min). 
Contrary to SPECT, these isotopes are commonly found in almost all biologically active 
molecules (for example all neurotransmitters and glucose) and they can be incorporated into 
other molecules-of-interest without changing the molecule’s pharmacological or physiological 
properties. 
The scintillation crystals used in PET cameras were originally the same as those used in 
SPECT cameras (sodium iodide crystals doped with thallium). Other materials with better 
properties have become available for use in PET cameras, the most important being BGO 
(bismuth germinate oxide), GSO (germanium oxyorthosilicate) and LSO (lutetium 
oxyorthosilicate). The advantages of these new materials for detection in PET are higher 
density, faster decay times and higher light output.  
The higher sensitivity and resolution (1.5 – 2 mm) of PET compared to SPECT is the most 
obvious advantage of positron emission tomography. Drawbacks include the costs of the 
instrumentation and the requirement of having a cyclotron installed on-site, due to the very 
short half-life of most positron-emitting isotopes. 
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1.2. Tracers/radiopharmaceuticals 
 
The use of radiopharmaceuticals in diagnosis and treatment of different diseases is currently 
on the rise. In this thesis only the diagnostic use of radiopharmaceuticals will be discussed. 
Radiopharmaceuticals can also be used in the treatment of for example certain types of 
cancer. SPECT or PET imaging is performed a certain amount of time after injection (mostly 
intravenously) of the radiopharmaceutical, to allow the tracer to distribute in the body and (for 
brain tracers) reach the brain. When preparing a radiopharmaceutical, a radio-isotope is 
chemically bound to a molecule of interest. In most cases, this molecule has a specific target 
in the body, for example a certain receptor (sub)type. The goal of PET or SPECT imaging is 
to visualize this target in vivo. 
All products administered to humans must meet certain minimum quality requirements. Since 
almost all (brain) tracers are injected intravenously, special measures have to be taken into 
account, as required for any substance-to-be-injected. Specific requirements for intravenous 
injection include sterility, pyrogenicity, isotonicity and pH requirements. Furthermore, 
radiopharmaceuticals have to comply with a set of demands, specific to radiopharmaceuticals. 
Of particular importance are chemical, radiochemical and radionuclidic purity. The tracer 
preparation needs to be chemically pure: no unlabelled impurities should be present; 
radiochemical purity is also important: the only labelled compound present in the preparation 
should be the desired radiopharmaceutical, no labelled impurities or unbound radioisotopes 
should be present. Finally, the tracer preparation needs to have a certain radionuclidic purity: 
only one radionuclide should be present in the preparation, and no contaminations with other 
radionuclides may occur. 
Other demands have to be met before a molecule qualifies as a radiopharmaceutical.  
The molecule must show high affinity towards its target (for example, the 5-HT2A receptor) 
and must be highly selective for the target (for example selectivity for the 5-HT2A receptor 
over the 5-HT2C receptor is important for a 5-HT2A brain tracer, a selectivity of at least 10 is 
desirable). Furthermore, the molecule should be able to reach its target; for a brain tracer, this 
means it needs to be able to cross the blood-brain barrier (BBB). As discussed earlier, for a 
molecule to pass the BBB, it needs certain characteristics, of which the logP is probably one 
of the most important. Too hydrophilic, and a molecule will not be able to pass through the 
BBB. Too lipophilic, and the molecule will show a high degree of aspecific binding in the 
brain, making good quality imaging impossible.  
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The partition coefficient (or logP) is the distribution coefficient between n-octanol and water. 
For radiotracers, it is calculated by dividing the tracer concentration present in the n-octanol 
layer with the tracer concentration present in the aqueous layer. For optimal penetration 
through the blood-brain barrier, a molecule needs to have a logP value between 1.5 and 2.7.  
Since metabolites can interact with the imaging process, it is important that the tracer has an 
adequate metabolisation profile. Aspecific binding to tissue should be as low as possible. 
Incorporation of a suitable radio-isotope should also be straightforward.  
Lastly, specific activity is of critical importance. Specific activity of a radioligand can be 
defined as the ratio of the radioligand concentration to the total ligand concentration 
(radioligand + cold ligand with identical chemical structure). Specific activity is expressed as 
Ci/mol or GBq/mol. A preparation is carrier-free when only radioligand, and no cold 
ligand is present. As a general rule, specific activity needs to be as high as possible. 
 
A lot of tracers currently exist for receptor brain imaging, spanning almost all receptor types 
and subtypes. Selective radioligands are available for the various neurotransmitter systems, 
enabling the visualization of receptor distribution in the normal brain and changes in receptor 
binding during various physiologic activities or resulting from pathologic conditions [7]. 
Studying these receptor systems with PET or SPECT will improve our understanding of 
complex brain functions and will provide more insight into the pathophysiology of neurologic 
and psychiatric diseases. PET and SPECT are techniques that provide methods of high 
sensitivity for measuring in vivo neurochemical and pharmacological effects at specific 
target-receptor proteins. Imaging of the 5-HT2A receptor in vivo can be used to asses receptor 
occupancy, guide dosing, examine cerebral and plasma pharmacokinetics and perhaps predict 
efficacy of a treatment with antipsychotic and mood-altering drugs that interact with targeted 
sites [8]. 
Brain tracers can be divided in two groups (PET tracers and SPECT tracers), depending on 
the isotope used for labelling. The most important clinically used SPECT tracers for brain 
receptor imaging are [123I]--CIT (dopamine transporter tracer), [123I]-R91150 (serotonin 5-
HT2A receptor tracer), [123I]-ADAM (serotonin transporter tracer) and [123I]-iomazenil 
(benzodiazepine receptor tracer) (figure 1.5). 
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Figure 1.5: SPECT brain receptor tracers 
 
The most important clinically used brain tracers for PET are [11C]-Raclopride (selective 
dopamine D2 tracer), [11C]-WAY100635 (serotonin 5-HT1A receptor tracer), [18F]-Altanserin 
(serotonin 5-HT2A receptor tracer), [11C]-MDL100907 (serotonin 5-HT2A receptor tracer), 
[11C]-PK11195 (peripheral benzodiazepine receptor tracer), [11C]-Carfentanyl (opioid  
receptor tracer) and [11C]-Flumazenil (tracer for GABAA and benzodiazepine receptors) 
(figure 1.6). 
 
 
Figure 1.6: Brain receptor tracers for PET 
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1.3. Blood-brain barrier transport 
 
The vertebrate brain and spinal cord, unlike other organs, are separated from the blood pool 
by the blood-brain barrier, which separates the circulating blood from interstitial fluid in the 
brain or spinal cord. The anatomic basis of the blood-brain barrier is situated at the brain 
microvascular endothelial wall, which has epithelial-like, high-resistance tight junctions. 
These tight junctions eliminate pores in the walls of brain capillaries, which are normally 
present in capillaries perfusing peripheral tissues[9].  
The vertebrate brain capillary contains some special anatomic features[10] (figure 1.7): 
  * high resistance, epithelial-like tight junctions 
* minimal endothelial pinocytosis 
* investment of more then 99 % of the brain surface of the endothelium by astrocyte 
foot processes. 
 
 
Figure 1.7: General scheme of anatomic specializations of the brain capillary 
endothelium[11]. 
 
The endothelium and not the astrocyte foot process comprises the permeability barrier. For 
example, the inability of horseradish peroxidase to cross the blood-brain barrier was 
demonstrated by light microscopic histochemistry[9]. 
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For brain imaging studies, the radioligands have to be able to reach the brain. Most 
radioligands are injected intravenously, and are transported through the body to reach the 
brain by penetration of the blood-brain barrier (= influx). Compounds can penetrate the blood-
brain barrier in different ways: an energy-dependent active transport process and transport 
based on passive diffusion. Compounds are cleared from the brain (= efflux) by different 
energy-dependent active transport processes. Some compounds can also be cleared from the 
brain by passive diffusion. 
The different transport mechanisms through the blood-brain barrier are presented in figure 
1.8. 
 
 
Figure 1.8: Blood-brain barrier transport mechanisms. Figure adapted from Tamai et al[12]. 
 
Several mechanisms exist for efflux of drugs out of the brain to the blood: P-glycoprotein, 
carrier-mediated transport and passive diffusion. The most important influx mechanisms are 
transcytosis (absorptive-mediated and receptor-mediated), passive transport and carrier-
mediated transport.  
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1.3.1. Influx into the brain 
 
1.3.1.1. Introduction 
 
Two strategies exist to transport compounds into the brain. The first is a local invasive 
strategy where a compound is injected directly into the brain with a catheter. This method is 
rarely used. The second strategy is the non-invasive (systemic) strategy, where a compound is 
injected intravenously. It needs to penetrate the blood-brain barrier to be able to reach the 
brain. 
 
* Local invasive strategies: Traditional invasive methods of brain drug delivery require access 
to the brain by a neurosurgeon (intracerebroventricular infusion, intracerebral implant). 
Disruption of the blood-brain barrier can also be used: the endothelial tight junctions may be 
transiently disrupted by infusion of 2M mannitol directly in the carotid artery[13], although 
there is evidence for chronic neuropathologic changes when the blood-brain barrier of normal 
brain is disrupted[14]. These effects may be related to the toxic effects of plasma albumin on 
astrocytes[15]. The use of multivesicular liposomes or intranasal pharmaceutical 
administration may hold promises for future drug delivery into the brain. Intranasal drug 
administration allows for direct entry of drugs into the olfactory lobe. 
 
* Non-invasive (systemic) strategies: Traditional non-invasive drug delivery to the brain is 
based on transport through the blood-brain barrier. The delivery of drugs to the brain 
following systemic administration requires that the drug undergoes transport through the 
microvascular endothelial wall of the brain, which comprises the blood-brain barrier in vivo. 
Blood-brain barrier (BBB) transport occurs if the compound has access to endogenous 
transport pathways within the BBB. The systemic administration of drugs that have been 
formulated specially to enable the pharmaceutical to undergo transport through the brain 
capillary endothelium will allow for broad distribution of drugs into the entire brain 
parenchyma, as opposed to the local distribution in the brain that results from the use of 
localized invasive drug delivery. There are about 600 km of brain capillaries in human brain, 
and the surface area of the human brain capillary endothelium is about 12 m2[16, 10]. This 
capillary endothelium is the major barrier preventing uptake of circulating drugs into the 
brain. 
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1.3.1.2.. Active influx mechanisms 
 
There are several nutrient transport systems – intended to supply the brain with adequate 
nutrients - that mediate the influx of circulating nutrients from blood into brain interstitial 
fluid[17]. These transporters can also be portals of entry for drugs[12]. For a drug to be able 
to use these transporter systems, the drug must have a molecular structure mimicking the 
endogenous nutrient. For example, L-DOPA is an active CNS pharmaceutical, because this 
drug undergoes carrier-mediated transport across the blood-brain barrier on the neutral amino 
acid transport system in the brain capillary endothelium[18].  
The GLUT1 isoform of the sodium-independent glucose transporter gene family is present 
within the BBB[19], and it has been suggested that glucuronidation of drugs may be a viable 
strategy for brain drug delivery[20]. Still it is more advantageous that the structure of the drug 
closely resembles that of an endogenous nutrient. 
 
 
1.3.1.3. Passive diffusion 
 
Two properties are of critical importance for a drug molecule to cross the blood-brain barrier: 
lipid solubility and molecular weight. Lipophilicity of a molecule is determined by its logP, or 
partition coefficient. LogPpH7.4 values of 2 - 3 are ideal for adequate drug penetration into the 
brain[21]. A linear relationship exists between blood-brain barrier permeability and lipid 
solubility if the molecular weight of the molecule is under a certain threshold (figure 1.9). 
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Figure 1.9: Blood-brain barrier permeability-surface area (PS) product plotted versus the 1-
octanol/saline partition coefficient for different drugs. 
 
This molecular weight threshold is about 400-600 Dalton[22]. Larger molecules (for example 
antibodies, large proteins) are not able to cross the blood-brain barrier. 
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1.3.2. Efflux out of the brain 
 
Several drugs are actively transported out of the brain. For example, azidothymidine (AZT) 
actively effluxes from brain to blood across the blood-brain barrier[23, 24], and this accounts 
for the marked reduction in AZT penetration into brain parenchyma[25]. Other examples of 
blood-brain barrier efflux of small molecules include baclofen[26] and valproate[27]. Given 
the presence of active efflux systems for drugs at the blood-brain barrier, a new strategy for 
drug delivery to the brain, which emanates from an understanding of brain capillary transport 
biology, is based on the discovery of inhibitors of these active efflux systems. The 
coadministration of the inhibitor with the drug could allow for enhanced central nervous 
system (CNS) penetration of the pharmaceutical into the brain. 
P-glycoprotein (Pgp) functions as an active efflux system at the brain capillary 
endothelium[28]. The concept that microvascular P-glycoprotein functions at the brain 
endothelium and acts as an active efflux system arose from observations that immunoactive 
P-glycoprotein is found in the microvasculature in either brain tissue sections or isolated brain 
capillaries[29, 30]. As shown in the bottom-right part of figure 1.9, some drugs (cyclosporin 
A, anthracyclines and the Vinca alkaloids vincristine and vinblastine) exhibit lower 
accumulation in the brain than would be expected from their lipophilic properties. Drug efflux 
by P-glycoprotein could account for this decreased accumulation. Tumor cells exposed to 
antitumor drugs such as the Vinca alkaloids or anthracyclines, sometimes acquire cross-
resistance to other structurally unrelated compounds[31]. The function and structure of P-
glycoprotein will further be discussed in detail. 
 
 
 
 
 
 
 
 
 
 
 
Introduction                                                                                                                               19 
1.3.3. P-glycoprotein 
 
The ATP-binding cassette (ABC) transporters are a transmembrane family of proteins[32] 
that extrude various molecules across all cell membranes by using ATP hydrolysis energy. 
The transporters efflux compounds from the cytoplasm to the outside of the cell or into an 
intracellular compartment, such as the endoplasmatic reticulum, the mitochondria or the 
peroxisome[33]. In humans, 49 ABC genes, organized into seven subfamilies (A – G), have 
been reported, and many of these genes are involved in human genetic diseases and in 
multidrug resistance (MDR)[34]. The mechanism of MDR is mainly the cell overexpression 
of some ABC transporters localized in cell membrane such as P-glycoprotein (Pgp), breast 
cancer resistance protein (BCRP), multidrug resistance protein 1 – 7 (MRP1-7) and lung 
resistance protein (LRP)[35]. In recent years, many drugs have been evaluated as potential 
efflux pump inhibitors, such as the calcium channel blocker verapamil and the antisteroids 
such as tamoxifen. 
 
This multidrug resistance is frequently characterized by overexpression of a 150 – 180 kDa 
transmembrane glycoprotein, P-glycoprotein, and a concomitant decrease of drug 
accumulation in the resistant cells compared with the drug-sensitive cell line[36, 37]. P-
glycoprotein was thought to function as an ATP-dependent efflux pump that transports 
various drugs out of cells, thereby decreasing their accumulation within cells and 
consequently their efficacy[12]. P-glycoprotein has a very broad substrate specificity and the 
drugs involved in the multidrug resistance phenotype bind specifically to this glycoprotein[38, 
39, 12]. Mammalian P-glycoproteins are encoded by a gene family containing two members 
in humans (MDR1 and MDR3) and three members in mice and Chinese hamsters (mdr1a, 
mdr1b and mdr2)[40, 40, 41]. In rats, mdr1b and mdr2 genes have been cloned[42, 43]. It has 
been shown that MDR1, mdr1a and mdr1b genes confer multidrug resistance, since they have 
drug transport activities, whereas the closely related MDR3 and mdr2 genes do not mediate 
such drug transport. From the viewpoint of multidrug resistance of cancer cells and influence 
on the pharmacokinetics of drugs (or brain tracers), P-glycoprotein encoded by MDR1, mdr1a 
and mdr1b genes is the most important.  
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Table 1.1: Tissue distribution of human and mouse P-glycoprotein-mediated multidrug 
resistance-related genes. 
 
P-glycoprotein is present in the plasma membrane of several normal tissues and tumor 
cells[29, 44]. These tissues include liver, kidney, intestine, adrenal gland, placenta, brain, 
testes and others. Since the expression in secretory organs such as liver and kidney is 
localized to the apical surface, P-glycoprotein could play a role in the excretion of drugs and 
metabolic products, and several studies have confirmed the importance of P-glycoprotein in 
the excretory functions of these tissues[45, 46]. 
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More interesting is the expression in brain and testes, especially on the endothelial cells of 
capillary blood vessels of these tissues, since they are blood-tissue barrier sites which limit 
the entry of many toxic compounds. Accordingly, it is suggested that P-glycoprotein functions 
as a barrier, by excluding toxic compounds from cells. Table 1.1 summarizes the tissue 
distribution of P-glycoprotein encoded by human MDR1 and mouse mdr1a and mdr1b, 
evaluated by RNA analysis[47, 48]. Care is needed in interpreting results obtained in the 
mdr1a gene-knockout mice, because an increase or alteration of some other protein 
functionally related to the mdr1a gene product may compensate for loss of functions of the 
mdr1a gene product, leading to apparent absence of changes in drug pharmacokinetics in the 
knockout animals. 
The transport function of P-glycoprotein at the blood-brain barrier was demonstrated using 
primary cultures of bovine brain capillary endothelial cells[49]. By immunohistochemical 
analysis, P-glycoprotein was found to be localized on the apical (blood-lumen) side 
membrane of a monolayer of primary cultured brain capillary endothelial cells. Such a 
localization at the luminal side was also demonstrated in bovine brain cortical slices. The 
expression of P-glycoprotein at the luminal side of the membrane was also demonstrated in 
mice[50]. Other animal species have also been shown to express P-glycoprotein. It was shown 
that a unidirectional P-glycoprotein-mediated flux occurs to the apical side of the membrane, 
out of the capillary endothelial cells. 
The in vivo significance of P-glycoprotein can be examined by studying the effect of specific 
P-glycoprotein inhibitors on the brain disposition of P-glycoprotein substrates. Wang et al 
showed that [123I]-rhodamine accumulation in the brain increases with co-administration of a 
P-glycoprotein inhibitor, cyclosporin A, by using a brain microdialysis technique to quantify 
[123I]-rhodamine in the brain extracellular fluid[51].  
Identification and classification of pharmaceuticals (or PET and SPECT tracers) as possible 
P-glycoprotein substrates or inhibitors is of crucial importance in the development of new 
CNS drugs or (brain) tracers. Several tracers for PET and SPECT have already been evaluated 
for P-glycoprotein modulation, amongst others [11C]-verapamil, [99mTc]-sestamibi, [131I]-
MIBG and [11C]-WAY100635 (figure 1.10). 
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* [11C](R)-(-)-RWAY: Liow et al[52] investigated how P-glycoprotein and its blocking with 
cyclosporin A (CsA) affected rodent brain uptake of [11C](R)-(-)-RWAY, a radioligand for 
visualization of central serotonin 5-HT1A receptors. Pgp knockout mice had 2.8-fold greater 
brain uptake of [11C]-WAY than wild type ones. Similarly, cyclosporin A increased rat brain 
uptake 5-fold. CsA increased the plasma free fraction of the tracer in rats with a factor 2.7. 
Regional rat brain binding potential (BP) increased 27-70 % in the CsA-treated rats and the 
Pgp knockout mice. It was demonstrated that [11C](R)-(-)-RWAY is a Pgp substrate in 
rodents.  
 
* [131I]-MIBG: It was clarified by Kiyono and others[53] whether [131I]-MIBG is a substrate 
for Pgp or not. Using a human cell line overexpressing P-glycoprotein, the researchers 
determined that [131I]-MIBG is not a substrate for P-glycoprotein. 
 
 
Figure 1.10: Tracers evaluated for potential P-glycoprotein modulation. 
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* [11C]-Verapamil: Lee et al investigated the P-glycoprotein function at the blood-brain 
barrier in vivo in non-human primates using [11C]-verapamil[54] and PET-scanning 
techniques. The inhibition of Pgp by PSC833 increased the brain uptake of [11C]-verapamil 
4.61-fold. Treatment with PSC833 did not affect the blood [11C]-verapamil profile. It was 
concluded that [11C]-verapamil could be a powerful tool for evaluating Pgp function at the 
BBB in a non-invasive manner. Biodistribution studies by Hendrikse et al revealed 9.5-fold 
and 3.4-fold higher [11C]-verapamil concentration in the brain and testes of mdr1a(-/-) mice 
than in mdr1a(+/+) mice[55]. Cyclosporin A (50 mg/kg) increased [11C]-verapamil 
concentrations in brain and testes of mdr1a(+/+) mice with a factor 10.6 and 4.1 respectively. 
[11C]-Verapamil accumulation in the brain of mdr1a(+/+) mice was increased by cyclosporin 
A to levels comparable with those in mdr1a(-/-), indicating that reversal of Pgp mediated 
efflux can be monitored by PET. It was concluded that cyclosporin A could fully block the 
Pgp function in the blood-brain barrier, and that PET enables the in vivo measurement of Pgp 
function and reversal of its function non-invasively[55]. 
 
* [99mTc]-Sestamibi: [99mTc]-Sestamibi[56, 57] (figure 1.10) is widely used in nuclear 
medicine for assessment of myocardial perfusion[58]. It was demonstrated that [99mTc]-
sestamibi is excreted from cells by P-glycoprotein[57]. 
 
* [18F]-MPPF: [18F]-MPPF, a 5-HT1A receptor ligand, showed a five- to ten-fold increase in 
brain uptake in rats after treatment of the animals with cyclosporin A[59].  
 
* Brain uptake of the -adrenergic receptor ligands [11C]-carazolol and [18F]-fluorocarazolol 
was increased in Pgp knockout mice and cyclosporin-treated rats. After cyclosporin A 
modulation, the uptake of [11C]-carazolol increased five- to six-fold. The regional distribution 
of the radioligands in the brain was not affected[59].  
 
Quantitative PET studies in rodents on Pgp functionality demonstrated a dose-dependent 
increase of radioligands after administration of cyclosporin A. Brain uptake studies in rats 
were performed with [11C]-carvedilol using increasing concentrations of cyclosporin A (0, 5, 
10, 15, 30 and 50 mg/kg animal weight) [59]. The results of this study are shown in figure 
1.11. 
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We can conclude from figure 1.11 that maximal modulation of cyclosporin A on the brain 
radioactivity concentration of [11C]-carvedilol in rats was achieved at a cyclosporin A dosage 
of 50 mg/kg rat body weight. 
 
 
Figure 1.11: Influence of increasing concentrations of cyclosporin A on the accumulation of 
[11C]-carvedilol in rat brain. Data adapted from Elsinga et al[59]. 
 
The same dosage of 50 mg/kg cyclosporin A will be administered to the animals in our own 
cyclosporin A studies with [123I]-R91150 and [123I]-3-I-CO. Cyclosporin A will be 
administered through the penile vein in Sprague-Dawley rats, dissolved in a mixture of saline, 
ethanol and polyethoxylated castor oil for reasons of solubility, one hour before injection of 
the tracers. 
The unusually low blood-brain barrier penetration of cyclosporin A has been explained in 
terms of the function of P-glycoprotein. Cyclosporin A is lipid-soluble, and it has a logP of 
3.0. Since cyclosporin A inhibited the binding of the Vinca alkaloids to the P-glycoprotein 
expressed in multidrug-resistant tumor cells[60], it was thought that cyclosporin A is actively 
transported out of the brain. Great potential may lie in possibly enhancing the efficacy, or 
reduce the side effects, of drugs in the CNS by modulating the P-glycoprotein-mediated 
transport function, to increase or decrease the apparent blood-brain barrier permeability to the 
drugs, respectively[12]. 
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A problem of human studies is the lack of potent Pgp modulators that can be administered to 
patients and healthy volunteers. In humans, cyclosporin A cannot be used as a modulator, 
since it acts as an immunosuppressive agent. Side effects that can occur are nephrotoxicity, 
pancreatitis, liver toxicity, tremors and GI-tract dysfunctions. In rodent studies, these 
undesired effects of cyclosporin A were not problematic since cyclosporin A was 
administered just before the study and the animals were sacrificed afterwards under isoflurane 
anaesthesia.  
Data on application of other Pgp modulators in humans are available from studies in cancer 
patients only; their modulatory effect on Pgp in the brain barrier has not yet been reported. 
Ideally, Pgp modulators should lack pharmacokinetic interactions, e.g. via cytochrome P-450 
3A4, and they should be non-toxic themselves.  
Newly developed so-called ‘third-generation’ Pgp modulators such as OC 144-093, GF 
120918, XR 9576 and VX 710 meet these requirements[61, 62, 63].  
XR 9576 was successfully applied in studies of [18F]-paclitaxel in nonhuman primates[64]. 
The increased accumulation of this radiotracer after XR 9576 was consistent with Pgp 
inhibition.  
Ketoconazole, an antifungal agent, is also an inhibitor of Pgp function[65]. Ketoconazole has 
inhibitory potency for not only Pgp but for CYP3A4 also. The inhibitory potency of 
ketoconazole for Pgp was half that of cyclosporin A. Its main advantage is that it can be 
administered orally, and it is less toxic in humans than cyclosporin A. Possible effects of 
ketoconazole on neurotransmitter systems have to be taken into account when using this 
molecule for blocking Pgp activity. 
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2. SEROTONERGIC NEUROTRANSMISSION 
 
2.1. Serotonin 
 
Serotonin was first isolated from blood in 1948, and was called serotonin because of its 
vasoconstrictive properties. The molecule was later identified as 5-hydroxytryptamine (5-
HT). Serotonin is a well-known neurotransmitter, and its presence was demonstrated in 
central nervous system (CNS) and in the periphery of the body. In the CNS, serotonin plays a 
major role in regulating mood, appetite, sleep, anxiety, aggression and sexual functions. In the 
blood serotonin plays a role in the blood clotting process. Smooth muscle cells in the gastro-
intestinal tract are also influenced by serotonin. 
Dysfunctions in the serotonergic neurotransmission system are involved in several 
pathologies of the central nervous system. It has been demonstrated that serotonergic 
neurotransmission malfunctioning is implicated in pathologies such as anorexia nervosa, 
aggression, anxiety, schizophrenia and depression[1]. 
The biosynthesis of serotonin starts from L-tryptophane, an amino acid present in our daily 
diet (figure 2.1). L-Tryptophane is actively transported into the neurons in the brain, where it 
is hydroxylated to 5-hydroxytryptophane. The enzyme responsible for this conversion is 
tryptophane 5-hydroxylase. 5-Hydroxytryptophane is decarboxylated by an amino acid 
decarboxylase to yield serotonin, or 5-hydroxytryptamine (5-HT). 
 
 
Figure 2.1: Biosynthesis of serotonin 
 
Serotonin is stored in vesicles inside the neuron, which are transported into the synaps. After 
activation of the neuron, the vesicles fuse with the cell membrane and serotonin is released in 
the synaptic cleft.  
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Serotonin can be cleared from the synaptic cleft by re-uptake in the presynaptic neuron by a 
serotonin transporter, or it can be metabolised (figure 2.2) and removed from the body. The 
serotonin transporter recycles serotonin present in the synaptic cleft. It is actively pumped 
back into the presynaptic nerve terminal. Certain drugs (for example SSRI’s) inhibit the 
function of the serotonin transporter, hereby increasing the amount of serotonin present in the 
synaptic cleft.  
The most important pathways for metabolism of serotonin are shown in figure 2.2. 
 
 
Figure 2.2: Main routes of serotonin metabolism. 
 
The main enzyme responsible for the metabolism of serotonin is monoamineoxidase A (MAO 
A). Serotonin is transformed by MAO A to 5-hydroxyindol-3-acetaldehyde, which is further 
oxidised to 5-hydroxyindol-3-acetic acid by a aldehyde dehydrogenase enzyme. 5-
Hydroxyindol-3-acetaldehyde can also be reduced to the corresponding alcohol, 3-(2-
hydroxyethyl)-5-hydroxyindol, by a aldehyde reductase enzyme. 
Serotonin can also be acetylated by an acetylase enzyme to N-acetylserotonin. N-
Acetylserotonin can be methylated by an O-methyl transferase enzyme to yield melatonin, a 
hormone playing an important role in the regulation of the circadian rhythms of different 
biological functions. 
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2.2. The serotonergic system 
 
The cell bodies of serotonergic neurons are located in the brain stem (figure 2.3).  
 
 
Figure 2.3: Serotonergic pathways in the brain[2] 
 
There are two different serotonin pathways: the caudal and the rostral serotonergic pathway. 
The caudal pathway consists of serotonergic neurons with cell bodies located in the caudal 
raphe nuclei and caudal pons, and the axons projecting to the spinal cord. The cell bodies of 
serotonergic neurons in the rostral serotonergic pathway are located in the rostral raphe nuclei 
and have axons projecting to the limbic system (hippocampus, amygdala), basal ganglia 
(striatum and pallidum), hypothalamus, thalamus and cerebral cortex (figure 2.3). 
Serotonergic neurons in the hippocampus are known to be involved in the regulation of 
memory, serotonergic neurons in limbic areas such as the amygdala regulate mood. 
The 5-HT neurons in the frontal cortex are responsible for cognition, memory and perception.  
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With the exception of the 5-HT3 receptor, all serotonin receptors belong to the large family of 
G-protein coupled receptors (GPCR). These receptors are characterized by the presence of 
seven transmembrane helices, with the N-terminal located intracellular and the C-terminal 
located outside of the cell. The G-protein contains two functional units: the -subunit  and the 
-subunit. The -subunit has a large affinity for GDP, and shows GTP-ase activity. When 
the -subunit is associated with GDP, the -subunit is bound to the -subunit. The GDP-
-complex is the inactive form of the G-protein. The activation mechanism is shown in 
figure 2.4. 
 
 
Figure 2.4: Mechanism of G-protein coupled receptor activation 
 
Upon activation (by binding of serotonin or other 5-HT agonists to the receptor), the receptor 
conformation changes, resulting in the dissociation of the -subunit from the receptor, GDP 
and the -subunit, and association of the -subunit with GTP. The activated -subunit 
interacts with effector proteins (adenylate cyclase, phospholipase A and C) or ion channels.  
These effector proteins catalyse the production of second messenger molecules (cAMP, 
cGMP, DAG, IP3), which in turn interact with ion channels or catalyse the production of 
mediating enzymes (protein kinase A and protein kinase C).  
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Phosphorylation of other enzymes by these protein kinases results in the biological effect of 
receptor activation. At the end of the cycle, the GTP-ase activity of the -subunit is 
responsible for hydrolysis of the bound GTP to GDP. This hydrolysis results in dissociation 
of the -GDP complex from the effector protein and re-association with the -subunit. 
G-protein coupled receptors generally have two ‘states’: a high affinity state and a low-
affinity state. In the high affinity state, the receptor is coupled to the G-protein; in the low-
affinity state, receptor and G-protein are not associated. Agonists only show affinity for the 
high-affinity state of a receptor, and can only bind to receptors coupled with the G-protein. 
Binding of the agonist results in dissociation of the receptor-G-protein complex, resulting in a 
drastically lowered affinity of the agonist for the receptor. This in turn causes dissociation of 
the agonist from the receptor. The affinity of antagonists for both receptor states is the same. 
The 5-HT3 receptor is not a GPCR, but rather a Na+/K+ ion channel, consisting of 5 individual 
units. Activation of the receptor leads to a rapid depolarisation of the neuron by an influx of 
Na+ and Ca2+ and a K+ efflux. 
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2.3. Serotonin receptors 
 
Two types of serotonin receptors were discovered in 1957: the D- and the M-receptor type. 
The D-type receptor mediates the serotonin-induced contraction of smooth muscle cells. The 
M-type receptor mediates the serotonin-induced release of acetylcholine by the nerve 
terminals[3].  
 
Receptor Location Agonist Antagonist Transduction Sec. Messenger
5-HT1A Hippocampus 8-OH-DPAT WAY100635 Gi/0 cAMP  
 Raphe nuclei     
5-HT1B Striatum CP931259589 SB224289 Gi/0 cAMP  
 Hippocampus     
 Olf. tubercle     
5-HT1D Raphe nuclei L694247 GR127935 Gi/0 cAMP  
 Subst. Nigra     
 Globus pallidus     
5-ht1E Subst. nigra / / Gi/0 cAMP  
 Globus pallidus     
5-ht1F Hippocampus / / Gi/0 cAMP  
 Fr. Cortex     
  Raphe nuclei         
5-HT2A Frontal cortex DOI Ketanserin Gq/ll IP3/DAG  
 Olf. Tubercle     
 Blood platelets     
5-HT2B Periphery BW 723C86 SB204741 Gq/ll IP3/DAG  
5-HT2C Choroid plexus Ro 60-0175 SB 242084 Gq/ll IP3/DAG  
 Subst. Nigra     
  Globus pallidus         
5-HT3 Hippocampus m-CPBG Granisetron   Na+ , K+  
  Trig. Nucleus         
5-HT4 Olf. Tubercle Cisapride GR113808 Gs cAMP  
 Striatum     
 Globus pallidus     
  Subst. Nigra         
5-ht5A Hippocampus / / Gs  ?  
 Hypothalamus     
5-ht5B Hippocampus / / unknown  
5-ht6 Striatum 5-CT / Gs cAMP  
 Hippocampus     
 Olf. Tubercle     
  Frontal cortex         
5-HT7 Hippocampus 5-CT SB258719 Gs cAMP  
  Thalamus         
Table 2.1: Serotonin receptor classification and characteristic properties, adapted[4]. 
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Many different (sub)types of serotonin receptors have been found in the human body. At 
present, the serotonin receptors are divided into seven classes, based on their structural, 
transductional and operational properties[1].  
An overview of all serotonin receptors with their location, transduction and second messenger 
systems and an example of an agonist and antagonist at each receptor is given in table 2.1. 
Receptor type and subtype, receptor structure, signal transduction, second messenger systems 
and localisation in the brain will be discussed in detail. 
Many other neurotransmitter systems are present in the human body (a.o. noradrenalin, 
dopamine, GABA, acetylcholine, etc). Although their function is equally important, a 
discussion of these receptors falls outside the scope of this thesis. Other receptor types will 
not be discussed. 
In 1986 the existence of three 5-HT receptor families, 5-HT1-3 (comprising five 
receptors/binding sites in total), was acknowledged, although more were suspected. At that 
time the function of individual 5-HT receptor subtypes in the brain was largely unclear. The 
application of molecular biological techniques has had a major impact on the 5-HT field, 
allowing the discovery of many additional 5-HT receptors[1].  Since 1986, the number of 
recognised mammalian 5-HT receptor subtypes in the CNS has more than doubled to 14, and 
these have been classified into seven receptor families (5-HT1-7) on the basis of their 
structural, functional and to some extent pharmacological characteristics[5, 6].  
The 5-HT receptor family are mostly seven putative transmembrane spanning, G-protein 
coupled metabotropic receptors, but one member of the family, the 5-HT3 receptor, is a 
ligand-gated ion channel. In the brain the function of many 5-HT receptors can now be 
equivocally associated with specific physiological response, ranging from modulation of 
neuronal activity and transmitter release to behavioural change. 
Much effort has been directed towards understanding the function attributable to individual 5-
HT receptors in the brain. This has been helped by the synthesis of a number of compounds 
that selectively interact with individual 5-HT receptor subtypes – although some 5-HT 
receptors still lack any selective ligands (e.g. 5-HT1E, 5-HT5A and 5-HT5B receptors). 
In this chapter we will briefly discuss the serotonin receptor family, focussing particularly on 
the receptor of interest in this thesis, the serotonin 5-HT2A receptor. 
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2.3.1. The 5-HT1 receptors 
 
The initial characterisation of the 5-HT1 receptor family originated from radioligand binding 
studies which found high affinity binding sites for tritiated serotonin in rat cortex with low 
affinity for spiperone[7]. Subsequent studies identified further heterogeneity within the [3H]-
5-HT site, which initially accounted for the 5-HT1A and 5-HT1B receptors, and subsequently 
the 5-HT1C (now 5-HT2C), 5-HT1D (now recognised as a combination of the species variant of 
the 5-HT1B receptor and the closely related 5-HT1D receptor), 5-HT1E and 5-HT1F 
receptors[1].  
 
 
Table 2.2: Comparison of the percentage amino acid identity between the different human 5-
HT receptor subtypes[1] 
 
 
Table 2.3: Summary of recent important changes in 5-HT receptor nomenclature[1] 
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From table 2.2 it can be concluded that all receptors of the 5-HT1 family have a high degree 
of amino acid sequence homology. All couple negatively to adenylate cyclase via G-proteins. 
Recent changes in 5-HT receptor nomenclature are indicated in table 2.3. 
 
 
2.3.1.1. The 5-HT1A receptor 
 
The first selective 5-HT1A receptor agonist that was discovered was 8-OH-DPAT. The 
synthesis of tritiated [3H]-8-OH-DPAT and its application in in vitro assays provided the first 
pharmacological profile of the 5-HT1A binding site[8]. Buspirone and a series of structurally 
related 5-HT1A ligands had an anxiolytic and antidepressant effect when used in patients[9]. 
The 5-HT1A receptor was the first receptor to be fully sequenced and cloned, and it is perhaps 
the most extensively studied receptor, the main reason being the availability of the selective 
agonist 8-OH-DPAT that has allowed extensive biochemical, physiological and 
pharmacological receptor characterization. The distribution of the 5-HT1A receptor in brain 
has been mapped extensively by receptor autoradiography using a range of ligands including 
[3H]-5-HT, [3H]-8-OH-DPAT, [3H]-ipsapirone and more recently [125I]-p-MPPI and [3H]-
WAY100635. PET studies with [11C]-WAY100635 have also been used to visualize 5-HT1A 
receptors in the living human brain[10]. 
The density of 5-HT1A binding sites is high in limbic brain areas, notably hippocampus, 
lateral septum, cortical areas (particularly cingulate and entorhinal cortex), and also the 
mesencephalic raphe nuclei (both dorsal and median raphe nuclei). In contrast, levels of 5-
HT1A binding sites in the basal ganglia and cerebellum are barely detectable[1]. The 
distribution of mRNA encoding the 5-HT1A receptor is almost identical to that of the 5-HT1A 
binding site[11].  
5-HT1A receptors are located both postsynaptic to 5-HT neurons (in forebrain regions), and 
also on the 5-HT neurons themselves at the level of the soma and dendrites in the 
mesencephalic and medullary raphe nuclei. At the cellular level, the presence of 5-HT1A 
receptors was demonstrated in cortical pyramidal neurons as well as pyramidal and granular 
neurons of the hippocampus[11]. In addition, the 5-HT1A receptor is expressed in serotonin-
containing neurons in the raphe nuclei, cholinergic neurons in the septum and probably 
glutamergic neurons in cortex and hippocampus[12]. A recent detailed study of the 
ultrastructural location of the 5-HT1A receptor reports evidence that the receptor is present 
both at synaptic membranes and extrasynaptically[13]. 
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Selective 5-HT1A receptor agonists include 8-OH-DPAT, dipropyl-5-CT and gepirone. 
Recently a number of ‘silent’ 5-HT1A receptor antagonists have been developed. These 
include WAY 100135, WAY 100635 and NAD-299.  
The 5-HT1A receptor couples negatively via G-proteins (i) to adenylate cyclase in both rat 
and guinea pig hippocampal tissue and cell-lines stably expressing the cloned 5-HT1A 
receptor[14]. Electrophysiological experiments have established that 5-HT1A receptor 
activation causes neuronal hyperpolarisation, an effect mediated through the G-protein 
coupled opening of K+ channels, and without the involvement of diffusible intracellular 
messengers such as cAMP[15]. The 5-HT1A receptor is reported to induce the secretion of a 
growth factor (protein S-100) from primary astrocyte cultures[16] and increase markers of 
growth in neuronal cultures[17]. 
Microdialysis studies have shown that 5-HT1A receptor agonists induce a fall in release of 5-
HT in the forebrain of the rat in vivo, an effect which involves activation of the 5-HT1A 
autoreceptor. Many 5-HT1A receptor agonists cause a fall in 5-HT output, and these effects are 
blocked by selective 5-HT1A receptor antagonists[18]. 
8-OH-DPAT increases the release of acetylcholine in the cortex and hippocampus of guinea 
pigs and rats[19]. This effect is blocked by both selective (WAY100635) and non-selective 
(propanolol) 5-HT1A receptor antagonists[19] and appears to involve postsynaptic 5-HT1A 
receptors[20]. 
 
 
Table 2.4: Functional responses associated with activation of the central 5-HT1A receptor[1] 
 
8-OH-DPAT increases the release of noradrenalin in many brain areas including the 
hypothalamus, hippocampus, frontal cortex and ventral tegmental area[21].  
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This effect is blocked by WAY100635. Other 5-HT1A ligands also increase noradrenalin, 
including buspirone and NAN-190[21]. 
In rats, administration of 8-OH-DPAT and other 5-HT1A receptor agonists causes a wide 
range of behavioural and physiological effects including hyperphagia, hypothermia, altered 
sexual behaviour and a tail flick response. A large amount of basic and clinical data attesting 
to the anxiolytic and antidepressant activity of 5-HT1A receptor agonists can be found in 
literature[22].  
Further functional responses associated with activation of the central 5-HT1A receptor can be 
found in table 2.4 and will not be discussed further.  
 
 
2.3.1.2. The 5-HT1B receptor 
 
The 5-HT1B binding site was found in high levels in rodents (rats, mouse, hamster). The 
nomenclature for serotonin receptor classification was changed recently. This nomenclature 
change recognised that despite differing pharmacology, the human 5-HT1D receptor is a 
species equivalent of the rodent 5-HT1B receptor. Therefore, the 5-HT1D receptor was 
realigned to the 5-HT1B classification[23]. 
Autoradiographic studies using [3H]-5-HT (in the presence of 8-OH-DPAT) demonstrate a 
high density of 5-HT1B sites in the rat basal ganglia (particularly the substantia nigra, globus 
pallidus, ventral pallidum and entopeduncular nucleus), but also many other regions[24]. 
The 5-HT1B receptors are located presynaptically and postsynaptically relative to the 5-HT 
neurons. Overall, the anatomical location of the 5-HT1B receptor provides strong evidence to 
support the idea that the 5-HT1B receptor has a role as both a 5-HT autoreceptor and 5-HT 
heteroreceptor, i.e. controlling neurotransmitter release. 
A large number of ligands with high affinity for the 5-HT1B receptor is available, but most are 
not selective. The most difficult problem at present is discriminating between human 5-HT1B 
and 5-HT1D receptors. 
The 5-HT1B receptor couples negatively to adenylate cyclase[25]. A number of compounds 
(for example ketanserin) demonstrate inverse agonist properties for the 5-HT1B receptor. 
There is convincing evidence that the 5-HT1B receptor functions as a 5-HT autoreceptor: 5-
HT1B agonists inhibit the release of serotonin from the 5-HT nerve terminals. 
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In some brain regions, the 5-HT1B receptor is transported to the nerve terminals and functions 
as a 5-HT heteroreceptor (i.e. a modulatory receptor located on non-5-HT terminals)[26]. 
Clear functional evidence of a heteroreceptor role for the 5-HT1B receptor comes from 
electrophysiological studies[27]. 
 
 
Table 2.5: Functional responses associated with activation of the brain 5-HT1B receptor[1] 
 
There is evidence in mice that activation of the 5-HT1B receptor has a locomotor stimulant 
effect. The locomotor activating effects of for example the illicit drug MDMA may also be 
mediated via activation of the postsynaptic 5-HT1B receptor[28]. Other behavioural and 
physiological effects of activation of the central 5-HT1B receptor are shown in table 2.5 and 
include increased corticosterone and prolactin secretion, hypophagia and hypothermia. For 
example, 5-HT1B knock-out mice are more aggressive towards intruders then the wild-type 
mice. 
 
 
2.3.1.3. The 5-HT1D receptor 
 
The distribution of the 5-HT1D receptor has been difficult to determine because levels appear 
to be very low, and there is a lack of selective radioligands able to discriminate this receptor 
from the 5-HT1B receptor. Receptor autoradiographic studies in rats utilising [125I]-GTI 
suggest that the 5-HT1D site is present in various regions but especially the basal ganglia 
(particularly the globus pallidus, substantia nigra and caudate putamen) and also the 
hippocampus and cortex[26]. A recent study in human brain revealed the presence of 5-HT1D 
receptors in the basal ganglia (globus pallidus and substantia nigra) as well as specific regions 
of the midbrain (periaqueductal grey) and spinal cord[29]. 
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The human 5-HT1D and 5-HT1B receptors have drug binding profiles that are almost 
indistinguishable[14]: many of the ligands with high affinity for the 5-HT1B binding site also 
have high affinity for the 5-HT1D binding site. Ketanserin and ritanserin have some selectivity 
(15 – 30 fold) for the 5-HT1D receptor. 
As of yet no second messenger response can be safely attributed to the 5-HT1D receptor 
expressed in native tissue. 
The 5-HT1D receptor, like the 5-HT1B receptor, is located presynaptically on both 5-HT and 
non-5-HT neurons. There are several reports suggesting that the 5-HT1D receptor may have a 
5-HT autoreceptor role in both the raphe nuclei and serotonergic nerve terminal regions. 
Some studies reported the 5-HT1D autoreceptor to actually be the 5-HT1B receptor instead. 
The presence of a 5-HT1D autoreceptor in brain remains a possibility although such a receptor 
may be restricted to some brain regions and/or be present amongst higher levels of 5-HT1B 
autoreceptors. There is limited functional data regarding a possible heteroreceptor role for the 
5-HT1D receptor that certain anatomical data suggest. As yet no in vivo functional response 
can be safely ascribed to activation of the 5-HT1D receptor in the central nervous system. The 
most important problem is the lack of selective ligands that can discriminate between the 5-
HT1B and the 5-HT1D receptor. Also, the very low levels of 5-HT1D receptors in human brain 
present a problem. 
 
 
2.3.1.4. The 5-HT1E receptor 
 
The human gene encoding for the 5-HT1E receptor was isolated in 1992[30]. 
Autoradiographic studies have revealed that in all species, high levels of 5-HT1E receptors 
were present in the cortex (particularly entorhinal cortex), caudate putamen and claustrum. 
Detectable levels were found in other areas, including hippocampus and amygdala. 
Currently, there are no 5-HT1E receptor selective ligands available[1]. The 5-HT1E receptor is 
characterized by its high affinity for serotonin and lower affinity for 5-CT. A relative low 
affinity for sumatriptan sets it apart from the 5-HT1F binding site. 
Little is known about the physiological role of the 5-HT1E receptor and its effects on neurons, 
although in expression systems the human 5-HT1E receptor has been shown to mediate a 
modest inhibition of adenylate cyclase[31]. 
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2.3.1.5. The 5-HT1F receptor 
 
The structural characteristics of the 5-HT1F receptor are similar to those of other members of 
the 5-HT1 receptor family (e.g. intronless, seven transmembrane spanning regions), and the 
receptor has a high degree of homology with the 5-HT1B, 5-HT1D and 5-HT1E receptors[32]. 
The distribution of 5-CT-insensitive [3H]-sumatriptan binding sites demonstrates a very good 
correlation with the distribution of 5-HT1F mRNA in the guinea pig[26], with the highest 
levels of binding in cortical and hippocampal areas, claustrum and caudate nucleus. Although 
the receptor is located in parts of the basal ganglia, in contrast to 5-HT1B and 5-HT1D binding 
sites, 5-HT1F binding sites appear to be barely detectable in the substantia nigra[33], and 
generally the 5-HT1F receptor has a low abundance with a restricted distribution in the brain. 
The high affinity for sumatriptan discriminates the 5-HT1F receptor from the 5-HT1E receptor. 
Recently, selective agonists for the 5-HT1F receptor have been synthesized[34]. 
The cloned human and mouse 5-HT1F receptors couple negatively to adenylate cyclase[32]. 
On the basis of its anatomical location, it is speculated that the 5-HT1F receptor plays a role in 
visual and cognitive function and as a serotonergic autoreceptor[33]. Initial studies with a 
novel 5-HT1F receptor agonist, LY334370, suggest that it does not evoke overt behavioural 
effects when administered to rats[35, 36]. 
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2.3.2. The 5-HT2 receptor family 
 
The 5-HT2 receptor family currently includes three receptor subtypes (5HT2A, 5-HT2B and 5-
HT2C receptors) which are similar in terms of molecular structure, pharmacology and signal 
transduction pathways. The amino acid sequences of the 5-HT2 receptor family have a high 
degree of homology within the seven transmembrane domains but they are structurally 
distinct from other 5-HT receptors[37]. All genes in the 5-HT2 receptor family have either 
two or three introns in the coding sequence[38], and all are coupled positively to 
phospholipase C and receptor activation results in mobilisation of intracellular calcium. 
Affinities of various ligands for the 5-HT2 receptor family are shown in table 2.6. 
 
 
Table 2.6: Affinity (pKi) of various ligands for the 5-HT2 receptor family[1] 
 
Serotonergic Neurotransmission  50 
Some 5-HT2 antagonists are currently undergoing clinical assessment as potential treatment 
for a range of central nervous system disorders including schizophrenia, anxiety, sleep and 
feeding disorders and migraine[37].  
 
 
2.3.2.1. The 5-HT2A receptor 
 
The central 5-HT2A receptor was initially detected in rat cortical membranes as a binding site 
with high affinity for [3H]-spiperone[39, 7]. The human 5-HT2A receptor is located on 
chromosomes 13q14-q21 and has a relatively high amino acid sequence identity with the 5-
HT2C receptor. The human 5-HT2A receptor is 87% homologous with its rat counterpart. 
Receptor autoradiography studies using [3H]-spiperone or [3H]-ketanserin revealed high 
levels of 5-HT2A binding sites in many forebrain regions, but particularly cortical areas 
(neocortex, entorhinal and pyriform cortex, claustrum), caudate nucleus, nucleus accumbens, 
olfactory tubercle and hippocampus, in all species studied[24]. 
Various studies have investigated the cellular location of the 5-HT2A receptor in the brain. 5-
HT2A mRNA has been found in neurons. In different brain locations, including the cortex, the 
5-HT2A receptor is located on local (GABAergic) interneurons[40]. Recent data also indicate 
the presence of 5-HT2A receptors in cortical pyramidal (projection) neurons[40], which are 
known to be glutamergic. It is reported that 5-HT2A receptor-like immunoreactivity may be 
located in cholinergic neurons in the basal forebrain and specific nuclei in the brain stem[41]. 
A number of selective antagonists are available which greatly aid the delineation of the 5-HT2 
receptors in both in vitro and in vivo models (see table 2.6). MDL100907 is a newly 
developed, potent and selective antagonist of the 5-HT2A receptor which has lower affinity for 
the 5-HT2C receptors or other receptors[42]. 
All three 5-HT2 receptor subtypes couple positively to phospholipase C and lead to an 
increased accumulation of inositol phosphate and intracellular Ca2+[14]. Stimulation of the 5-
HT2A receptor activates phospholipase C in brain tissue via G-protein coupling[43]. The 
hallucinogenic drugs DOI, DOB, DOM and LSD, have partial agonist properties at the 5-
HT2A receptor. All 5-HT2 receptors desensitize following prolonged exposure to serotonin and 
other agonists, although the sensitivity to agonists and mechanisms underlying desensitisation 
of each subtype (particularly 5-HT2A versus 5-HT2C) may be different[44, 45].  
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Of current interest is evidence that stimulation of the 5-HT2A receptor causes activation of a 
biochemical cascade leading to altered expression of a number of genes including that of 
brain-derived neurotrophic factor (BDNF)[46]. These changes may be linked at least in part to 
the increase in expression of BDNF seen following repeated treatment with 
antidepressants[47, 48]. 
5-HT2 receptor activation results in neuronal excitation in a variety of brain regions. Clear 
evidence for a 5-HT2A receptor mediated excitation in the cortex comes from intracellular 
recordings of interneurons in slices of rat pyriform cortex. 5-HT induced neuronal 
depolarisations have also been detected in slice preparations of the nucleus accumbens, 
neocortex, hippocampus, and all have the pharmacological characteristics of 5-HT2A receptor 
activation[1]. The excitatory responses to 5-HT2A receptor activation are associated with a 
reduction of potassium conductances[49]. Activation of the 5-HT2A receptor has an inhibitory 
effect on noradrenergic transmission. There is evidence from microdialysis studies in the 
awake rat that 5-HT2A receptor antagonists increase noradrenalin release[21]. The effects of 5-
HT2 receptor activation on noradrenergic neurons are likely to be indirect, possibly involving 
afferents to the locus coeruleus from the brain stem[49]. 
 
 
Table 2.7: Functional responses associated with activation of the central 5-HT2A receptor[1] 
 
Different behavioural effects of 5-HT2A receptor activation are shown in table 2.7. Head 
twitches (in mice) and wet dog shakes (rats) induced by drugs such as DOI are mediated by 
the 5-HT2A receptor (5-HT2A selective antagonists such as MDL100907 inhibit the head shake 
response while 5-HT2B/2C receptor selective antagonists do not[50]). 
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Activation of the 5-HT2A receptor leads to a discriminative stimulus in rats. For example, 
animals trained to discriminate 5-HT2 receptor agonists such as DOM, recognize its structural 
derivatives (DOI, DOB) but not 5-HT1 receptor agonists. 
An agonist action at 5-HT2 receptors is likely to be involved in the mechanism of action of 
hallucinogenic drugs since there is a close correlation between the human hallucinogenic 
potency of 5-HT2 receptor agonists and their affinity for the 5-HT2 binding sites[51]. 
Currently, there is considerable interest in the role of the 5-HT2A receptor in antipsychotic 
drug action. 
Other responses to 5-HT2 receptor agonists that may be mediated by the 5-HT2A receptor 
include hyperthermia and neuroendocrine responses such as increased secretion of cortisol, 
ACTH, renin and prolactin[52] (see table 2.7). 
 
 
2.3.2.2. The 5-HT2B receptor 
 
The human 5-HT2B receptor (481 amino acids) is relatively homologous with the human 5-
HT2A and 5-HT2C receptors. The distribution of the 5-HT2B receptor in brain is very limited 
(relative to 5-HT2A and 5-HT2C receptors) but potentially of functional importance. Its 
distribution in rat brain is restricted to a few brain regions, particularly cerebellum, lateral 
septum, hypothalamus and amygdala. 
As expected from the homologous sequences of the 5-HT2 receptor family, the receptor 
binding properties of the human 5-HT2B receptor compare well with those of the 5-HT2A and 
5-HT2C receptors. For instance, the 5-HT2B receptor has a low affinity for ritanserin but higher 
affinity for yohimbine than either the 5-HT2A or 5-HT2C receptor. The novel antagonist 
SB204741 is more than 20-60-fold more selective for the 5-HT2B receptor versus the 5-HT2A, 
5-HT2C and other receptors at which it has been tested[53, 37]. The affinity of a variety of 
ligands for the different 5-HT2 receptor subtypes is shown in table 2.6. 
Limited data are available regarding the functional effects of activation of the central 5-HT2B 
receptor. It is thought that the native 5-HT2B receptors in brain couple to phosphatidylinositol 
hydrolysis, a feature it has in common with the other two members of the 5-HT2 receptor 
family. But this still needs to be proven for the 5-HT2B receptor. Also, the 5-HT2B receptor 
may play a role in anxiety[54]. 
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2.3.2.3.The 5-HT2C receptor 
 
The human 5-HT2C receptor is located on chromosome Xq24, and the 5-HT2C receptor gene 
has three introns. There is a high sequence homology with the mouse, rat and human 5-HT2C 
receptors (> 80% in the transmembrane regions)[1]. 
There is little evidence for expression of the 5-HT2C receptor outside of the central nervous 
system. In addition to the very high levels detected in the choroid plexus, 5-HT2C binding 
sites are widely distributed and present in areas of the cortex (olfactory nucleus, pyriform, 
cingulate and retrosplenial), limbic system (nucleus accumbens, hippocampus, amygdala) and 
the basal ganglia (caudate nucleus, substantia nigra). The 5-HT2C receptor is located 
postsynaptically. 
Most 5-HT2 ligands do not discriminate sufficiently between the different 5-HT2 receptor 
subtypes. A number of atypical and typical antipsychotic agents (including clozapine and 
chlorpromazine) have a relative high affinity for 5-HT2C binding sites, as do some 
conventional and atypical antidepressants (e.g. tricyclics, trazodone)[55]. 
Activation of the 5-HT2C receptor increases phospholipase C activity in choroid plexus of 
various species[43] and stably transfected cells via a G-protein coupled mechanism[14]. 5-
HT2C receptors, in common with 5-HT2A receptors, also down-regulate in response to chronic 
exposure to both agonists and antagonists, which could in part relate to apparent inverse 
agonist properties[56].  
Several behavioural responses have been associated with activation of central 5-HT2C 
receptors. These include hypolocomotion, hypophagia, anxiety, penile erections and 
hyperthermia[57]. Behavioural and other physiological responses of activation of the 5-HT2C 
receptor are shown in table 2.8. 
 
 
Table 2.8: Functional responses associated with activation of the central 5-HT2C receptor[1] 
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When administered alone, 5-HT2C receptor antagonists are anxiolytic in various animal 
models[58].  
 
 
2.3.3. The 5-HT3 receptor 
 
Contrary to the other serotonin receptor subtypes, the 5-HT3 receptor is a ligand-gated ion-
channel[59] which is comprised of multiple subunits. The ion channel is cation selective (with 
near equal permeability to both Na+ and K+) and is prone to rapid desensitization. 
Highest levels of 5-HT3 receptor binding sites are found within the dorsal vagal complex in 
the brainstem[60]. This region comprises the nucleus tractus solitarius, area postrema and 
dorsal motor nucleus of the vagus nerve which are intimately involved in the vomiting reflex; 
antagonism of 5-HT3 receptors in these nuclei is likely to contribute to the anti-emetic effect 
of 5-HT3 antagonists. 5-HT3 receptor expression in the forebrain is low. Highest levels are 
expressed in regions such as the hippocampus, amygdala and superficial layers of the cerebral 
cortex.  
Different ligands interact selectively with the 5-HT3 receptor (e.g. antagonists granisetron, 
ondansetron and tropisetron). In addition to the 5-HT binding site, the 5-HT3 receptor 
possesses additional pharmacologically distinct sites which mediate allosteric modulation of 
the receptor complex. For instance, electrophysiological data demonstrate that both ethanol 
and the active metabolite of chloral hydrate, trichloroethanol, increase the potency with which 
agonists activate the 5-HT3 receptor complex[61]. 
Originally, 5-HT3 receptor antagonists generated much optimism in the search for novel 
psychotropic agents. 5-HT3 receptor antagonists were forwarded as potential therapeutic 
agents for a number of CNS disorders including anxiety, cognitive dysfunction and 
psychosis[1]. However, most of the clinical reports do not substantiate the predicted efficacy 
from the preclinical investigations. 
Behavioural, neurochemical and electrophysiological investigations indicate that the 5-HT3 
receptor modulates dopaminergic neuron activity in the brain. 5-HT3 receptor antagonists 
prevent the behavioural hyperactivity following an increase in extracellular dopamine levels 
in the nucleus accumbens, induced by a variety of pharmacological manipulations[62].  
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Neurochemical studies also support a facilitatory role of the 5-HT3 receptor with respect to 
central dopaminergic function. Thus, dopamine release is increased from slices of rat nucleus 
accumbens[63] and striatum[64] following 5-HT3 receptor activation. 
A summary of functional responses associated with activation of the central 5-HT3 receptor is 
shown in table 2.9. 
 
 
Table 2.9: Functional responses associated with activation of the central 5-HT3 receptor[1] 
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2.3.4. The 5-HT4 receptor 
 
The 5-HT4 receptor gene has been mapped to the long arm of human chromosome 5 (5q31-
q33)[65]. The gene appears to be highly fragmented, containing at least five introns.  
A consistent finding across all species investigated so far is the presence of relatively high 
levels of the 5-HT4 receptor in the nigrostriatal and mesolimbic systems of the brain[66]. A 
number of highly selective ligands for the 5-HT4 receptor is available (e.g. GR113808, 
SB204070).  The 5-HT4 receptor couples positively to adenylate cyclase[67]. Phosphorylation 
of native 5-HT4 receptors expressed by both neurons and smooth muscle would appear to be 
largely responsible for the desensitisation of the 5-HT4 receptor[68]. 
There are numerous reports demonstrating the ability of the 5-HT4 receptor to modulate the 
activity of various neurons in the central nervous system. The ability of the 5-HT4 receptor to 
facilitate acetylcholine release in the gastro-intestinal tract is well documented[69]. There is 
increasing evidence that the 5-HT4 receptor also modulates dopamine release in the brain[70]. 
An overview of the functional responses associated with activation of the central 5-HT4 
receptor is shown in table 2.10.  
 
 
Table 2.10: Functional responses associated with the activation of the central 5-HT4 
receptor[1] 
 
Several reports indicate that activation of central 5-HT4 receptors facilitates cognitive 
performance[71]. For instance, the 5-HT4 receptor agonist BIMU1 has been shown to enhance 
the performance of rats in different behavioural models investigating both short-term and 
long-term memory[72]. Given the well-known association of acetylcholine and memory[73], 
the proposed ability of the 5-HT4 receptor to facilitate cholinergic function within relevant 
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regions of the brain (e.g. cerebral cortex, hippocampus) provides a plausible explanation for 
the facilitation of cognitive performance following 5-HT4 receptor activation.  
The 5-HT4 receptor has also been implicated in anxiety. The ability of 5-HT4 receptor 
agonists to increase (and 5-HT4 receptor antagonists to decrease) serotonin release in the 
dorsal hippocampus provides a relevant neurochemical mechanism for 5-HT4 receptor-
mediated modulation of anxiety. 
 
 
2.3.5. 5-HT5 receptors 
 
The genomic structure of 5-HT5A and 5-HT5B genes was deduced by screening a mouse 
genomic library with probes corresponding to the mouse 5-HT5A and 5-HT5B receptor cDNAs. 
Both genes contain an intron at an identical position corresponding to the middle of the third 
cytoplasmatic loop[74]. The 5-HT5A gene was located on mouse chromosome 5 (position 5B) 
and human chromosome 7 (position 7q36). The 5-HT5B gene is located on mouse 
chromosome 1 (position 1F) and human chromosome 2 (position 2q11-13). 
Both the 5-HT5A and 5-HT5B receptors are members of the seven putative transmembrane 
domain-G-protein coupled superfamily. 
 
* 5-HT5A receptor:   
In situ hybridisation studies revealed the presence of 5-HT5A receptor mRNA in both mouse 
and rat brain. In mouse brain, 5-HT5A receptor transcripts are associated with neurons within 
the cerebral cortex, the dentate gyrus and the pyramidal cell layer within the 
hippocampus[75]. Use of PCR detected 5-HT5A mRNA in mouse and human forebrain and 
cerebellum. Little information has been published concerning the effects of knocking out the 
5-HT5A receptor, although mice lacking the receptor display increased locomotor activity and 
exploratory behaviour relative to wild-type animals[76]. 
 
* 5-HT5B receptor:  
In situ hybridisation studies demonstrated a low specific signal in the supraoptic nucleus of 
the hypothalamus and some other rat brain regions (hippocampus, olfactory bulb, entorhinal 
cortex and pyriform cortex)[77]. 
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2.3.6. The 5-HT6 receptor 
 
The 5-HT6 receptor has seven hydrophobic regions spanning the cell membrane, which places 
the receptor in the G-protein-coupled, seven putative transmembrane domain receptor 
superfamily[78]. The receptor is prone to agonist-induced desensitisation which appears to be 
due principally to receptor phosphorylation catalysed by a cAMP-dependent protein 
kinase[79]. Genomic mapping identified the human 5-HT6 receptor gene in the p35-36 
portion of human chromosome 1[1]. A number of reports have demonstrated the differential 
distribution of 5-HT6 receptor mRNA. The transcripts appear to be largely confined to the 
central nervous system, although low levels have been detected in the stomach and adrenal 
glands[80]. Within the brain, high levels of 5-HT6 receptor mRNA are consistently detected 
within the striatum (caudate nucleus) of the rat, guinea pig and humans[80]. Relatively high 
levels are also detected in the olfactory tubercles, nucleus accumbens and hippocampus[78]. 
The level of expression of the 5-HT6 receptor in the brain is generally low, making detailed 
investigation of the central localisation of the receptor difficult. It was speculated that 5-HT6 
receptors are located postsynaptically on the dendrites of excitatory pyramidal and granule 
cell neurons in the hippocampus[81]. 
Several antipsychotic and antidepressant drugs show interaction with the 5-HT6 receptor. 
Recently, different compounds have been identified as selective 5-HT6 receptor antagonists 
(e.g. Ro 04-6790 and Ro 63-0563[82]). 
Consistent with its structure (i.e. seven transmembrane domains) , the 5-HT6 receptor couples 
positively to a metabotropic transduction system which enhances adenylate cyclase 
activity[14]. Administration of the 5-HT6 receptor selective agent Ro 04-6790 resulted in a 
higher incidence of yawning and stretching in rats[82]. The increase in the numbers of yawns 
and stretches was dose-related. An interaction between the 5-HT6 receptor and the central 
acetylcholine system was also demonstrated[82]. 
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2.3.7. The 5-HT7 receptor 
 
The 5-HT7 receptor gene is located on human chromosome 10 (10q21-q24[83]) and contains 
two introns. The amino acid sequence of the 5-HT7 receptor displays the characteristic seven 
putative membrane spanning regions[84] of the G-protein coupled receptor superfamily.  
The 5-HT7 receptor exhibits a distinct distribution in the central nervous system. In rat and 
guinea pig brain, both the mRNA and receptor binding sites display a similar distribution 
indicating that the receptor is expressed close to the site of synthesis[85]. 5-HT7 receptor 
expression is relatively high within regions of the thalamus, hypothalamus and hippocampus, 
with generally lower levels in areas such as the cerebral cortex and amygdala[85]. 
The ability of a range of clinically utilised psychoactive agents to interact with the 5-HT7 
receptor at relevant concentrations (typical and atypical antipsychotics and antidepressants 
including clozapine[85]), similar to the 5-HT6 receptor, suggests that this receptor may be 
important as a target in psychiatric conditions, although genetic variation within the 5-HT7 
receptor gene does not appear to be associated with either schizophrenia or bipolar affective 
disorder[86].  
Activation of the 5-HT7 receptor stimulates adenylate cyclase[84]. Consistent with other 
members of the G-protein coupled receptor superfamily, amino acid residues within the third 
intracellular loop of the 5-HT7 receptor are likely to be involved in the coupling to GS[87]. 
A summary of functional responses associated with activation of the central 5-HT7 receptor is 
shown in table 2.11. 
 
 
Table 2.11: Functional responses associated with activation of the central 5-HT7 receptor[1] 
 
A number of reports implicate a role for the 5-HT7 receptor in the regulation of circadian 
rhythms. 5-HT7 antagonists might have the ability to prevent audiogenic seizures in mice[88]. 
Whilst highly speculative, these studies might indicate a role for 5-HT7 receptor antagonists in 
the treatment of epilepsy. 
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2.3.8. Summary 
 
A striking feature of the 5-HT receptor subtypes is that each has a highly distinct pattern of 
distribution in the central nervous system, such that individual brain regions contain their own 
complement of 5-HT receptor subtypes. All of the receptors are located postsynaptically 
where some are known to modulate ion flux and cause neuronal depolarisation (5-HT2A, 5-
HT2C, 5-HT3 and 5-HT4 receptors) or hyperpolarisation (5-HT1A receptor). Certain 5-HT 
receptor subtypes (5-HT1A, 5-HT1B and possibly 5-HT1D) are located on the 5-HT neurons 
themselves where they serve as 5-HT autoreceptors at the somatodendritic or nerve terminal 
level. Some 5-HT receptors (5-HT1B,D, 5-HT2A,C, 5-HT3 and 5-HT4 receptors) are also located 
on the nerve terminals of non-5-HT neurons where they appear to function as heteroreceptors, 
regulating neurotransmitter release. 
Activation of specific serotonin receptor subtypes can be linked with the modulation of 
specific behaviours. The 5-HT1A, 5-HT2A and 5-HT2C receptors currently stand out in terms of 
the wide range of behaviours and physiological responses that agonists for these receptors can 
evoke. Selective antagonists have established a key role for the 5-HT2C receptor in feeding 
and anxiety (along with the 5-HT3 and 5-HT4 receptor[1]). The clinical utility of certain 5-HT 
receptor selective ligands has been established in various neuropsychiatric disorders including 
major depression and anxiety (buspirone) and migraine (sumatriptan). Several clinical trials 
are ongoing, investigating the therapeutic usefulness of selective serotonin receptor ligands, 
including 5-HT1A (auto)receptor antagonists (depression), 5-HT2A antagonists (schizophrenia) 
and 5-HT2C antagonists (anxiety). 
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3. INFLUENCE OF CYCLOSPORIN A 
ADMINISTRATION ON THE BRAIN UPTAKE 
OF [123I]-R91150 IN RODENTS 
 
 
While initially evaluating the potential of [123I]-R91150 to visualize the 5-HT2A receptor in 
vivo with pinhole SPECT, image quality was rather poor. In our search to increase the brain 
uptake of [123I]-R91150 in rodents to enable good quality pinhole SPECT images, we 
discovered that the pre-administration of cyclosporin A had a dramatic effect on the levels of 
[123I]-R91150 radioactivity in rodent brain. Brain radioactivity concentrations increased 5 - 6 
fold. This led us to further characterize the influence of cyclosporin A on the brain uptake of 
[123I]-R91150.  
Regional brain biodistribution studies and ketanserin displacement studies with and without 
cyclosporin A pre-treatment will be performed in rodents. The effect of increasing dosages of 
cyclosporin A on the brain uptake of [123I]-R91150 will be studied in NMRI mice. The 
influence of cyclosporin A administration on pinhole SPECT imaging will also be discussed. 
To exclude the effect of potential increased tracer metabolism under the influence of 
cyclosporin A, metabolite assays with [123I]-R91150 will also be performed. 
The obtained results will be used as a ‘standard’ to compare with the results from the 
biodistribution studies with a potential, in-house developed 5-HT2A tracer, [123I]-3-I-CO 
(chapter 4). 
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3.1 Introduction 
 
The first proposed SPECT tracer for the serotonin 5-HT2A receptor was 2-
radioiodoketanserin, developed at the end of the 1980’s[1]. This compound was used 
clinically for SPECT imaging of 5-HT2A receptors in depressed patients. The iodinated 
compound showed properties almost comparable to those of ketanserin (poor selectivity for 5-
HT2 versus H1 and 1-receptors) and high binding to serum proteins resulting in rather poor 
brain to blood ratios[2]. 
Later on R91150 was discovered and developed by the Janssen Research Foundation (Beerse, 
Belgium). R91150 or N-[(3-p-fluorophenyl-1-propyl)-4-methyl-4-piperidinyl]-4-amino-2-
methoxybenzamide (structure shown in figure 3.1) is the precursor molecule for the 
radiosynthesis of the 5’ iodo-derivative, named R93274. For reasons of simplicity and 
corresponding to the literature, we will further refer to the precursor as R91150 and to the 
[123I]-5’-iodo-derivative as [123I]-R91150. In view of a potential increased brain uptake due to 
an increase in lipophilicity, researchers at the Janssen Research Foundation also developed a 
derivative, mono-methylated on the 4-amino-function of the benzamide chain. N-methylation 
did not significantly increase the specific brain uptake, so it was decided to use the 5’-
radioiodinated derivative [123I]-R91150 in further research. 
 
 
Figure 3.1: Chemical structure of R91150 and [123I]-R91150 
 
R93274 (5-I-R91150 or N-[(3-p-fluorophenyl-1-propyl)-4-methyl-4-piperidinyl]-4-amino-5-
iodo-2-methoxybenzamide) is a selective iodinated 5-HT2A antagonist with high affinity (Kd = 
0.11 ± 0.1 nM) and selectivity for 5-HT2A receptors.  
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The selectivity of [123I]-R91150 for 5-HT2A receptors with regard to other neurotransmitter 
systems such as other 5-HT receptors (including 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2C, 5-HT3), 
dopamine receptors, 1 and 2 adrenergic receptors and histamine receptors is at least a factor 
of 50[2, 3, 4]. IC50 values for the different neurotransmitter systems are indicated in table 3.1. 
 
  5-HT2A1 5-HT2C2 5-HT1A dopamine D2 1-adrenergic
IC50 (nM) 0,79 21 316 45 30 
1 IC50 for inhibition of [3H]-ketanserin binding to rat frontal cortex membranes, Ki = 0.38 nM 
2 IC50 for inhibition of [3H]-mesulergine binding to pig choroid plexus, Ki = 14.5 nM 
Table 3.1: Selectivity of [123I]-R91150 for different neurotransmitter systems 
 
In vitro binding studies with [123I]-R91150 to membrane preparations of rat frontal cortex 
revealed saturable binding (Kd = 0.11 ± 0.01 nM, Bmax = 38.0 ± 0.7 fmoles/mg) and 
displacement of radioactivity by ketanserin and ritanserin. In vivo uptake of [123I]-R91150 has 
been studied in rodents[2, 4]. In the in vivo studies, radioactivity concentrated in the cortical 
regions, with frontal to cerebellar ratios of 10 at 3h post injection. Frontal cortex to blood 
ratios of 6 were obtained. Radioactivity concentration values were dramatically reduced by 
either pre-treatment with the 5-HT2A-selective antagonist ritanserin or displacement by 
ketanserin[2].  
Brain radioactivity uptake of [123I]-R91150 was also characterized in baboons[3]. The 
radioligand crossed the blood-brain barrier and concentrated in 5-HT2A receptor rich regions 
where it displayed specific, selective and reversible binding. However, brain uptake and target 
to background ratios were lower in baboons than in rodents, and [123I]-R91150 was 
metabolized much more rapidly in baboons than in rats (at 3 h post injection, the parent 
compound radioactivity represented 95% of the plasma radioactivity in the rat, as opposed to 
25% in baboons). The brain uptake of [123I]-R91150 seems to be species-dependent[3].  
Also, high radioactivity uptake was observed at the level of the eyes and orbital perioccular 
region (3.4 ± 0.4 % ID/g). Because of the proximity of the eye-area to the frontal cortex, 
frontal region-of-interest (ROI) radioactivity measurements could be contaminated by 
radioactivity originating from the eyes. In future experiments we will have to take this effect 
into account. The injection of ketanserin reduced the uptake in 5-HT2A receptor-rich regions 
to the levels observed in cerebellum. The cerebellar radioactivity was not affected by 
ketanserin administration, which confirmed the nonspecific nature of the uptake, as expected 
from the reported absence of 5-HT2A receptors in the cerebellum[5]. 
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[123I]-R91150 was evaluated in normal healthy dogs[6, 7, 8, 9]; influence of age and gender 
on the binding index of [123I]-R91150 in canine brain was demonstrated. The tracer was also 
used in impulsive-aggressive dogs[10, 11, 12], and the effect of administering citalopram on 
the biodistribution of [123I]-R91150 in impulsive-aggressive dogs was also investigated[13]. 
A number of clinical studies have already been performed with [123I]-R91150 in healthy 
human volunteers[14, 15, 16, 17]. Maximal brain uptake was approximately 2% of total body 
counts at 180 min post injection[15] of [123I]-R91150. Radioligand binding in the frontal 
cortex increased steadily over time, reaching a peak at approximately 100-120 min post 
injection. Frontal cortex-cerebellum activity ratios reached values of 1.4, and remained stable 
from approximately 100 min post injection onwards.  
Age and gender had a significant effect on the 5-HT2A binding index in healthy human 
subjects[14, 18]. [123I]-R91150 was also used to help elucidate the mechanism of action of 
MDMA[19]. 
Several clinical studies have also been performed in psychiatric patients. Psychiatric 
indications were a.o. anorexia nervosa[20], deliberate self-harm[21], schizophrenia[22], 
bulimia nervosa[23] and depression[24, 25]. [123I]-R91150 was also used to monitor the effect 
of different antidepressant drugs on 5-HT2A binding index in human brain[26]. 
To demonstrate specificity of binding to the 5-HT2A receptor, specific 5-HT2A antagonists are 
used, such as ketanserin and ritanserin. We will use ketanserin tartrate and ritanserin for the in 
vivo displacement and blocking studies in this thesis (figure 3.2). 
 
 
Figure 3.2: Structure of ketanserin and ritanserin 
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Ketanserin[27] (used as the tartrate salt, Tocris Cookson Inc, UK, figure 3.2 and table 3.2) is a 
selective 5-HT2A serotonin receptor antagonist. It is also used to discriminate between 5-HT1D 
and 5-HT1B receptor subtypes. The correct amount of product was weighed and dissolved in 
warm 0.9% NaCl after sonication to a concentration of 5 mg/ml. A dosage of 1 mg per kg of 
bodyweight was used for in vivo displacement studies. 
Ritanserin[28, 29] (Tocris Cookson Inc, UK, figure 3.2 and table 3.2) is a potent and long-
acting 5-HT2A receptor antagonist with in vivo anxiolytic properties. It was dissolved in 10% 
ethanol after sonication, and the dosage used was 2.5 mg per kg of bodyweight. 
Receptor binding profiles of ketanserin and ritanserin for the different neurotransmitter 
systems were determined[30] at Janssen Research Foundation and are indicated in table 3.2. 
 
  5-HT2A histamine-H1 dopamine-D2 1-adrenergic 2-adrenergic 5-HT1 
Ketanserin 1,7 ± 0,5 16 ± 5 620 ± 50 31 ± 2 > 1000 > 1000 
Ritanserin 0,9 ± 0,1 35 ± 5 70 ± 30 97 ± 13 150 ± 25 > 1000 
IC50 values are expressed as mean ± standard error in nanomolar (nM). Data adapted from Leysen et al[30]. 
Table 3.2: Receptor binding profiles of ketanserin and ritanserin 
 
It is well established that the pharmacological properties of some serotonin receptors diverge 
widely across animal species[31]. For example, significant differences were observed when 
comparing the regional brain biodistribution of [123I]-R91150 in different species. 
In vivo studies in rats with [123I]-R91150 showed preferential retention of radioactivity in the 
frontal cortex. Frontal cortex-to-cerebellum ratios increased from about 3 at 30 min post 
injection to a steady value of about 10 from 1h to 3h after radioligand injection. Displacement 
experiments with ketanserin demonstrated a reduction in frontal cortex radioactivity of about 
40%[2]. Nevertheless, activity in frontal cortex after ketanserin displacement was still three 
times higher than the radioactivity levels observed in cerebellum. On the other hand, a 
blocking experiment with ritanserin demonstrated a decrease of frontal cortex activity to the 
level of radioactivity observed in cerebellum. 
Brain uptake of [123I]-R91150 was also characterized in baboons[3]. Highest brain uptake was 
observed in cortical areas, lowest uptake was observed in cerebellum and striatum. Injection 
of pharmacological doses of a 5-HT2A antagonist (ketanserin) resulted in reduction of cortical 
and striatal radioactivity concentrations to the levels observed in cerebellum. However, brain 
uptake and target-to-background ratios were lower in baboons than in rats[4]: ratios of 
cortical tissues to cerebellum were about 1.5 at 150 min after injection of [123I]-R91150.  
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The density of 5-HT2A receptors is about three times higher in the rat cortex compared to 
primate cortex[27]. For [123I]-R91150, a higher nonspecific binding in baboon brain also 
contributed to the lower cortical to cerebellar ratio observed in baboons (1.5) compared to rats 
(10)[3]. 
We will investigate whether modulation of the drug efflux pumps in the blood-brain barrier 
will have an effect  on the pharmacokinetic behaviour of [123I]-R91150 in rodents. It has 
already been demonstrated by several authors[32, 33, 34, 35, 36] that tracer brain uptake is 
increased when P-glycoprotein efflux pumps are modulated by previous injections of 
cyclosporin A. It has been demonstrated that cyclosporin A is a potent modulator of P-
glycoprotein[36, 37], and a dose-dependent inhibition of P-glycoprotein function by 
cyclosporin A has also been observed[32]. 
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3.2. Radiosynthesis and purification of [123I]-R91150 
 
3.2.1. Introduction 
 
[123I]-R91150 was synthesized according to a modification of the original method [4]. Radio-
iodination was performed by electrophilic substitution on the precursor R91150 (4-amino-N-
[1-[3-(4-fluorophenoxy)-propyl]-4-methyl-4-piperidinyl]-2-methoxybenzamide). The 5-
position of the methoxybenzamide group was iodinated. The precursor, R91150, was kindly 
donated by the Janssen Research Foundation (J&J, Beerse, Belgium). Samples of the 
precursor and the cold standard N-[(3-p-fluorophenyl-1-propyl)-4-methyl-4-piperidinyl]-4-
amino-5-iodo-2-methoxy-benzamide were obtained from Janssen Pharmaceutica (Beerse, 
Belgium). 
The reaction mechanism of the radiosynthesis is shown in figure 3.3. 
 
 
Figure 3.3: [123I]-R91150 radiosynthesis: iodination reaction mechanism 
 
The reaction mechanism of the radiosynthesis is an electrophilic substitution reaction.  
The electrophilic species is the iodonium ion, I+. The iodonium ion I+ is formed in situ from 
the oxidation of radioiodide, I-, under influence of 30 % hydrogen peroxide present in the 
reaction environment. The solvent used is glacial acetic acid, which provides the acidic 
environment necessary for the radiosynthesis reaction. At the end of the reaction, the excess 
H2O2 is neutralised by reduction with sodium sulphite. The used quenching solution is 
strongly basic (sodium sulphite in 3M NaOH solution) to neutralise the acid radiosynthesis 
mixture (containing glacial acetic acid). This is necessary prior to purification to avoid 
damage to the HPLC columns. 
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3.2.2. Radiosynthesis and purification of [123I]-R91150 
 
3.2.2.1. Radiosynthesis of [123I]-R91150 
 
0.5-1 mg of precursor was dissolved in 350 L glacial acetic acid in a V-vial, and no carrier 
added [123I]-solution (NaI in 0.05M NaOH, Amersham) was added. Cold sodium iodide was 
added as carrier (0.1 nmol cold NaI per 37 MBq of 123I) to adjust the specific activity of the 
final tracer solution to 10 Ci/mol. At 0, 10, 20 and 25 min, 35 L of a H2O2-solution (30%, 
Sigma-Aldrich Belgium) was added to the vial. At 30 min the reaction was quenched by 
addition of 1 ml of sodium sulphite solution (126 mg/ml in 3M NaOH-solution). The 
radiosynthesis mixture was transferred to the HPLC system for purification. 
 
 
3.2.2.2. Purification of [123I]-R91150 
 
Since the synthesis of [123I]-R91150 was performed on a routine basis with high activities, a 
special purification-setup was constructed, allowing for a nearly hands-off semi-automatic 
purification of the radiotracer. This also provided a simple radioprotection solution during 
synthesis of the radiotracer.  
The setup for purification of [123I]-R91150 with HPLC (high performance liquid 
chromatography) is pictured in figure 3.4. 
The routine synthesis setup is constructed with 3 valves: one 6-way HPLC valve (left on 
figure 3.4, Hamilton), one small 3-way rotary valve (Hamilton), and finally one HPLC 
injection valve (most right in figure 3.4, Valco HPLC injection valve). The valves are 
connected with HPLC tubing as indicated in figure 3.4. The system further consists of two 
peristaltic pumps (PP1 and PP2 on figure 3.4, Gilson Mini-Pulse 3, flow rate of respectively 5 
ml/min and 1 ml/min), a HPLC pump (Waters 515 HPLC pump at a flow of 0.8 ml/min), a 
pre-column (in-house made using LichroPrep RP-8 25-40 m silica gel, Merck), and a HPLC 
column (Lichrospher RP select B, 250 x 4 mm, 5 m particle diameter). For detection, a 
single-channel UV-detector (Pye Unicam LC3 UV-detector at 254 nM) and radioactivity 
detector (Ludlum model 2200 scaler rate meter with NaI scintillation probe) were used, 
coupled to a data-recorder (Ankersmit A41 2-channel data recorder). 
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Figure 3.4: [123I]-R91150 routine synthesis set-up 
 
Another 3-way valve is connected to the outlet of the HPLC tubing, one outlet going to the 
waste bottle and the other outlet connected to a sterile collection vial via a syringe filter (0.22 
m, FP 13/0.2 RC-S, Schleicher&Schuell, Germany).  
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The purification process consists of 4 steps, which are indicated with their respective valve 
positions in figure 3.4: 
 
* Step 1: This step is a rinsing step. Sterile, pyrogen- and dust-free water is used 
to rinse the 2 ml loop and pre-column. Flow rate: 5 ml/min. Time: 5 
min. 
* Step 2: Valves are positioned as depicted in figure 3.4. The synthesis vial 
containing the synthesis mixture is placed in a shielded vial, and 
connected to the first 6-way valve. Using peristaltic pump 2, the 
synthesis mixture is transferred to the 2-ml loop. Flow rate: 1 ml/min. 
Time: 2 min. 
* Step 3: After changing valve positions, diluted sodium hydroxide solution (1 
mM) and peristaltic pump 1 are used to transfer the reaction mixture (in 
the loop) to the pre-column. Radioactivity concentration on the pre-
column is monitored, and the flow is stopped when the radioactivity 
concentration reaches a maximum. Flow rate: 5 ml/min. Time: 1 min. 
* Step 4: In the final step the HPLC valve is switched, transferring the 
radioactivity contained on the precolumn to the HPLC column, and the 
HPLC run is started. A sterile sodium acetate buffer/ethanol solution 
(2.28 g NaOAc.3H2O in 60 ml H2O + 40 ml EtOH, adjusted to pH5) is 
used as eluent.  Time: ± 25 min. 
 
The fraction corresponding to [123I]-R91150 (TR = 22 min) was collected during 4 minutes 
(collection volume: 3.2 mL) (figure 3.5). Sterile water for injection is added (8-9 mL) to the 
collection vial to yield a sterile solution of [123I]-R91150 (containing 10 % ethanol), ready for 
use. An aliquot of the tracer solution is withdrawn with a syringe for quality control purposes. 
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3.2.2.3. Results 
 
A typical UV- and radio-chromatogram for a routine [123I]-R91150 synthesis run is shown in 
figure 3.5. 
 
 
Figure 3.5: [123I]-R91150 synthesis chromatogram. The red graph represents the UV-
chromatogram (AUFS-values, detection at 254 nm), the blue graph is the radiochromatogram 
(Log Activity). 
 
As can be seen in figure 3.5, the tracer elutes at about 22 minutes and is collected during 4 
minutes. The large UV-peak, situated around 8 minutes, is the remainder of the precursor 
eluting from the  HPLC column. The total synthesis, from the start of the radiosynthesis 
reaction to the collection of the purified tracer in the vial, could be completed in one hour. 
Exposure to radiation is kept to a minimum by using the synthesis unit. 
With the setup described above, large amounts of [123I]-R91150 (5 – 50 mCi of starting 
activity, resulting in 4 – 40 mCi of purified [123I]-R91150 per synthesis run) could be 
routinely produced. The average yield of the radiosynthesis reaction was 75-80 %. 
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3.2.3. Quality control 
 
3.2.3.1. Materials and methods 
 
Quality control of the tracer was performed after synthesis by injecting an aliquot (50 L) of 
the tracer solution onto an analytical HPLC column (Waters Lichrospher RP-8, 125 x 4 mm, 5 
m) using methanol/acetonitrile/water/acetic acid/triethylamine (190:260:550:1.5:2) as the 
eluent. A Waters Breeze HPLC system was used for quality control, consisting of a binary 
gradient system pump (flow rate: 1 ml/min), a Waters 2487 UV-detector (wavelength: 254 
nm, AUFS: 0.001) and a Ludlum 2200 scaler rate meter equipped with a NaI scintillation 
probe.  
 
 
3.2.3.2. Results 
 
A typical quality control chromatogram can be found in figure 3.6.  
In figure 3.6, the upper graph represents the UV-chromatogram, the lower graph represents 
the radiochromatogram. It is evident from the figure that only one peak was present in the 
radiochromatogram; by comparing its retention time with the retention time of an authentic 
cold standard of iodinated R91150, we were able to identify the product as genuine [123I]-
R91150. Only the injection peak was visible in the UV-chromatogram, no other peaks were 
present. The amount of product present in the tracer preparation was below the detection limit 
of the UV-detector (sensitivity 0.001 AUFS).  
 
 
Figure 3.6: Analysis chromatogram of [123I]-R91150 quality control 
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This is in accordance to the expected high specific activity of the tracer preparation (10 
Ci/mol). 
Synthesis of [123I]-R91150 and the subsequent quality control were performed on a weekly 
basis for several years. Starting activities of 5 to 50 mCi of [123I]-NaI were used. Quality 
control of [123I]-R91150 with the setup described above was fast (20 minutes) and accurate. 
Radiochemical purity was always higher then 95 %, and no UV-signal was ever present in the 
prepared tracer solution. Stability of the tracer was tested by injecting aliquots of the tracer 
preparation on the quality control HPLC system. The tracer was stable for at least 36 hours 
after synthesis (radiochemical purity > 95 %). 
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3.3. In vivo evaluation of [123I]-R91150 in rodents 
 
3.3.1. Influence of cyclosporin A on the biodistribution of [123I]-R91150 in 
NMRI mice 
 
3.3.1.1. Materials and methods 
 
Male NMRI mice (weight 20 - 25 g) were obtained from Bioservices Inc. The animals were 
allowed to acclimatise for at least two days after arrival in the laboratory, with free access to 
water and food, under a light/dark cycle. Belgian law regulations on test animal well-being 
were followed to accommodate the housing for the animals. All experiments were pre-
approved by the Ghent University Animal Ethics Committee under permit number ECP 
06/18. 
Male NMRI mice (n = 3 per time point) were injected in the tail vein with [123I]-R91150 (10 -
15 Ci dissolved in ethanol/water for injection 10/90 v/v). At appropriate time points after the 
injection of [123I]-R91150 (10 min, 30 min, 1 hour and 2 hours) the animals were sacrificed by 
decapitation under isoflurane anaesthesia. Blood was collected. The brain and other organs of 
interest (heart, lungs, stomach, liver, kidney, spleen, intestines, bladder and fat tissue) were 
rapidly removed. Blood and organs were weighed and counted for radioactivity in an 
automated gamma counter (Cobra, Packard Canberra). Aliquots of the injected tracer solution 
(n = 3) were weighed and counted for radioactivity to determine the injected radioactivity 
dose received by the animals. Results were corrected for decay and tissue radioactivity 
concentrations were expressed as a percentage of the injected dose per gram of tissue (% ID/g 
tissue, mean ± standard deviation values, n = 3).  
A second group of animals was treated with cyclosporin A 1 hour before injection of [123I]-
R91150. Cyclosporin A (50 mg/ml[38], obtained from Sandoz, Basel, Switzerland) was 
formulated in cremophore EL (polyethoxylated castor oil, 650 mg/ml) containing 10% 
ethanol. The resulting solution was diluted ten times with water for injection before 
administration to the animals. The cyclosporin A dosage used was 50 mg per kg of 
bodyweight. The same biodistribution protocol as described above was followed.  
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To demonstrate the influence of cyclosporin A dosage on the brain uptake of [123I]-R91150, a 
third group of NMRI mice was injected in the tail vein with different dosages of cyclosporin 
A (0, 10, 20, 35 and 50 mg/kg bodyweight, n = 3 per concentration of cyclosporin A). Half an 
hour after the injection of the cyclosporin A solution, [123I]-R91150 (10 – 15 Ci dissolved in 
ethanol/water-for-injection 10/90 v/v) was injected in the tail vein. One hour after tracer 
injection, the animals were sacrificed by decapitation under isoflurane anaesthesia. The same 
biodistribution protocol as described above was applied, with the exception that only brain 
and blood samples were collected.  
Results of the different groups were compared using non-parametric analysis (Mann-Whitney 
test, p-values < 0.05 were considered as statistically significant). 
 
 
3.3.1.2. Results and discussion 
 
The results of the biodistribution study with [123I]-R91150 in NMRI mice are shown in table 
3.3 for the normal group, and table 3.4 for the cyclosporin A pre-treated group. Radioactivity 
concentrations for [123I]-R91150 in brain and blood are also shown in figure 3.7 for both the 
normal and the cyclosporin A pre-treated group. 
 
    Time (min)     
  10 30 60 120 
Blood 0,65 ± 0,05 0,57 ± 0,07 0,28 ± 0,05 0,22 ± 0,07 
Brain 0,95 ± 0,02 0,87 ± 0,2 0,73 ± 0,01 0,44 ± 0,05 
Heart 2,42 ± 0,4 1,28 ± 0,25 0,49 ± 0,09 0,22 ± 0,002 
Lungs 23,0 ± 3,2 11,3 ± 3,2 3,54 ± 0,2 1,30 ± 0,03 
Stomach 2,3 ± 0,4 5,89 ± 0,44 3,0 ± 1,2 3,84 ± 1,01 
Spleen 4,12 ± 0,5 2,64 ± 0,32 0,99 ± 0,2 0,47 ± 0,008 
Liver 8,2 ± 1,6 18,8 ± 5,7 5,7 ± 0,1 4,66 ± 0,97 
Kidney 11,2 ± 0,5 9,07 ± 1,66 3,76 ± 0,45 2,78 ± 1,4 
Small Int. 2,65 ± 0,6 7,42 ± 2,0 10,8 ± 2,1 8,06 ± 1,5 
Large Int. 0,94 ± 0,2 0,85 ± 0,3 1,1 ± 0,12 6,13 ± 2,1 
Bladder 1,89 ± 0,2 2,01 ± 0,6 4,42 ± 2,4 0,78 ± 0,41 
Fat Tissue 1,67 ± 0,8 1,28 ± 0,6 4,6 ± 0,9 0,37 ± 0,1 
Table 3.3: Results of [123I]-R91150 biodistribution in NMRI mice. Results are expressed as % 
ID/g tissue. Mean ± standard deviation values are shown (n = 3). 
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    Time (min)     
  10 30 60 120 
Blood 0,76 ± 0,36 0,92 ± 0,40 0,77 ± 0,3 0,78 ± 0,4 
Brain 3,65 ± 1,1 5,24 ± 0,9 5,2 ± 0,7 3,12 ± 1,1 
Heart 0,90 ± 0,65 2,75 ± 0,5 1,6 ± 0,5 0,99 ± 0,18 
Lungs 2,69 ± 1,3 9,18 ± 0,8 8,31 ± 0,6 1,70 ± 0,13 
Stomach 3,04 ± 0,35 2,3 ± 0,15 3,74 ± 0,3 2,44 ± 0,6 
Spleen 1,54 ± 0,7 4,02 ± 0,5 3,14 ± 0,2 2,56 ± 1,01 
Liver 4,05 ± 0,78 6,97 ± 3,13 11,7 ± 6,1 3,89 ± 0,28 
Kidney 5,49 ± 2,6 10,34 ± 5,1 8,32 ± 3,2 4,9 ± 1,77 
Small Int. 4,78 ± 2,1 3,17 ± 0,49 9,92 ± 4,01 3,82 ± 1,49 
Large Int. 0,32 ± 0,30 1,33 ± 0,5 0,92 ± 0,28 1,46 ± 0,64 
Bladder 2,9 ± 0,49 7,9 ± 3,0 6,21 ± 2,69 4,87 ± 1,14 
Fat Tissue 6,45 ± 1,2 2,75 ± 1,5 1,04 ± 0,07 0,61 ± 0,06 
Table 3.4: Biodistribution with [123I]-R91150 in NMRI mice after treatment with cyclosporin 
A (50 mg/kg). Results are expressed as % ID/g tissue (mean ± standard deviation, n = 3). 
 
For the control group, the brain uptake of [123I]-R91150 reached a maximum at 10 min after 
injection (0.95 ± 0.02 % ID/g tissue) and slowly decreased over time (0.44 ± 0.05 % ID/g 
tissue at 2 hours after injection). Brain radioactivity concentration was always higher than the 
blood radioactivity concentration (on average, the radioactivity concentration in blood was 
half of the concentration in brain). Blood radioactivity also decreased slowly over time (from 
0.65 ± 0.05 % ID/g tissue to 0.22 ± 0.07 % ID/g tissue).  
For the cyclosporin A pre-treated group, brain uptake was initially high (3.65 ± 1.1 % ID/g 
tissue at 10 min after injection) and remained high over time (3.12 ± 1.1 % ID/g tissue at 2 
hours after injection). A maximum brain uptake of 5.24 ± 0.9 % ID/g tissue was reached 30 
min after injection. Radioactivity uptake in blood was lower (between 0.76 % ID/g tissue and 
0.92 % ID/g tissue) and remained constant over the examined time frame. Brain-to-blood 
ratios varied between 4.00 and 6.75. 
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The biodistribution data for blood and brain in the control group and the cyclosporin A pre-
treated group were compared. The results of the comparison are depicted in figure 3.7. 
 
 
Figure 3.7: [123I]-R91150 biodistribution data for blood and brain of NMRI mice. Results of 
the normal and the cyclosporin-treated group are shown. Results are expressed as % ID/g 
tissue (mean ± standard deviation values, n = 3 per time point). 
 
The increase in brain radioactivity is clearly visualized: at 10 min post injection the uptake in 
brain was 3.8 times higher for the cyclosporin A pre-treated group compared to the control 
group. This difference became even higher at later time points (up to 7.1 times higher at 2 
hours post injection). Consequently, the brain-to-blood ratios were much higher for the 
cyclosporin A pre-treated group compared to the non-treated control group. Although the 
blood radioactivity concentrations were higher after cyclosporin A pre-treatment (ratios 
between the cyclosporin A pre-treated group and the control group varied between 1.1 and 
3.5), the uptake of radioactivity in the brain is much more increased (ratios between the 
cyclosporin A pre-treated group and the control group varied between 3.8 and 7.1), indicating 
that the difference in blood radioactivity concentration between the control group and the 
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cyclosporin A pre-treated group (and thus tracer influx to the brain) is not fully responsible 
for the increased cerebral radioactivity concentration.  
The time difference between the cyclosporin A injection and the tracer injection was kept 
constant at 30 min. This influence has already been studied by other authors who 
demonstrated that the influence of cyclosporin A on the drug efflux of [11C]-verapamil was 
constant at 15 min post injection of cyclosporin A [39]. 
These data are in good accordance with the function of P-glycoprotein as a drug efflux pump, 
and the blocking of its function by administration of cyclosporin A. 
 
To further evaluate the possibility of [123I]-R91150 as a substrate for the P-glycoprotein efflux 
pump, the sensitivity of [123I]-R91150 brain uptake for cyclosporin A dosage was investigated 
in a dose-response study in NMRI mice. The results are shown in figure 3.8.  
 
 
Figure 3.8: Influence of cyclosporin A dosage on the brain uptake of [123I]-R91150 in NMRI 
mice. Results are expressed as % ID/g tissue (mean ± standard deviation values, n = 3 per 
dosage group). 
 
 
 
Cyclosporin A and [123I]-R91150  91 
Administration of cyclosporin A had a dose-dependent effect on the brain uptake of [123I]-
R91150 in mice. The highest influence was observed for the highest dosage of cyclosporin A 
(50 mg/kg). Lower dosages of cyclosporin A resulted in lower cerebral uptake. At all dosages 
uptake was significantly higher compared to the control group. 
Unfortunately, we could not demonstrate a sigmoid relationship between the cyclosporin A 
dosage and the uptake of radioactivity in the brain, as some other authors did for [11C]-
GR218231 and [11C]-verapamil [35, 38]. Due to the toxic effect of cyclosporin A, dosages 
higher than 50 mg/kg could not be administered to mice. 
A small but continuous increase (not statistically different) in blood radioactivity 
concentration was observed, correlated to the cyclosporin A dosage examined. This could be 
explained by a possible influence of cyclosporin A on the plasma kinetics of [123I]-R91150. A 
similar influence has been observed for etoposide [39]. It’s also interesting to note that Liow 
et al. [40] demonstrated that under influence of cyclosporin A, the free non-protein-bound 
fraction in plasma of [11C]-(R)-(-)-WAY, a radioligand for the 5-HT1A receptor, was increased 
2.7-fold. The authors conclude that the increased brain uptake of [11C]-(R)-(-)-WAY induced 
by cyclosporin A may be partly caused by displacement of the radioligand from the plasma 
proteins. The effect of cyclosporin A on the free fraction of [123I]-R91150 and subsequent 
uptake in the brain has not been investigated. 
Despite the fact that saturation could not be demonstrated by a sigmoid curve, and that 
cyclosporin A might have some effect on tracer plasma kinetics, the correlation between the 
cyclosporin A dosage and the dramatic increase in brain radioactivity concentration at all time 
points indicates that the P-glycoprotein efflux transporter is probably involved in the 
pharmacokinetics of [123I]-R91150 in the brain. 
 
Radioactivity concentrations for [123I]-R91150 in lungs and heart were initially high, but 
decreased rapidly. These curves are probably a reflection of the blood pool radioactivity 
concentration. This might be the reason why some of the concentrations in heart and lungs are 
higher in the cyclosporin A pre-treated group compared to the control animals (especially at 
later time points). 
The high tracer uptake in liver could be explained by biotransformation in the liver, followed 
by renal or biliary excretion of [123I]-iodide or [123I]-R91150. 
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Uptake in spleen is decreased in the cyclosporin A pre-treated group at 10 min post injection, 
but is elevated at all other time points, compared to the control group. Splenic P-glycoprotein 
pumps are supposed to be involved in the protection of the spleen. P-glycoprotein in the 
spleen extrudes the toxic unconjugated bilirubin, formed during haemolysis. Blockade of the 
efflux pump by cyclosporin A could give an explanation for the increased radioactivity levels 
in the spleen for the cyclosporin A pre-treated group. 
 
From these experiments we can conclude that [123I]-R91150 is a substrate for the P-
glycoprotein efflux transporter. When the efflux pumps are inhibited by cyclosporin A, brain 
uptake is severely and dose-dependently increased (up to 7.1 times compared to the control 
group at a dosage of 50 mg/kg cyclosporin A). Studies in larger rodents (rats) are necessary to 
determine the effect of P-glycoprotein blocking on the regional brain distribution of [123I]-
R91150. 
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3.3.2. Influence of cyclosporin A on the regional brain biodistribution with 
[123I]-R91150 in Sprague-Dawley rats 
 
3.3.2.1. Materials and methods 
 
Male Sprague-Dawley rats (weight 200 - 250 g) were obtained from Bioservices Inc. The 
animals were allowed to acclimatise for at least two days after arrival in the laboratory, with 
free access to water and food, under a light/dark cycle. Belgian law regulations on test animal 
well-being were followed to accommodate the housing for the animals. All experiments were 
pre-approved by the Ghent University Animal Ethics Committee under permit number ECP 
06/18. 
The animals (n = 3 per time point) were anesthetized with isoflurane and injected in the penile 
vein with [123I]-R91150 (100-150 Ci dissolved in 10% ethanol in water for injection). At 
appropriate time points after injection of [123I]-R91150 (10 min, 30 min, 1 hour, 2 hours and 4 
hours) the animals were sacrificed by decapitation under isoflurane anaesthesia. Blood was 
collected by heart puncture. The brain was rapidly removed and dissected into the different 
brain regions: the cortex (which was further dissected into the frontal cortex, parietal cortex, 
occipital cortex and temporal cortex), cerebellum and the subcortical region. Brain and blood 
samples were weighed and counted for radioactivity with an automated gamma counter 
(Cobra, Packard Canberra). Aliquots of the injected tracer solution (n = 3) were weighed and 
counted for radioactivity to determine the injected radioactivity dose received by the animals. 
Results were corrected for decay and tissue radioactivity concentrations were expressed as a 
percentage of the injected dose per gram of tissue (% ID/g tissue, mean ± standard deviation 
values, n = 3). 
The same biodistribution protocol was applied to a group of animals receiving cyclosporin A 
(50 mg/kg, preparation protocol: 3.3.1.1) one hour before injection of [123I]-R91150. Results 
after cyclosporin A treatment were compared to the values obtained without pre-treatment.  
To exclude possible interference of cremophore EL (used for solubilisation of cyclosporin A), 
three animals were injected with only the vehicle (cremophore EL, saline and 10% ethanol) 
1h before [123I]-R91150 injection. 
 
 
 
Cyclosporin A and [123I]-R91150  94 
3.3.2.2. Results 
 
Results for the regional brain biodistribution study with [123I]-R91150 in Sprague-Dawley rats 
are shown in table 3.5 for the normal group and table 3.6 for the cyclosporin-treated group. 
 
   Time (min)   
 10 30 60 120 240 
Blood 0,07 ± 0,007 0,052 ± 0,02 0,033 ± 0,002 0,024 ± 0,008 0,027 ± 0,003 
Subcortical 0,17 ± 0,01 0,13 ± 0,002 0,070 ± 0,005 0,036 ± 0,006 0,034 ± 0,008 
Temporal 0,20 ± 0,02 0,19 ± 0,02 0,13 ± 0,01 0,071 ± 0,01 0,080 ± 0,03 
Frontal 0,28 ± 0,05 0,38 ± 0,001 0,24 ± 0,01 0,19 ± 0,02 0,18 ± 0,01 
Parietal 0,20 ± 0,01 0,22 ± 0,001 0,23 ± 0,05 0,13 ± 0,01 0,10 ± 0,006 
Occipital 0,19 ± 0,02 0,22 ± 0,08 0,16 ± 0,03 0,13 ± 0,05 0,05 ± 0,01 
Cerebellum 0,12 ± 0,003 0,06 ± 0,002 0,04 ± 0,002 0,017 ± 0,002 0,01 ± 0,001 
Table 3.5: Results of brain biodistribution study with [123I]-R91150 in Sprague-Dawley rats 
(control group). Results are expressed as % ID/g tissue (mean ± standard deviation, n = 3). 
 
                  Time (min)     
  10 30 60 120 240 
Blood 0,11 ± 0,04 0,08 ± 0,01 0,06 ± 0,004 0,05 ± 0,02 0,02 ± 0,01 
Subcortical 0,71 ± 0,17 0,83 ± 0,09 0,65 ± 0,03 0,35 ± 0,09 0,10 ± 0,01 
Temporal 1,36 ± 0,36 1,14 ± 0,21 0,78 ± 0,07 0,64 ± 0,05 0,29 ± 0,2 
Frontal 1,49 ± 0,1 1,84 ± 0,1 1,58 ± 0,09 0,58 ± 0,14 0,57 ± 0,01 
Parietal 1,11 ± 0,4 1,23 ± 0,22 1,35 ± 0,12 1,21 ± 0,27 1,13 ± 0,14 
Occipital 1,08 ± 0,3 1,05 ± 0,26 1,07 ± 0,11 0,86 ± 0,17 0,34 ± 0,13 
Cerebellum 0,43 ± 0,15 0,51 ± 0,02 0,45 ± 0,01 0,24 ± 0,01 0,09 ± 0,01 
Table 3.6: Results of brain biodistribution study with [123I]-R91150 in Sprague-Dawley rats 
after treatment with cyclosporin A (50 mg/kg). Results are expressed as % ID/g tissue (mean 
± standard deviation, n = 3). 
 
The results of the regional brain biodistribution study with [123I]-R91150 in Sprague-Dawley 
rats are shown in figure 3.9 for both the normal and the cyclosporin A group. Radioactivity 
concentration values are indicated for blood, frontal cortex and cerebellum. 
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Figure 3.9: Results of the regional brain biodistribution study with [123I]-R91150  in male 
Sprague-Dawley rats, with and without cyclosporin A pre-treatment (50 mg/kg). Results are 
expressed as % ID/g tissue (mean ± standard deviation, n = 3 per time point). 
 
It is clear from figure 3.9 that no significant difference in blood radioactivity concentration 
values could be observed between the normal and the cyclosporin group. For the cyclosporin-
treated group, radioactivity concentration values in brain were substantially higher than those 
found in the control group. For example, at 1 hour after injection, radioactivity concentration 
in frontal cortex increased from 0.24 ± 0.0092 % ID/g tissue to 1.58 ± 0.097 % ID/g tissue 
after treatment with cyclosporin A. In the reference tissue, the cerebellum, radioactivity 
concentration increased from 0.038 ± 0.0023 % ID/g tissue at 1 hour after injection of [123I]-
R91150 to 0.45 ± 0.017 % ID/g tissue after treatment of the animals with cyclosporin A.  
 
For the control group, the highest [123I]-R91150 radioactivity concentration in brain was 
observed in the frontal cortex (0,38 ± 0,001 % ID/g tissue at 30 min post injection, decreasing 
to 0.18 ± 0.01 % ID/g tissue at 4 hours post injection of [123I]-R91150). Radioactivity 
concentration in blood was substantially lower than in the brain: frontal cortex-to-blood 
radioactivity concentration ratios of about 7 were obtained throughout the study for the 
control group. 
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Radioactivity concentration levels in cerebellum approached the values found in blood, and 
starting from 1 hour after tracer injection, cerebellar radioactivity concentrations were lower 
than the blood radioactivity concentration values.  
Minimal frontal cortex-to-cerebellum radioactivity concentration ratios of about 7 were 
observed starting 30 min after tracer injection, and the ratio reached a value of 18 at 4 hours 
after injection of [123I]-R91150 for the control group. 
 
For the cyclosporin A pre-treated group, highest [123I]-R91150 radioactivity concentration in 
brain was observed in the frontal cortex (1.84 ± 0.1 % ID/g tissue at 30 min after tracer 
injection). Frontal cortex-to-blood radioactivity concentration ratios averaged 20 throughout 
the study. Cerebellum-to-blood radioactivity concentration ratios were substantially lower: an 
average ratio of about 4 was obtained throughout the study. 
Frontal cortex-to-cerebellum radioactivity concentration ratios averaged around 4 in the 
cyclosporin A pre-treated group, which is substantially lower than the ratio of 7 obtained in 
the control group. No significant difference in blood radioactivity concentration could be 
observed between both groups. 
 
On average, there was a five to six-fold increase in [123I]-R91150 concentration in brain after 
cyclosporin A treatment. The other brain regions (temporal, parietal and occipital cortex) 
showed a similar increase in [123I]-R91150 radioactivity concentration after treatment of the 
animals with cyclosporin A.  
 
To exclude possible effects of cremophore EL, a blank test was performed. No modulating 
effects of cremophore EL on [123I]-R91150 accumulation in the brain of Sprague-Dawley rats 
were measured (data not shown). These results are in accordance to the data obtained by other 
authors[41].  
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3.3.2.3. Discussion 
 
The increase in [123I]-R91150 concentration in the brain of male Sprague-Dawley rats is as 
expected after cyclosporin A treatment considering the conclusion from the mouse 
cyclosporin A study that [123I]-R91150 is a substrate for P-glycoprotein in vivo in rodents.  
Theoretically, an increased brain uptake could be the result of a higher blood radioactivity 
concentration, resulting in an increased supply of tracer to the brain. Because no significant 
difference in blood radioactivity concentration was observed between the normal and the 
cyclosporin group, this situation could be ruled out, especially since a dose-response relation 
was observed between the amount of cyclosporin A administered and the corresponding tracer 
concentration in the brain. 
The regional brain radioactivity concentration values for the normal group are in accordance 
with the original regional brain biodistribution study results obtained by Terriere et al[2], and 
can be compared with the results obtained with other 5-HT2A tracers, for example [11C]-
MDL100907[42] and [18F]-altanserin[43, 44]. Both MDL and altanserin concentrated 
preferentially in (frontal) cortical tissues, and showed a (relative) absence of binding in 
cerebellum, confirming the usability of the cerebellum as a reference region in 5-HT2A brain 
studies when performing kinetic modelling studies according to the reference tissue model. 
However, [18F]-altanserin also showed considerable aspecific binding, for example to 
cerebellar tissues. 
The results obtained in our studies with [123I]-R91150 and cyclosporin A can be compared 
with the results obtained by other authors with other (brain) tracers; generally, administration 
of cyclosporin A resulted in a large increase in brain radioactivity uptake. Regional tracer 
distribution in the brain was not affected by Pgp modulation. For example, the effect of 
cyclosporin A on the brain uptake of the 5-HT1A tracer [11C]-WAY100635 was investigated 
by Liow et al[40]. Cyclosporin A increased brain uptake of [11C]-WAY100635 in rats by a 
factor of five, which is in good accordance to our results obtained with [123I]-R91150 in rats. 
Similarly, [18F]-MPPF (also a 5-HT1A tracer) uptake in rat brain increased five- to tenfold 
after treatment of the animals with cyclosporin A[45].  
Brain uptake of the -adrenergic receptor ligands [11C]-carazolol and [18F]-fluorocarazolol 
was also increased in Pgp knockout mice and cyclosporin-treated rats[45]. Administration of 
cyclosporin A increased the levels of [11C]-verapamil about ten-fold in rat brain[46]. 
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A significant difference was observed in the frontal cortex-to-cerebellum ratio between the 
control and the cyclosporin A treated group: average ratios of about 4 were obtained for the 
control group, and average ratios of about 7 were obtained for the cyclosporin A treated 
group. A possible explanation could be that the distribution of P-glycoprotein efflux pumps is 
not homogenous throughout the brain, resulting in regional effects. Also, aspecific binding in 
cerebellum could be higher than the aspecific binding in other brain regions, for example the 
cortex, resulting in a lower frontal cortex-to-cerebellum ratio in the cyclosporin A group. 
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3.3.3. Influence of cyclosporin A on the displacement of [123I]-R91150 in the 
brain of Sprague-Dawley rats 
 
3.3.3.1. Materials and methods 
 
Ketanserin and ritanserin were used for the displacement studies in rodents. Ketanserin 
tartrate (1 mg/kg, dissolved in water/ethanol 95/5, Tocris, UK) was used for displacement 
studies. Male Sprague-Dawley rats (weight 200 – 250 g, n = 3 per group) were treated with 
cyclosporin A (50 mg/kg) 1 hour before the injection of [123I]-R91150. Ketanserin was 
injected into the penile vein 30 min after injection of [123I]-R91150. Ritanserin (obtained from 
Tocris Cookson, UK) was dissolved in a 5% ethanol solution at a concentration of 5 mg/ml. A 
dosage of 2.5 mg/kg bodyweight (0.5 ml injected solution) was administered to the animals 
30 minutes after injection of [123I]-R91150. The amount of radioactivity injected was 
approximately 100 – 200 Ci of [123I]-R91150. The animals were sacrificed by decapitation 
under isoflurane anaesthesia one hour after tracer injection. Blood was collected and the brain 
was rapidly removed. The brain was dissected into different regions: cortex (frontal, temporal, 
parietal and occipital cortex), cerebellum and subcortical region. Blood and brain parts were 
weighed and counted for radioactivity with an automated gamma counter (Cobra, Packard 
Canberra). The results were corrected for decay and tissue radioactivity concentrations were 
expressed as a percentage of the injected dose per gram of tissue (% ID/g).  
The biodistribution protocol described above was also applied to a group of animals that did 
not receive a pre-treatment with cyclosporin A. Results obtained from the cyclosporin-treated 
group were compared with the results obtained from the control group, and the results 
obtained after ketanserin and ritanserin were also compared. 
For statistical analysis, the non-parametric Mann-Whitney test was used. P-values < 0.05 
were considered statistically significant. All values are given as mean  ± standard deviation, n 
= 3 animals per time point. 
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3.3.3.2. Results 
 
The influence of the displacement with ketanserin on the biodistribution with [123I]-R91150 in 
Sprague-Dawley rats is shown in table 3.7 and figure 3.10 for the control group and the 
cyclosporin-treated group. 
 
    Treatment group   
 Normal Ketanserin Cyclo Cyclo-ket 
Blood 0,033 ± 0,002 0,038 ± 0,002 0,06 ± 0,004 0,06 ± 0,003 
Subcortical 0,070 ± 0,005 0,07 ± 0,006 0,65 ± 0,03 0,59 ± 0,06 
Temporal 0,13 ± 0,01 0,10 ± 0,002 0,78 ± 0,07 0,68 ± 0,01 
Frontal 0,24 ± 0,01 0,18 ± 0,005 1,58 ± 0,09 1,14 ± 0,17 
Parietal 0,23 ± 0,05 0,15 ± 0,005 1,35 ± 0,12 0,90 ± 0,12 
Occipital 0,16 ± 0,03 0,13 ± 0,02 1,07 ± 0,11 0,85 ± 0,03 
Cerebellum 0,04 ± 0,002 0,04 ± 0,0004 0,45 ± 0,01 0,45 ± 0,04 
Table 3.7: Results of the ketanserin displacement study with [123I]-R91150 in male Sprague-
Dawley rats. Results are expressed as % ID/g tissue (mean ± standard deviation, n = 3).  
 
 
Figure 3.10: Influence of ketanserin displacement on the biodistribution of [123I]-R91150 in 
Sprague-Dawley rats (results at 1 h). Results are expressed as % ID/g tissue (mean ± standard 
deviation, n = 3 per group). Significant differences between groups are indicated with * (p-
value < 0.05). 
 
Cyclosporin A and [123I]-R91150  101 
Uptake of [123I]-R91150 decreased with about 30% in frontal cortex after ketanserin 
displacement for the control group. No significant differences in [123I]-R91150 radioactivity 
concentration were observed in blood, subcortical regions and the cerebellum (figure 3.10). 
For example, radioactivity concentration values for frontal cortex decreased from 0.24 ± 
0.0092 % ID/g tissue for the normal group to 0.18 ± 0.005 % ID/g tissue for the ketanserin 
displacement group (a decrease in radioactivity concentration of 25 %). 
 
For the cyclosporin pre-treated group, the same reduction in frontal cortex radioactivity 
concentration (about 30%) was observed after displacement of the radioligand with 
ketanserin. Radioactivity concentration in cerebellum did not change significantly after 
displacement with ketanserin. Other cortical areas showed the same behaviour, both for the 
control as for the cyclosporin-treated group (figure 3.10). Frontal cortex radioactivity 
concentration values for the cyclosporin-treated group were 1.58 ± 0.097 % ID/g tissue and 
1.14 ± 0.15 % ID/g tissue respectively (which amounts to the same reduction in radioactivity 
concentration as the untreated group, a 25 % decrease after displacement with ketanserin).  
As mentioned earlier, in cerebellum there was no significant difference between the normal 
and the ketanserin group, in both the control (0.038 ± 0.002 % ID/g tissue and 0.0379 ± 0.004 
% ID/g tissue respectively) and the cyclosporin A pre-treated animals (0.456 ± 0.017 % ID/g 
tissue and 0.450 ± 0.038 % ID/g tissue respectively). Radioactivity concentration in blood did 
not change significantly after ketanserin displacement. 
 
To exclude possible ketanserin-specific effects and as control, a displacement experiment 
with another known 5-HT2A antagonist, ritanserin, was performed. The results of this 
experiment can be found in figure 3.11 and table 3.8. 
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Figure 3.11: Results of the [123I]-R91150 biodistribution study after ketanserin and ritanserin 
displacement, 1 hour after injection of [123I]-R91150. Results are expressed as % ID/g tissue 
(mean ± standard deviation, n = 3 per time point, * indicates a p-value > 0.05). 
 
  Treatment group   
 Normal Ritanserin Cyclosporin Cyclo-Rit 
Blood 0,033 ± 0,002 0,03 ± 0,002 0,06 ± 0,004 0,045 ± 0,006 
Subcortical 0,070 ± 0,005 0,069 ± 0,005 0,65 ± 0,03 0,64  ± 0,09 
Temporal 0,13 ± 0,01 0,10 ± 0,005 0,78 ± 0,07 0,75  ± 0,06 
Frontal 0,24 ± 0,01 0,20 ± 0,02 1,58 ± 0,09 1,14  ± 0,13 
Parietal 0,23 ± 0,05 0,14 ± 0,05 1,35 ± 0,12 1,07  ± 0,18 
Occipital 0,16 ± 0,03 0,12 ± 0,03 1,07 ± 0,11 0,93  ± 0,08 
Cerebellum 0,04 ± 0,002 0,04 ± 0,004 0,45 ± 0,01 0,45  ± 0,06 
Table 3.8: Results of the ritanserin displacement study with [123I]-R91150 in male Sprague-
Dawley rats. Results are expressed as % ID/g tissue (mean ± standard deviation, n = 3). 
 
No significant differences were observed between the results obtained after ketanserin 
displacement and the results obtained after displacement of [123I]-R91150 with ritanserin, 
indicating that the used dosages of the displacing compound were adequate for fully 
displacing [123I]-R91150 from the 5-HT2A receptor.  
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Higher dosages of ketanserin were tested (up to 5 mg/kg, data not shown), but no further 
displacement of [123I]-R91150 was observed between this higher dosage and the ‘standard’ 
dosage (1 mg/kg ketanserin) obtained from literature[16, 17, 7]. 
 
 
3.3.3.3. Discussion 
 
The results obtained in the ketanserin displacement studies are in accordance with the known 
localization of 5-HT2A receptors in the brain[47]. The cerebellum is used as a reference region 
in 5-HT2A imaging studies because it contains very low levels of 5-HT2A receptors. Binding of 
the radioligand in cerebellum is generally regarded as aspecific binding of the tracer to 
proteins and lipids in the brain. 
However, our research demonstrated that a significant amount of [123I]-R91150 radioactivity 
remained present in frontal cortex after displacement with ketanserin or ritanserin. About 30% 
of the activity bound to frontal cortex could be displaced by 5-HT2A antagonists, and 
radioactivity levels in frontal cortex after displacement were about 3-4 times higher than the 
levels observed in cerebellum. The same observation was seen for the other cortical brain 
regions. The same reduction in cortical radioactivity concentration (about 30%) was obtained 
for the control group as for the cyclosporin A pre-treated group. 
Our results can be compared to the original results obtained in Wistar rats at the Janssen 
Research Foundation[2]: displacement of [123I]-R91150 by ketanserin (0.63 mg/kg) resulted 
in a reduction of activity in frontal cortex with about 35%, whereas cerebellar activity did not 
change significantly. Radioactivity levels in frontal cortex did not decrease to the levels 
observed in cerebellum after ketanserin displacement; on the other hand, after blocking of 
tracer binding by ritanserin (2.5 mg/kg), radioactivity concentration in frontal cortex 
decreased to the level observed in cerebellum. This result could not be repeated in our 
ritanserin displacement study; a considerable amount of aspecific binding remained in 
cerebellum. 
Other known 5-HT2A tracers, for example [11C]-MDL100907 and [18F]-altanserin showed 
acceptable aspecific binding in frontal cortex, but both tracers also showed higher aspecific 
binding in cerebellum. In all brain areas, the nonspecific binding of [18F]-altanserin was 
significantly higher than that for [11C]-MDL100907[43]. This finding can not be well-
explained by the estimated lipophilicity for the two radioligands, as their log P values are 
similar.  
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[123I]-R91150 shows even more aspecific binding in cerebellum, although the lipophilicity of 
[123I]-R91150 is comparable to those of [11C]-MDL100907 and [18F]-altanserin.  
It is known that the degree of nonspecific binding cannot be predicted from the lipophilicity 
(log P) of a tracer alone[48]. Nevertheless, a PET study in Cynomolgus monkeys with [11C]-
MDL100907 demonstrated that a considerable amount of radioactivity remained in frontal 
cortex after displacement or blocking with ketanserin[49], although it is generally accepted 
that, of all known 5-HT2A tracers, [11C]-MDL100907 demonstrates the least amount of 
aspecific binding to brain tissues[47, 50]. 
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3.3.4. Influence of cyclosporin A on pinhole SPECT imaging with [123I]-
R91150 in Sprague-Dawley rats 
 
3.3.4.1. Materials and methods 
 
SPECT image acquisition was performed on a U-SPECT-II (Milabs, Utrecht, the 
Netherlands) equipped with a dedicated 75 pinhole high-resolution rat collimator.  
Male Sprague-Dawley rats (250 – 266 g) were anesthetized with isoflurane and injected with 
cyclosporin A (50 mg/kg) in the tail vein. 30 minutes later [123I]-R91150 (800 Ci) was 
injected into the tail vein. Another 40 minutes later a U-SPECT-II scan was performed using 
the rat collimator (75 pinholes of 1.0 mm) for a continuous 60 minutes (12 frames of 5 
minutes) with list mode output enabled.  
As a reference animals were also scanned in a similar protocol but without administration of 
cyclosporin A.  A 20 % photo peak was selected around 159 keV while background 
correction was performed using two additional 10 % windows around 133 and 188 keV.   
The time frames from 45 to 75 min post-injection were selected and the data were 
reconstructed on 0.75 mm voxels by 3 iterations of 16 OSEM subsets.  The images were 3D 
postfiltered by a 15 pixel Gaussian kernel with a width of 1.5 mm.   
Two regions-of-interest (ROI’s) were drawn around the frontal cortex and the cerebellum 
using Amide (OpenSource) with 3D Freehand on the coronal slices.  The mean value and 
standard deviation over all voxels in the respective ROI’s were calculated for post-analysis.  
All experiments were conducted following the principles of laboratory animal care and the 
Belgian law on the protection of animals. Our research protocol was approved by the Ghent 
University Hospital ethical committee (ECP 06-18). 
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3.3.4.2. Results and discussion 
 
A pinhole SPECT scan with [123I]-R91150 after animal treatment with cyclosporin A is 
shown in figure 3.12. Highest uptake of [123I]-R91150 was found in cortical tissues, lowest 
concentration of radioactivity was observed in cerebellum.  
 
 
Figure 3.12: Brain pinhole SPECT imaging with [123I]-R91150 (800 Ci) in Sprague-
Dawley rats. The animals were treated with cyclosporin A (50 mg/kg) 30 minutes before 
tracer injection (time frame scanned: 45 to 75 minutes after tracer injection).  
 
Regions-of-interest (ROI) were drawn around cerebellum and frontal region of the cortical 
tissues. Tracer uptake in the cerebellum was used as a reference for non-specific binding.  
For semi-quantification, the binding index (BI) was estimated as (mean counts in frontal 
cortex)/(mean counts in cerebellum). 
 
Results of the pinhole SPECT imaging study for both the control and the cyclosporin A 
treated group are shown in figure 3.13. Regions-of-interest were drawn around cortical tissue 
and cerebellum. 
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Figure 3.13: Pinhole SPECT imaging with [123I]-R91150 in Sprague-Dawley rats. Part a: 
control group; part b: result after cyclosporin A treatment. Regions-of-interest were drawn 
around the frontal cortical tissues and around the cerebellum. 
 
A large difference in imaging quality was observed between the control and the cyclosporin A 
treated group. In the control group, hardly any brain radioactivity was observed (figure 3.13 
part a): cortical tissues were not visible on the images, and the low count rate made data-
analysis problematic. On the other hand, after treatment of the animals with cyclosporin A, 
the quality of the SPECT images with [123I]-R91150 improved markedly (figure 3.13 part b): 
cortical tissues could be clearly visualized, in contrast to the results obtained in the control 
group.  
 
A cortex-to-cerebellum ratio of about 3.2 was obtained for the cyclosporin A group, a value 
which is in accordance to the values obtained after dissection in the rat regional brain 
biodistribution studies with [123I]-R91150. 
 
These results confirm that [123I]-R91150 is a substrate for the P-glycoprotein efflux 
transporter in vivo in rodents; pre-treatment of the animals with cyclosporin A resulted in a 
markedly increased tracer concentration in the brain. 
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3.3.5. Influence of cyclosporin A administration on the metabolism of [123I]-
R91150 in Sprague-Dawley rats 
 
3.3.5.1. Materials and methods 
 
For determination of possible lipophilic metabolites of [123I]-R91150,  male Sprague-Dawley 
rats (200 - 250 g, n = 3) were injected with approximately 20 MBq of [123I]-R91150. One 
hour after tracer injection the animals were sacrificed by decapitation, blood was collected in 
heparinised tubes and the brain was quickly removed by dissection. Blood was centrifuged for 
3 min at 3000g and plasma was separated from the pellet. Plasma (500 l) was mixed with 
acetonitrile (1 ml). The mixture was vortexed on ice for 10 sec and centrifuged for 3 min at 
3000g. Brain tissue was homogenized in acetonitrile (2 ml) for 30 sec and the mixture was 
centrifuged for 3 min at 3000g. The acetonitrile fraction was filtered through a 0.22 m 
syringe filter to remove insoluble impurities, and injected onto the HPLC system for 
metabolite analysis. The HPLC system consisted of a semi-preparative HPLC pump 
(Shimadzu LC-8A pump, flow rate of 5 ml/min), a semi-preparative HPLC column (Alltech 
Econosphere RP-C18 10 mm ID x 250 mm, 10 m) and radioactivity detector (Ludlum Model 
2200 scaler rate meter equipped with a Ludlum 402 NaI scintillation crystal). A 40/60 mixture 
of ethanol and buffer (0.02 M phosphate buffer pH 7.4) was used as the eluent. An aliquot of 
authentic [123I]-R91150 solution was also injected on the HPLC system to determine the 
retention time of unmetabolised [123I]-R91150. Blood and brain samples were analyzed. 
Radioactivity extraction efficiency was calculated. 
The same procedure was applied to blood and brain samples of mice pre-treated with 
cyclosporin A (50 mg/kg) one hour before injection of the radioligand [123I]-R91150. Results 
for both groups were compared. 
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3.3.5.2. Results 
 
Efficiency of the [123I]-R91150 radioactivity extraction process was always higher then 90%. 
Metabolites of [123I]-R91150 in blood and brain samples of Sprague-Dawley rats were 
determined. The metabolite assay results for the brain samples can be seen in figure 3.14. 
 
 
Figure 3.14: [123I]-R91150 HPLC metabolite assay: reference standard and brain sample 
 
As can be seen in figure 3.14, only one radiolabelled product was present in the brain samples 
of the normal group. This product was identified as unmetabolised [123I]-R91150 by 
comparison of the retention time with the retention time of an authentic [123I]-R91150 
reference standard. No lipophilic metabolites could be detected in blood or brain of the 
normal group. Besides unmetabolised [123I]-R91150, a small amount of free radioiodide was 
present in the blood samples, probably due to in vivo dehalogenation of the tracer. These 
results are in good accordance with the data obtained from human and dog metabolite 
studies[16, 17, 7, 9]. 
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Metabolites in blood and brain of Sprague-Dawley rats pre-treated with cyclosporin A (50 
mg/kg, one hour before tracer injection) were determined to exclude possible interference of 
cyclosporin A with the in vivo metabolism of [123I]-R91150. No lipophilic metabolites could 
be detected in blood or brain after cyclosporin A treatment. The only radiolabelled product 
found in brain samples was unmetabolised [123I]-R91150. A small amount of free radioiodine 
was present in the blood samples, probably due to in vivo deiodination of the tracer. 
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3.4. Discussion 
 
The human mdr1 gene (that encodes P-glycoprotein) has several single nucleotide 
polymorphisms that  can change the pharmacokinetics of drugs that are substrates for this 
transporter [36]. This could possibly lead to successful scans in one patient, and failed scans 
in another, and is very important in patients treated with high doses of Pgp modulators such as 
cyclosporin A. Therefore it is necessary in the development of new tracers to determine if 
their brain efflux is modulated by P-glycoprotein. It is also of interest to know whether the 
biodistribution of tracers presently used in clinic is influenced by P-glycoprotein. In this 
regard, several clinically used tracers have already been examined as substrates for P-
glycoprotein [33, 34, 51, 36, 52, 53].  
The [123I]-R91150 NMRI mouse biodistribution studies, Sprague-Dawley rat regional brain 
biodistribution studies and the rat SPECT imaging study all revealed a 4 to 6-fold increase in 
brain [123I]-R91150 radioactivity concentration after blocking of P-glycoprotein with 
cyclosporin A. Radioactivity concentration in blood did not increase significantly after 
treatment of the rats with cyclosporin A. Theoretically, an increased brain uptake can be the 
result of an increased tracer influx in the brain, or a decreased tracer efflux out of the brain. 
Since we blocked the function of Pgp as a drug efflux protein, the increase in [123I]-R91150 
brain uptake should be the result of decreased tracer efflux out of the brain. This is in 
accordance with the localization and function of P-glycoprotein as efflux-protein at the blood-
brain barrier [36]. The results are also in accordance to the dose-response curve obtained in 
mice by administering different dosages of cyclosporin A and evaluating the influence on 
brain tracer concentration. Moreover, the rat biodistribution studies demonstrated no 
increased supply of tracer to the brain (blood radioactivity concentration did not increase 
significantly after treatment of the animals with cyclosporin A).  
The increased [123I]-R91150 uptake in Sprague-Dawley rat brain after cyclosporin A 
treatment could not be fully displaced by ketanserin or ritanserin (figure 3.11), indicating that 
at least part of the increase in [123I]-R91150 radioactivity concentration is due to increased 
aspecific binding of the tracer in the brain. This can also be seen in the increased radioactivity 
uptake after cyclosporin A treatment in the reference area, the cerebellum. Residual binding in 
brain cortical tissues of animals receiving [123I]-R91150 and ketanserin or ritanserin was also 
considerable.  
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Our results are in accordance with other, previously published studies investigating the effect 
of cyclosporin A administration on the brain uptake of different radiotracers [36]. Similarly to 
the results of Liow et al, brain uptake of [123I]-R91150 increased 4 to 6-fold. 
 
The fact that [123I]-R91150 radioactivity concentration in cortex remains high after ketanserin 
displacement can be caused by different factors: the amount of ketanserin administered could 
have been too low, resulting in only partial displacement of [123I]-R91150 from the 5-HT2A 
receptor. Another cause could be that the time period between radioligand injection and 
ketanserin displacement was too short. Different dosages of ketanserin (up to a dosage of 5 
mg/kg - or five times the standard dosage) were tested; higher dosages did not result in higher 
displacement of [123I]-R91150 in cortex. The time period between tracer injection and 
injection of the displacing compound was based on data obtained from literature, and is used 
by almost all researchers investigating brain neurotransmitter receptors.  
The remaining activity in cortex after displacement can also be the result of aspecific binding 
to brain tissue. In this case, the question remains why the amount of aspecific binding in 
cortex is higher than the amount of aspecific binding observed in cerebellum. 
It could also be possible that the high remaining radioactivity in cortex after displacement is 
the result of a certain affinity of [123I]-R91150 for other receptor (sub)types. This should be 
investigated further. 
 
Future work will reveal possible changes in [123I]-R91150 free plasma fraction under the 
influence of cyclosporin A, to exclude the effect of possible displacement of the tracer from 
plasma proteins, also resulting in an increased tracer influx to the brain and increased brain 
uptake. 
 
Cyclosporin A administration resulted in a vastly improved quality of the pinhole SPECT 
images with [123I]-R91150 in rodents. When visually inspecting the effect of cyclosporin A 
administration on the SPECT images, the increase in radioactivity concentration is very 
clearly visible, as shown in figure 3.13. The brain was hardly visible when only the tracer 
[123I]-R91150 was administered (figure 3.13 part a), in contrast with for example human trials 
where the tracer does show good brain uptake [16, 17]. After pre-treatment with cyclosporin 
A, the frontal cortex became clearly visible (figure 3.13 part b). 
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The consequences of these results are not clear yet. Perhaps there could be some future in 
using P-glycoprotein blocking agents to improve the brain uptake of tracers that otherwise 
show a limited penetration in the brain, and to improve PET or SPECT imaging quality. 
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3.5. Conclusion 
 
The influence of cyclosporin A pre-treatment on the biodistribution with [123I]-R91150 was 
evaluated in NMRI mice and Sprague-Dawley rats. The effect of cyclosporin A 
administration on the quality of the pinhole SPECT images in Sprague-Dawley rats with 
[123I]-R91150 was evaluated as well. From the obtained results it can be concluded that [123I]-
R91150 is a substrate for P-glycoprotein in NMRI mice and Sprague-Dawley rats.  
In NMRI mice, a dose-dependent influence of cyclosporin A on the brain uptake of [123I]-
R91150 was observed, indicating that the increased tracer brain concentration is the result of a 
decreased tracer efflux out of the brain after blocking of the P-glycoprotein efflux transporter 
by cyclosporin A. Pre-treatment of Sprague-Dawley rats with cyclosporin A resulted in an 
increased brain uptake of [123I]-R91150 and a drastically improved quality of the obtained 
SPECT images. Therefore, we suggest further exploration of the use of cyclosporin A (or 
other less toxic P-glycoprotein blocking agents) to improve the otherwise limited brain uptake 
of some radioligands for brain imaging.  
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4. SYNTHESIS OF [123I]-(4-FLUOROPHENYL) 
[1-(3-IODOPHENETHYL)PIPERIDIN-4-YL] 
METHANONE 
 
4.1. Selection of the molecule 
 
4.1.1. Introduction 
 
The aim of this research is the precursor synthesis and radiosynthesis of [123I]-(4-
fluorophenyl)[1-(3-iodophenethyl)piperidin-4-yl]methanone ([123I]-3-I-CO, figure 4.1). The 
potential of this tracer to visualize the serotonin 5-HT2A receptor in vivo with pinhole 
SPECT will be evaluated. The molecule was selected based on an article by Xing Fu and co-
workers, published in 2002 in the Journal of Medicinal Chemistry [1].  
3-I-CO is a 4-fluorobenzoyl-piperidine derivative structurally related to ketanserin and 
setoperone. (4-Fluorophenyl)[1-(3-iodophenethyl)piperidin-4-yl]methanone shows excellent 
affinity for the human serotonin 5-HT2A receptor (Ki = 0.51 nM). The assay was performed 
with the membranes of cells transfected with human 5-HT2A genes, using tritiated ketanserin 
(1.2 nM) as ligand and altanserin (10 M) for the blank test. 
 
 
Figure 4.1: [123I]-(4-fluorophenyl)[1-(3-iodophenethyl)piperidin-4-yl]methanone ([123I]-3-I-
CO) 
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4.1.2. The 5-HT2A receptor: modelling 
 
A good starting point for the homology building of G-protein coupled receptor models is the 
crystal structure of bovine rhodopsin, although the low-sequence homology (~ 20 %) between 
5-HT2 receptors and rhodopsin makes the application of standard homology modelling 
methods difficult. The structure of the 5-HT2A receptor model[2] with ketanserin docked in 
the binding site is shown in figure 4.2. The transmembrane helices are clearly visible in figure 
4.2. 
 
 
Figure 4.2: Structure of the 5-HT2A receptor model. The figure shows a molecule of 
ketanserin docked in the binding site. Adapted from Dezi et al[2]. 
 
The reasons for choosing ketanserin (figure 4.3) as ligand are two-fold: first, ketanserin is a 
well-known ligand for the 5-HT2A receptor and second, ketanserin exhibits a large chemical 
similarity with other 5-HT2A ligands (for example [123I]-3-I-CO).  
 
 
Synthesis of [123I]-3-I-CO  125 
 
Figure 4.3: Chemical structure of ketanserin. 
 
Several amino acid residues in the binding site are important for interaction with 5-HT2A 
ligands. In figure 4.4, ketanserin is docked in the active binding pocket of the 5-HT2A 
receptor, and the amino acid residues responsible for interaction with 5-HT2A ligands are 
shown. The most important amino acid residues, responsible for binding of ketanserin to the 
receptor, are also indicated in figure 4.4. 
The binding site is located approximately parallel to the transmembrane helices. The ligand 
makes polar contacts mainly with residues in helices 3 and 7, as well as with some residues of 
the extracellular loop 2. Hydrophobic contacts are observed with residues of helices 5 and 6. 
The amino acids making the most relevant interactions with ketanserin are Asp3.32, Ser3.36, 
Trp3.28, Phe6.51, Tyr7.43 and Ser161. Their mechanism of action will be discussed briefly. 
 
 
Figure 4.4: Binding site of the 5-HT2A receptor complexed with a molecule of ketanserin. 
Only residues involved in relevant interactions are depicted. Taken from Dezi et al[2]. 
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It is evident from figure 4.4 that the side chain of Asp3.32 and the charged nitrogen of 
ketanserin interact, making a charge-reinforced hydrogen bond.  
The phenyl ring of the Phe6.51 side chain adopts a conformation parallel to the ketanserin 
piperidine ring, where the aliphatic carbons directly linked to the charged ketanserin nitrogen 
(holding a positive partial charge) can make favorable interactions with the phenyl ring of the 
Phe6.51 side chain. The result is a kind of electrostatic “sandwich”, in which ketanserin 
makes favorable interactions with Asp3.32 on one side and with Phe6.51 on the opposite side.  
The other oxygen atom of the Asp3.32 side chain is at hydrogen-bonding distance of one of 
the carbonyl oxygen atoms of the ketanserin benzouracil moiety, which seems to be also 
involved in an additional hydrogen bond with the indolic nitrogen of Trp3.28.  
The benzouracil moiety seems to participate in two additional polar interactions: one between 
the remaining carbonyl oxygen and the hydroxyl of Ser161, the other between one nitrogen 
and the Tyr7.43 phenolic hydroxyl group. This last interaction seems to stabilize the position 
of Tyr7.43 in an orientation in which it can establish an additional hydrogen bond with 
Ser2.61. With respect to the p-fluorobenzoyl moiety, the carbonyl oxygen makes a hydrogen 
bond with the side chain of Ser3.36.  
The percentage of hydrogen bonding between the amino acid residues and ketanserin is 
shown in table 4.1. 
 
 
Table 4.1: Hydrogen bonding between ketanserin and the respective amino acid residues. 
Adapted from Dezi et al[2]. 
 
Deeper inside the binding pocket, the p-fluorobenzoyl is immersed in a hydrophobic pocket 
involving residues Val5.39 and Leu163. The size of this hydrophobic pocket is delimited by 
Phe6.52, a residue that is part of the so-called hydrophobic toggle switch, a set of three 
residues (Phe6.51, Phe6.52 and Trp6.48), which are known to participate in a coordinated 
conformational change, potentially important for the activation process[3, 4, 5, 6].  
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Apart from this role, the conformational changes of these three residues are very important for 
determining the size of the hydrophobic pocket, which in turn conditions the orientation of the 
p-fluorobenzoyl moiety.  
The fluorine substituent of the aromatic ring is located close to the Ser5.43 and Ser5.46, 
which are residues that have been postulated to be relevant for the binding of serotonin[7, 8]. 
Table 4.2 shows the effect of selectively ‘disabling’ one or more amino acid residues in the 
active binding site via mutagenesis experiments, hereby emphasizing the importance of the 
function of the different amino acid residues in the binding process. 
 
 
Table 4.2: Residues involved in the binding of ketanserin to the 5-HT2A receptor. Data 
obtained from mutagenesis experiments[2]. 
 
Most of the 5-HT2A antagonists share relevant structural features with ketanserin, like the 
presence of a piperidine ring, the linear shape with aromatic rings at both ends, and hydrogen-
bond acceptor and donor groups at an intermediate position.  
This similarity justifies the use of the above-described ketanserin-conditioned binding pocket 
to carry out docking simulations with other possible 5-HT2A antagonists. For example, the 
structure of  [123I]-3-I-CO and ketanserin are very similar, so we can assume that [123I]-3-I-CO 
uses the same interactions as ketanserin with the amino acid residues in the active binding site 
of the 5-HT2A receptor.   
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4.1.3. Properties of [123I]-3-I-CO 
 
Knowledge of the localization and the functional roles of the large number of serotonin 
receptors, including the 5-HT2A receptor, remains incomplete. A powerful method for 
contributing to such knowledge is the use of clinical anatomical and functional radionuclide 
brain imaging with PET (positron emission tomography) and SPECT (single photon emission 
computed tomography). These techniques provide methods of high sensitivity for measuring 
in vivo neurochemical and pharmacological effects at specific target-receptor proteins. 
Development of improved radiotracers for PET (labeled with 18F and 11C) and SPECT (123I) 
with high specific uptake and selectivity for 5-HT2A receptors would therefore be very useful. 
Among the reported ligands for the 5-HT2A receptor[9] , the two structurally related 
compounds altanserin and MDL-100907 have relative high affinity and selectivity for the 5-
HT2A receptor compared to other serotonin receptors[10, 11] (chemical structures are shown 
in figure 4.5). 
 
 
Figure 4.5: 5-HT2A selective ligands  
 
[18F]-Altanserin (Ki(5-HT2A): 0.30 nM, 20-fold 2A/2C selectivity) and [11C]-MDL-100907 
(Ki(5-HT2A): 0.36 nM, 300-fold selectivity 2A/2C) have been developed for in vivo 
imaging[12, 13]. However, neither is fully satisfactory, owing to limitations of potency, 
selectivity or biological half-life.  
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Notably, the selectivity of altanserin for 5-HT2A over 5-HT2C is about 20-fold. Quantitative in 
vivo imaging of 5-HT2A receptors with [18F]-altanserin has been problematic because of 
lipophilic radiometabolites that cross the blood-brain barrier, and slow kinetics[14, 15, 16]. 
Although MDL-100907 has a high affinity and selectivity for the 5-HT2A receptor, its 
radiolabelling with short-lived 11C (half-life of 20 min) limits its suitability to short-term 
studies, particularly because this tracer demonstrates slow in vivo kinetics[17]. 
Prabhakaran et al also developed a [11C]-labeled ligand ([11C]-AC90179) for PET imaging of 
the 5-HT2A receptors, but due to lack of tracer binding and specific binding, this ligand could 
not be used for in vivo imaging[18]. 
[18F]-Setoperone was also used to image the 5-HT2A receptors in humans with PET[19]. Also 
ritanserin was labelled with [18F] and used as a 5-HT2A receptor tracer[20]. 
Recently, [11C]-MPM was developed by Kumar et al[21] as a potential PET ligand for the 5-
HT2A receptor. Partial specific binding to cerebellum and high aspecific binding limit the 
clinical usefulness of this radioligand. 
[123I]-R91150 (see chapter 3) is currently used in evaluating patient condition with several 
psychiatric conditions[22, 23]. Limitations observed with this tracer were high aspecific 
binding in vitro and in vivo, which makes binding assays rather problematic. 
 
A more ideal radioligand for clinical in vivo imaging of 5-HT2A receptors would have high 5-
HT2A potency (Ki < 1 nM) and selectivity (> 50-fold) toward other, particularly 5-HT 
receptors, and be radiolabeled with 18F (half-life of 110 min) or 123I (half-life of 13.2 h)[1]. 
Novel compounds were developed by Fu et al[1] based on common structural features of 
altanserin and MDL-100907 to provide a new series of 4’-substituted phenyl-4-
piperidinylmethanol and benzoyl-4-piperidine derivatives, of which the evaluated tracer [123I]-
3-I-CO is a member.  
 
Potency and selectivity at the 5-HT2A receptor depended significantly on the length of the 
alkyl link of the piperidine ring to a phenyl moiety. Generally, compounds with an ethylene 
bridge (n = 2 carbon atoms) to the second phenyl moiety have higher 5-HT2A potency than 
those with a methylene bridge (n = 1 carbon atom). Some of the ethylene-bridge compounds 
show high 5-HT2A potency but only limited selectivity, limiting their candidacy for brain-
imaging radioligand development[1].  
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The nature of the linking moiety to a second phenyl ring (carbonyl or methanol) or the para-
substituent on that ring (F or NO2) all yielded some compounds with relatively high 5-HT2A 
affinity. Also, in general, for the other phenyl ring, para-substituted iodinated derivatives were 
found to be less potent at the 5-HT2A receptors than the corresponding ortho- and meta-
substituted positional isomers. 
Reduction of the carbonyl-function leads to the formation of a racemic alcohol by virtue of 
the asymmetric center introduced in the structure by NaBH4 reduction. One enantiomer may 
be more potent, as suggested by the previous report that (R)-(+)MDL-100907 had 30-times 
greater selectivity to 5-HT2A over 5-HT2C receptors than the (S)-(-)-enantiomer[24]. 
As mentioned earlier, one of the most important criteria for a good 5-HT2A receptor tracer is 
the selectivity over another serotonin receptor subtype, the 5-HT2C receptor. For example, 
altanserin has a 5-HT2A/5-HT2C selectivity ratio of 20[1]. The selectivity ratio of [123I]-3-I-CO 
for the 5-HT2C receptor compared to the 5-HT2A receptor is a factor of 33 (Ki (5-HT2C) = 16.6 
nM). It was determined on PO-1C cells transfected with human 5-HT2C genes, using tritiated 
mesulergine (1.0 nM) as the ligand and clozapine (10 M) for the blank assay. Selectivity for 
the 5-HT2A receptor compared to the human 5-HT6 receptor is a factor of 100 (Ki (5-HT6) = 48.9 
nM). Selectivity for the 5-HT2A receptor compared to the human 5-HT7 receptor is a factor of 
17 (Ki (5-HT7) = 8.76 nM). For the serotonin 5-HT6 and 5-HT7 assays, tritiated LSD (1.0 nM, 
lysergic acid diethylamide) was used for the binding test and clozapine (10 M) for the 
blanks. 
Selectivity of (4-fluorophenyl)[1-(3-iodophenethyl)piperidin-4-yl]methanone over other 
neurotransmitter receptors was also evaluated. Especially selectivity over dopamine D2 
receptors is important For the dopamine class of receptors, affinity for the dopamine D2 
receptor was tested on rat caudate-putamen brain tissue using tritiated nemonapride (0.075 
nM) as ligand and haloperidol (10 m) for the blank test. Selectivity of 3-I-CO for the 5-HT2A 
receptor compared to the dopamine D2 receptor was a factor 100 (Ki (D2) = 51.8 nM) (Table 
4.3). 
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Receptor type Membrane source [3H]-ligand (nM) Blank (m) 
5-HT2r rat forebrain ketanserin (1,2) cinanserin (1,0) 
5-HT2Ah GF-62 cells ketanserin (1,2) altanserin (1,0) 
5-HT2Ch PO-1C cells mesulergine (1,0) clozapine (10) 
5-HT6h HD-6 cells LSD (1,0) clozapine (10) 
5-HT7h HD-7 cells LSD (1,0) clozapine (10) 
D2 rat caudate nemonapride (0,075) haloperidol (10) 
1 rat brain prazosin (0,20) phentolamine (2) 
2 rat brain prazosin (1,0) phentolamine (10) 
Table 4.3: 3-I-CO radioaffinity assay conditions for different neurotransmitter receptors 
(adapted from Fu et al [1], J. Med. Chem. 2002, 45, 2319-2324). 
 
Affinity for the adrenergic receptor types was tested on rat whole brain tissue samples using 
tritiated prazosin (0.2 – 1 nM) for the binding assay and phentolamine (2 – 10 M) for the 
blank assay (Table 4.3). Selectivity for the serotonin 5-HT2A receptor compared to the 
adrenergic 1 receptor was only a factor 10 (Ki (1) = 4.92 nM). Selectivity over the 
adrenergic 2 receptor was a factor 500 (Ki (2) = 244 nM). All Ki values tested for 3-I-CO 
are shown in table 4.4. 
 
 
 Table 4.4: Receptor affinities of 3-I-CO for different neurotransmitter receptor systems. 
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4.1.4. Objectives 
 
In this chapter we will present the synthesis of the precursor for radiolabelling and the 
radiosynthesis of [123I]-3-I-CO, along with its purification and quality control. The in vitro 
properties of [123I]-3-I-CO (specific activity, partition coefficient) will also be determined.  
The potential tracer will be evaluated in vivo, starting with NMRI mouse biodistribution 
studies to assess the potential of [123I]-3-I-CO to penetrate the blood-brain barrier.  
Regional brain biodistribution studies will be performed in larger animals (Sprague-Dawley 
rats) to evaluate if [123I]-3-I-CO does indeed bind to brain regions containing large amounts of 
5-HT2A receptors.  
Specificity of tracer binding in rat brain will be determined by a displacement study with a 
known 5-HT2A antagonist, ketanserin. Metabolite assays will be performed on the brain and 
blood of all species studies, to guarantee that the measured activity in brain tissue is due to 
unchanged [123I]-3-I-CO, and not to possible metabolites of the tracer. 
Since the goal of this research is to evaluate whether [123I]-3-I-CO could possibly be used as a 
5-HT2A receptor tracer in vivo, a pinhole SPECT imaging study will be performed with 
[123I]-3-I-CO in Sprague-Dawley rats. 
It was recently discovered that the brain uptake of many clinically used SPECT and PET 
tracers could be improved by blocking the effect of P-glycoprotein (Pgp), an efflux pump at 
the blood-brain barrier [25, 26, 27, 28, 29, 30, 31]. Therefore, the effect of blocking Pgp 
function (for example by administration of cyclosporin A) on the brain uptake and 
biodistribution of [123I]-3-I-CO will also be evaluated. Possible increased tracer metabolism 
under the influence of cyclosporin A administration will be excluded. The influence of 
cyclosporin A administration on the pinhole SPECT imaging studies in Sprague-Dawley rats 
will also be evaluated. 
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4.2. Precursor synthesis 
 
[123I]-(4-fluorophenyl)[1-(3-iodophenethyl)piperidin-4-yl]methanone ([123I]-3-ICO) was 
synthesized starting from the corresponding tributylstannyl-derivative (4-fluorophenyl)[1-(3-
tributylstannylphenethyl)piperidin-4-yl]methanone (6). The tributylstannyl-precursor was 
synthesized in four steps starting from 3-bromophenylacetic acid (1), which was 
commercially available (figure 4.6). 
 
 
Figure 4.6: Synthesis of (4-fluorophenyl)(1-(3-(tributylstannyl)phenethyl)piperidin-4-
yl)methanone (6) 
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3-Bromophenylacetic acid (1) was reduced to the alcohol 2-(3-bromophenyl)ethanol (2) with 
borohydride-tetrahydrofuran (figure 4.6). The alcohol function was replaced by bromine with 
phosphorus tribromide, resulting in 1-bromo-3-(2-bromoethyl)benzene (3). This brominated 
compound (3) was then coupled with 4-(4-fluorobenzoyl)piperidine (4) in a nucleophilic 
substitution reaction, yielding (4-fluorophenyl)(1-(3-bromophenethyl)piperidin-4-
yl)methanone (5). Finally, the bromine-atom of (5) was replaced by a tributylstannyl-group by 
reaction with hexabutylditin, and (4-fluorophenyl)(1-(3-(tributylstannyl)phenethyl)piperidin-
4-yl)methanone (6) was obtained. This tributylstannylprecursor (6) was used for the 
radiosynthesis of [123I]-(4-fluorophenyl)[1-(3-iodophenethyl)piperidin-4-yl]methanone. It was 
also used to synthesize the cold iodinated compound (7), used as a reference during quality 
control of the tracer. 
Compound (4), 4-(4-fluorobenzoyl)piperidine, was synthesized in a 4-step reaction sequence, 
starting from piperidine-4-carboxylic acid (4a) (figure 4.7). 
 
 
Figure 4.7: Synthesis pathway of 4-(4-fluorobenzoyl)piperidine (4). a) K2CO3, H2O, 0 °C, 
then benzoyl chloride, 0 °C  room temperature; b) SOCl2, CH2Cl2, 40 °C; c) AlCl3, 
fluorobenzene, CH2Cl2, 40 °C; d) HCl, H2O, 100 °C. 
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Piperidine-4-carboxylic acid (4a) was protected by N-acylation with benzoyl chloride to yield 
the corresponding benzamide 1-benzoylpiperidine-4-carboxylic acid (4b). This benzamide 
was treated with thionylchloride to obtain the chlorinated compound (4d), which was 
immediately used in an aluminium chloride catalyzed Friedel-Crafts reaction with 
fluorobenzene to obtain the compound (1-benzoylpiperidin-4-yl)(4-flurophenyl)methanone 
(4e). The N-benzoyl protecting group of (4e) was removed under acidic conditions to afford 
compound (4), 4-(4-fluorobenzoyl)piperidine. 
 
All chemicals and reagents were purchased from Sigma-Aldrich (St-Louis, MO, USA) or 
Acros Organics (Geel, Belgium) and were used without further purification unless specified 
otherwise. HPLC and flash chromatography solvents were purchased from Chemlab NV 
(Belgium). Organic reactions were monitored by normal phase thin layer chromatography 
(TLC) with UV detection at 254 nm where possible (TLC, Polygram Sil G/UV254, 200 m, 
Machery-Nagel, Germany). Purification of non-radioactive products was achieved with flash 
column chromatography on silica gel (240-400 mesh, 60 Å, Sigma-Aldrich, Belgium) using a 
glass column (36 mm x 460 mm, Büchi) and a Waters LC-8A preparative HPLC pump at a 
flow rate of 60 ml/min. Solvent systems are indicated in the text. For mixed solvent systems, 
ratios are given with respect to volumes. 
1H-NMR spectra were recorded on a Varian 300 MHz FT-NMR spectrometer (Laboratory for 
Medicinal Chemistry, Ghent University, Belgium). Chemical shifts were recorded in ppm () 
relative to an internal tetramethylsilane (TMS) standard in either acetone-d6, dimethyl-
sulfoxide-d6 or chloroform-d3. Mass spectrometry was performed on a Waters Micromass 
ZMD mass-spectrometer with an electrospray-ionization (ESI) probe. Samples were recorded 
in the positive (MH+) mode. Samples were dissolved in methanol at a concentration of 0.050 
mg/ml. No carrier added (n.c.a.) [123I]-NaI (formulated in 0.05 M NaOH) was purchased from 
GE Healthcare Biosciences (Diegem, Belgium). 
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4.2.1. Synthesis of 2-(3-bromophenyl)ethanol (2) 
 
2-(3-Bromophenyl)ethanol (2) was synthesized from 3-bromophenylacetic acid (1) using a 
reduction with borohydride-tetrahydrofuran complex (borane, BH3.THF). The hydride 
addition reaction mechanism is shown in figure 4.8. 
 
 
Figure 4.8: Mechanism of 3-bromophenylacetic acid reduction with BH3 
 
3-Bromophenylacetic acid (1) (5g, 23 mmol) was added dropwise to a cooled solution of 
borohydride-tetrahydrofuran complex (BH3.THF, 35 mmol) under nitrogen atmosphere. The 
mixture was slowly warmed to room temperature and stirred for 2h. The reaction was 
quenched by addition of a 50/50 mixture of water and acetic acid (50 ml). THF was removed 
by evaporation under reduced pressure. Saturated NaHCO3 solution (100 ml) was added, and 
the mixture was extracted with dichloromethane (3 x 100 ml). The organic phases were 
combined, washed once with saturated NaCl solution (100 ml) and dried over anhydrous 
sodium sulphate. After filtration, the solvent was removed by evaporation under reduced 
pressure. A light yellow oil was obtained (3.7g, 80%) which was used without further 
purification. 
 
1H-NMR (d3-CH3Cl, ): 7.40-7.25 (m, 2H, 2-ArH and 4-ArH), 7.15-7.05 (m, 2H, 5-ArH and 
6-ArH), 4.78 (t, 1H, -OH), 3.86 (m, 2H, R-CH2-OH), 2.74 (t, 2H, Ar-CH2-R).  
ESI-MS: 183 (MH+ minus H2O). 
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4.2.2. Synthesis of 1-bromo-3-(2-bromoethyl)benzene (3) 
 
1-Bromo-3-(2-bromoethyl)benzene (3) was synthesized by reacting 2-(3-
bromophenyl)ethanol (2) with phosphorus tribromide. The reaction mechanism is shown in 
figure 4.9. First an ester is formed with PBr3. After protonation, this ester becomes a good 
leaving group for nucleophilic substitution with the bromide anion. Finally, 3 moles of 
brominated compound (3) and 1 mole of H3PO3 are formed for every mole of PBr3 used 
(figure 4.9). 
 
 
Figure 4.9: Bromination of 2-(3-Bromophenyl)ethanol (2) 
 
2-(3-Bromophenyl)ethanol (2) (4g, 20 mmol) was cooled to 0°C under nitrogen atmosphere, 
and phosphorus tribromide (6.8g, 25 mmol, 2.4 ml) was added dropwise. The reaction was 
stirred under nitrogen atmosphere for 16h. The mixture was poured onto crushed ice (100g). 
Saturated NaHCO3 solution (100 ml) was added and the mixture was stirred for 30 min. The 
product was extracted with dichloromethane (3 x 100 ml).  
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The combined extracts were washed with saturated NaCl solution (100 ml). The organic 
phase was dried over anhydrous sodium sulphate, filtered and evaporated under reduced 
pressure. The residue was dissolved in dichloromethane (200 ml) and filtered through silica 
gel. After removal of the solvent under reduced pressure, a slightly orange oil was obtained 
(4.7g, 90%). 
 
1H-NMR (d6-DMSO, ): 7.30-7.20 (m, 2H, 2-Ar-H and 4-Ar-H), 7.10-7.0 (m, 2H, 5-Ar-H 
and 6-Ar-H), 3.63 (t, 2H, R-CH2-Br), 3.05 (t, 2H, Ar-CH2-R). 
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4.2.3. Synthesis of (1-(3-bromophenethyl)piperidin-4-yl)(4-fluorophenyl) 
methanone (5) 
 
(1-(3-Bromophenethyl)piperidin-4-yl)(4-fluorophenyl)methanone (5) was synthesized by a 
nucleophilic substitution reaction, following an SN2 reaction mechanism (figure 4.10). 
 
 
Figure 4.10: Synthesis of (1-(3-bromophenethyl)piperidin-4-yl)(4-fluorophenyl)methanone 
 
To a solution of 4-(4-fluorobenzoyl)piperidine (4) (2.5g, 12 mmol) in dry dimethylformamide 
(DMF, 40 ml) was added 1-bromo-3-(2-bromoethyl)benzene (3) (4g, 15 mmol) under 
nitrogen atmosphere, followed by K2CO3 (4.2g, 30 mmol). The resulting mixture was heated 
to 90°C in an oil bath and stirred for 18h. After cooling to room temperature, the reaction 
mixture was filtered over celite and the filter cake was washed with DMF (2 x 10 ml). The 
combined filtrate was dried over anhydrous sodium sulphate, filtered, and stripped of solvent 
under reduced pressure. The residue was purified with flash column chromatography using 
dichloromethane/methanol/triethylamine (90/10/5) as eluent. An orange solid was obtained 
(60%). 
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1H-NMR (d6-DMSO, ): 8.10 (m, 2H, 2-Ar-F and 6-Ar-F), 7.37 (m, 2H, 3-Ar-F and 5-Ar-F), 
7.30-7.25 (m, 2H, 2-Ar-Br and 4-Ar-Br), 7.10-7.0 (m, 2H, 5-Ar-Br and 6-Ar-Br), 3.0 (q, 1H, 
F-Ar-CO-CH-R2), 2.70-2.65 (m, 4H, Br-Ar-CH2-CH2-R), 2.24 (m, 4H, N-(CH2)2), 1.65 (m, 
4H, F-Ar-CO-CH-(CH2)2-R). 
ESI-MS: 390/392 (MH+). 
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4.2.4. Synthesis of (4-fluorophenyl)(1-(3-tributylstannylphenethyl)piperidin-
4-yl) methanone (6) 
 
(1-(3-bromophenethyl)piperidin-4-yl)(4-fluorophenyl)methanone (5) was treated in toluene 
with hexabutylditin and tetrakistriphenylphosphinepalladium as a catalyst at 120°C for 18h, to 
yield (4-fluorophenyl)(1-(3-tributylstannyl-phenethyl)piperidin-4-yl)methanone (6) (figure 
4.11). 
 
 
Figure 4.11: Synthesis of (4-fluorophenyl)(1-(3-tributylstannyl-phenethyl)piperidin-4-
yl)methanone (6) 
 
The reaction mechanism is a Stille type coupling, in different steps (figure 4.12): the first step 
in the cycle is an oxidative addition of Pd0 to the carbon-bromine bond of (1-(3-
bromophenethyl)piperidin-4-yl)(4-fluorophenyl)methanone (5) (Pd0  PdII). The second step 
is a transmetallation with hexabutylditin, replacing the bromine for a tributylstannyl group. 
This is followed by isomerisation  and a reductive elimination step, in which the carbon-tin 
bond is formed. Simultaneously, PdII is reduced back to Pd0. 
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Figure 4.12: Reaction mechanism of Stille coupling 
 
 (1-(3-bromophenethyl)piperidin-4-yl)(4-fluorophenyl)methanone (5) (100mg, 0.25 mmol) 
was dissolved in anhydrous toluene (10 ml). Under nitrogen atmosphere a catalytic amount of 
tetrakistriphenylphosphinepalladium (10 mg) was added, followed by hexabutylditin (0.4 ml, 
0.75 mmol). The reaction mixture was heated in the dark to 120°C for 18h under nitrogen 
atmosphere. After cooling to room temperature, the mixture was filtered over celite. The filter 
cake was washed with anhydrous toluene (2 x 5 ml) and the combined filtrates were 
evaporated under reduced pressure. The residue was purified using preparative thin layer 
chromatography with dichloromethane/methanol/triethylamine (90/10/5) as the eluent. The 
zone containing the product was marked, the silica gel scraped off and extracted with 
methanol (50 ml). Silica gel was removed by filtration and the solvent was evaporated under 
reduced pressure to yield (4-fluorophenyl)(1-(3-tributylstannyl-phenethyl)piperidin-4-
yl)methanone (6) (45 mg, 30%). 
 
1H-NMR (d6-DMSO, ): 8.10 (m, 2H, 2-Ar-F and 6-Ar-F), 7.37 (m, 2H, 3-Ar-F and 5-Ar-F), 
7.2-7.1 (m, 4H, Sn(Bu)3-Ar-H), 3.0 (q, 1H, F-Ar-CO-CH-R2), 2.70-2.65 (m, 4H, Br-Ar-CH2-
CH2-R), 2.24 (m, 4H, N-(CH2)2), 1.65 (m, 4H, F-Ar-CO-CH-(CH2)2-R), 1.2-0.8 (m, 27H, 
tributylstannyl).  
ESI-MS: 602 (MH+). 
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4.2.5. Synthesis of (4-fluorophenyl)(1-(3-iodophenethyl)piperidin-4-yl) 
methanone (7) 
 
The reference compound (4-fluorophenyl)(1-(3-iodophenethyl)piperidin-4-yl) methanone (7) 
was synthesized by treatment of (4-fluorophenyl)(1-(3-tributylstannylphenethyl)piperidin-4-
yl)methanone (6) with iodine in chloroform. The reaction mechanism, an electrophilic 
aromatic substitution reaction, is shown in figure 4.13. In this case iodine acts as an 
electrophile (I+---I-), and the tributylstannyl group is a good leaving group. Reaction is 
quenched by the addition of sodium metabisulphite. 
 
 
Figure 4.13: Cold iodination of (4-fluorophenyl)(1-(3-tributylstannyl-phenethyl)piperidin-4-yl 
methanone 
 
(4-fluorophenyl)(1-(3-tributylstannylphenethyl)piperidin-4-yl)methanone (6) (50mg, 0.08 
mmol) was dissolved in anhydrous chloroform (10 ml) under nitrogen atmosphere. Iodine in 
chloroform (0.2 ml, 1M solution, 0.2 mmol) was added dropwise. The mixture was stirred for 
1h at room temperature. The reaction was quenched by addition of sodium metabisulphite 
(1.5 ml, 5% solution in water). The resulting mixture was stirred for 30 min and the phases 
were separated. The aqueous phase was extracted with chloroform (3 x 10 ml).  
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The combined organic phases were washed with brine (10 ml), dried over anhydrous sodium 
sulphate and filtered. The solvent was removed under reduced pressure and the residue was 
purified with preparative TLC using dichloromethane/methanol/triethylamine (90/10/5) as 
eluent. The band corresponding to the product was scraped off and extracted with methanol 
(50 ml). After solvent removal under reduced pressure, an orange solid was obtained (11 mg, 
0.025 mmol, 30%). 
 
1H-NMR (d6-DMSO, ): 8.10 (m, 2H, 2-Ar-F and 6-Ar-F), 7.60-7.50 (m, 2H, 2-Ar-I and 4-
Ar-I), 7.37 (m, 2H, 3-Ar-F and 5-Ar-F), 7.11-7.0 (m, 2H, 5-Ar-I and 6-Ar-I), 3.0 (q, 1H, F-
Ar-CO-CH-R2), 2.70-2.65 (m, 4H, Br-Ar-CH2-CH2-R), 2.24 (m, 4H, N-(CH2)2), 1.65 (m, 4H, 
F-Ar-CO-CH-(CH2)2-R). 
ESI-MS: 438 (MH+). 
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4.2.6. Synthesis of 4-(4-fluorobenzoyl)piperidine (4) 
 
The total synthesis of 4-(4-fluorobenzoyl)piperidine is shown above in figure 4.7. 
 
4.2.6.1. Synthesis of 1-benzoylpiperidine-4-carboxylic acid (4b) 
 
1-Benzoylpiperidine-4-carboxylic acid (4b) was synthesized by protection of piperidine-4-
carboxylic acid (4a) with a benzoyl function. The reaction mechanism (shown in figure 4.14) 
is a nucleophilic acyl substitution reaction, where the chloride anion acts as a good leaving 
group. The generated HCl is neutralised by K2CO3 as soon as it forms. 
 
 
Figure 4.14: Synthesis of 1-benzoylpiperidine-4-carboxylic acid (4b) 
 
Piperidine-4-carboxylic acid (4a, 25 g, 0.2 mol) was dissolved in distilled H2O (500 ml) and 
potassium carbonate (K2CO3, 64g, 0.45 mol) was added. The mixture was cooled to 0 °C. 
Benzoyl chloride (24,3 ml, 0.2 mol) was added dropwise under nitrogen atmosphere and the 
mixture was stirred for 30 min at 0 °C. The mixture was slowly warmed to room temperature 
and stirred for 2 h. At the end of the reaction, concentrated HCl (65 ml, 37% v/v in water) was 
added slowly. The mixture was placed in the fridge overnight. The precipitate was filtered off 
and dried, yielding 1-benzoylpiperidine-4-carboxylic acid (4b, 42 g, 90% yield).  
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4.2.6.2. Synthesis of 1-benzoylpiperidine-4-carbonyl chloride (4c) 
 
1-Benzoylpiperidine-4-carboxylic acid (4b) was chlorinated by treatment with thionyl 
chloride to obtain 1-benzoylpiperidine-4-carbonyl chloride (4c). The reaction mechanism is 
shown in figure 4.15 and takes place with formation of an intermediate reactive 
chlorosulphite-ester (*). 
 
 
Figure 4.15: Synthesis of 1-benzoylpiperidine-4-carbonyl chloride (4c) 
 
1-Benzoylpiperidine-4-carboxylic acid (4b, 42 g, 0.175 mol) was dissolved in 
dichloromethane (125 ml). Thionyl chloride (SOCl2, 20 ml, 0.275 mol) was added dropwise 
to the solution. When SOCl2 addition was complete, the mixture was slowly heated and 
refluxed under nitrogen for 2 h. After cooling to room temperature the solvent and excess 
reagent were evaporated under reduced pressure. The crude residue obtained, 1-
benzoylpiperidine-4-carbonyl chloride (4c), was used without further purification. 
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4.2.6.3. Synthesis of (1-benzoylpiperidin-4-yl)(4-fluorophenyl)methanone (4e) 
 
1-Benzoylpiperidine-4-carbonyl chloride (4c) was used in an aluminum chloride catalyzed  
Friedel-Craft’s acylation reaction with fluorobenzene to obtain (1-benzoylpiperidin-4-yl)(4-
fluorophenyl)methanone (4e). The reaction mechanism of this acylation reaction is shown in 
figure 4.16. Only the para-fluoro compound is formed because of the ortho/para directing 
effect of the fluorine atom. 
 
 
Figure 4.16: Friedel-Craft’s acylation of fluorobenzene and 1-benzoylpiperidine-4-carbonyl 
chloride (4c) 
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The crude acid chloride 1-benzoylpiperidine-4-carbonyl chloride (4c, 42g, 0.175 mol) was 
dissolved in dichloromethane (80 ml). Aluminum chloride (AlCl3, 61 g, 0.45 mol) was 
suspended in dichloromethane (80 ml) under nitrogen. Fluorobenzene (25 ml, 0.45 mol) was 
quickly added to the reaction mixture at room temperature. The mixture was cooled to 0 °C, 
stirred and the crude acid chloride 1-benzoylpiperidine-4-carbonyl chloride (4c, 42g, 0.175 
mol dissolved in 80 ml of dichloromethane) was added dropwise under nitrogen. The mixture 
was slowly warmed to room temperature and stirred for 2 h. The reaction mixture was poured 
on ice (500 g) and extracted with dichloromethane (3 x 250 ml). The organic phase was 
washed with HCl (1N in water, 200 ml), saturated NaHCO3-solution (200 ml) and water (100 
ml). The organic layer was dried with anhydrous sodium sulphate, filtered and evaporated 
under reduced pressure. The residue was recrystallized from tert-butyl methyl ether and (1-
benzoylpiperidin-4-yl)(4-fluorophenyl)methanone (4e, 50g, 90 % yield) was obtained. 
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4.2.6.4. Synthesis of 4-(4-fluorobenzoyl)-piperidine (4) 
 
This reaction is a deprotection reaction, in which the protecting benzoyl function is 
hydrolysed from the piperidine nitrogen under acidic conditions to obtain the title compound, 
4-(4-fluorobenzoyl)-piperidine (4). The hydrolysis reaction mechanism is shown in figure 
4.17. 
 
 
Figure 4.17: Acid hydrolysis of (1-Benzoylpiperidin-4-yl)(4-fluorophenyl)methanone (4e) 
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(1-Benzoylpiperidin-4-yl)(4-fluorophenyl)methanone (4e, 50g, 0.16 mol) was dissolved in 
HCl (200 ml, 37% in water) and water (100 ml). The resulting solution was refluxed under 
nitrogen for 6 h. After cooling to room temperature, the mixture was extracted with tert-butyl 
methyl ether (150 ml). The aqueous phase was cooled to 0 °C, basified with 5M sodium 
hydroxide solution and extracted with dichloromethane (3 x 100 ml). The organic phase was 
washed once with water (100 ml) and once with brine (100 ml). The organic layer was dried 
over anhydrous sodium sulphate, filtered and evaporated under reduced pressure. The residue 
was dissolved in ethanol (100 ml) and HCl (1M solution in diethylether, 100 ml) was added at 
15 °C. The mixture was allowed to precipitate at 15 °C for 12 h. The mixture was filtered and 
4-(4-fluorobenzoyl)-piperidine (4) was obtained (16.5 g, 50 %). 
 
1H-NMR (d6-DMSO, ): 8.11 (m, 2H, 2-Ar-F and 6-Ar-F), 7.35 (2H, m, 3-Ar-F and 5-Ar-F), 
3.74 (m, 1H, F-Ar-CO-CH), 3.31-3.24 (m, 4H, H-N-(CH2)2-R), 2.48 (s, 1H, R2-N-H), 1.76-
1.92 (m, 4H, F-Ar-CO-CH-CH2)2-R).  
ESI-MS: 208 (MH+). 
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4.3. Radiolabelling 
 
4.3.1. Methods 
 
[123I]-(4-Fluorophenyl)(1-(3-iodophenethyl)piperidin-4-yl)methanone ([123I]-3-I-CO) was 
labelled with 123I using an electrophilic iododestannylation on the tributylstannylprecursor (6). 
Chloramine-T was used as an oxidant for the in situ oxidation of the radioiodide. Sodium 
metabisulphite was used to terminate the reaction. The reaction scheme is shown in figure 
4.18. 
 
 
Figure 4.18: Radiosynthesis of [123I]-3-I-CO (8). (a) (i) Na123I, 0.01N NaOH, ethanol, (ii) 
acetic acid, chloramine T, 10 min, (iii) NaHS03, 85%, radiochemical purity > 95%. 
 
The mechanism of the radioiodination reaction is an electrophilic aromatic substitution 
reaction of the tributylstannyl-compound (6) and is shown in figure 4.19. The electrophilic 
species is the iodonium ion H2OI+, which is formed in situ and reacts with the precursor (6) in 
an electrophilic substitution reaction, to yield the iodinated tracer [123I]-3-I-CO (8). 
Chloramine-T is used as the oxidant in this reaction, to oxidise [123I]-I- to [123I]-I+. In reality, 
the oxidative species is hypochlorous acid (HOCl), formed by the hydrolysis of N-chloro-p-
toluenesulphonamide (= chloramine-T) in acidic medium. The reaction is quenched by the 
addition of sodium metabisulphite (NaHSO3), used to remove the excess of chloramine-T. 
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Figure 4.19: Radioiodination of the tributylstannyl precursor (6) 
 
The precursor (6) (100 g, 0.16 mol) was dissolved in absolute ethanol (50 l). No carrier 
added (nca) [123I]-NaI (in 0.05 M sodium hydroxide, 5 - 30 l, 37 - 1000 MBq), chloramine-T 
(15 l, 18.8 mg/ml solution in water) and glacial acetic acid (20 l) were added. The 
radiolabelling proceeded for 10 min at room temperature. The reaction was quenched by the 
addition of sodium metabisulphite (15 l, 19 mg/ml solution in water). HPLC mobile phase 
(100 l, 50/50 acetonitrile/phosphate buffer pH7) was added. The mixture was injected onto a 
reversed-phase C18 HPLC column (Alltech Apollo C18 7 x 250 mm) for purification and 
eluted with 50/50 acetonitrile/0.02M phosphate buffer pH7 as eluent at a flow rate of 4 
ml/min. The fraction corresponding to [123I]-3-I-CO (TR = 70 min) was collected and diluted 
with water for injection to decrease the concentration of acetonitrile to maximum 10%.  
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The diluted mixture was passed over a C18-cartridge (Alltech Maxi-Clean SPE Prevail C18 
Sep-PAK previously activated with 1 ml methanol and rinsed with 1 ml of water). The 
cartridge was rinsed with water (5 ml) and the tracer was eluted with absolute ethanol (1 ml). 
Ethanol was evaporated under a nitrogen flow, and the tracer was redissolved in sterile 5% 
ethanol in water. The solution was sterilized by sterile filtration over a 0.22 m filter 
(Schleicher & Schuell, FP 013/AS 0.22 m filter) for use in biodistribution and brain studies. 
A typical chromatogram of a [123I]-3-I-CO synthesis run is shown in figure 4.20. 
 
 
Figure 4.20: HPLC Chromatogram of [123I]-3-I-CO synthesis. The UV-chromatogram is 
shown in the upper part of the figure, the radiochromatogram can be found in the lower part. 
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4.3.2. Results 
 
Radiochemical purity of the tracer was determined by re-injecting a tracer aliquot on the same 
HPLC-system as described above (but with a 55/45 acetonitrile/buffer mixture as eluent). 
Radiochemical yield of the radioiodination was 85% ± 5%. Radiochemical purity was always 
>95% as determined on HPLC. A typical quality control chromatogram is shown in figure 
4.21. 
 
 
Figure 4.21: HPLC chromatogram of [123I]-3-I-CO quality control. The upper part of the 
figure shows the UV-chromatogram; the radiochromatogram is shown in the lower part. 
 
Stability of the tracer was tested by incubating the tracer (± 100 KBq) at room temperature in 
phosphate buffered saline solution (PBS buffer, pH 7.4). Aliquots of the tracer solution were 
taken at different time points and injected onto the same HPLC system as described above. 
Radiochemical purity of the tracer solution remained >95% until 48 hours after synthesis. 
Varying amounts of radioactivity were used in this synthesis. We produced up to 20 mCi of 
[123I]-3-I-CO in one synthesis and purification run, which is more then enough for possible 
clinical SPECT imaging studies with the tracer in humans. 
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4.4. Measurement of partition coefficient (LogP) and specific 
activity of [123I]-3-I-CO 
 
4.4.1. Determination of LogP 
 
4.4.1.1. Methods 
 
The partition coefficient of the tracer [123I]-3-I-CO was me assured according to the ‘shake 
flask’ method[32]. [123I]-3-I-CO (30 l, 0.1 mCi) was added to a tube containing n-octanol (5 
ml) and phosphate buffered saline (PBS buffer, pH = 7.4, 5 ml). The tube was shaken in a 
vortex mixer for 5 min followed by centrifugation for 5 min. After separation of the layers, 
the aqueous layer was discarded to remove possible free iodide, and fresh PBS-buffer (5 ml) 
was added to the tube. The tube was vortexed and centrifuged; 0.5 ml aliquots of both phases 
were taken and counted for radioactivity with an automated gamma counter (Cobra 
Autogamma, five 1 in X 1 in NaI(Tl) crystals, Packard Canberra). All radioactivity 
measurements were corrected for decay. The aqueous phase in the tube was discarded, and 
fresh PBS buffer (4.5 ml) was added. The tube was vortexed and centrifuged, aliquots were 
taken and counted, and the aqueous layer was again discarded. This process was repeated 
once more after addition of fresh PBS buffer (4 ml). All experimental measurements were 
performed in triplicate, and mean ± standard deviation values are indicated. 
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4.4.1.2. Results 
 
The partition coefficient P was calculated as: P = (counts/g in n-octanol)/(counts/g in PBS). 
A log P value of 3.10 ± 0.10 was obtained. An ideal log P value should be between 2 and 3 
for optimal brain penetration of a given molecule. Higher log P values implicate a risk of 
increased aspecific binding, due to lipophilicity issues. Nevertheless, a log P value of 3.10 
should provide adequate blood-brain barrier penetration for our animal biodistribution studies, 
without compromising lipophilicity too much. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Synthesis of [123I]-3-I-CO  157 
4.4.2. Specific activity determination 
 
The specific activity of a tracer can be defined as the amount of radioactivity present per mole 
of product. Specific activity is usually expressed as Ci/mol. 
Tracer specific activity is usually determined using HPLC: the peak area of the tracer in the 
UV-chromatogram (after injection of a known amount of tracer radioactivity) is compared to 
the peak area values of a standard curve, obtained by injection of varying amounts of cold 
unlabelled product. 
In this case no detectable carrier UV-signal could be obtained after HPLC injection of the 
[123I]-3-I-CO synthesis mixture. A standard curve was obtained by injecting known amounts 
of cold 3-I-CO and recording the UV peak area. Decreasing amounts of cold 3-I-CO were 
used, until there was no more UV signal present. This lowest concentration was used to 
calculate a minimum specific activity. It was not possible to determine the real specific 
activity of our [123I]-3-I-CO tracer. Only an minimum specific activity could be obtained by 
determining the detection limit of the used UV-detector (Waters 2487 UV detector). 
Nevertheless, the use of no carrier added [123I]-NaI with very high specific activity 
(approaching the theoretical specific activity value of 22000 Ci/mol for [123I]-iodide) ensures 
that the labelled end product will be of high specific activity, probably approaching the 
theoretical value because no carrier should be present in any of the reagents/recipients used 
during radiosynthesis. 
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5. In vivo evaluation in rodents of [123I]-3-I-CO 
 
5.1. Evaluation of [123I]-3-I-CO in NMRI mice 
 
5.1.1. Introduction 
 
Several conditions have to be met before [123I]-3-I-CO can be considered as a potential 5-
HT2A receptor tracer. The molecule must be able to pass through the blood-brain barrier and 
bind to the 5-HT2A receptor dense regions with good specificity and selectivity. Aspecific 
binding should be minimal and tracer selectivity is important. Besides good in vitro 
characteristics, the in vivo characteristics should be optimal. 
To verify the ability of [123I]-3-I-CO to pass through the blood-brain barrier, a mouse 
biodistribution study was performed. This study will also provide information about the in 
vivo pharmacokinetic behaviour of the compound. A blocking study with a known specific 5-
HT2A antagonist (ketanserin) will be performed to demonstrate specific binding to the 5-HT2A 
receptor in vivo. 
It is also important to verify possible metabolism of the tracer into labelled lipophilic 
metabolites, because these can also cross the blood-brain barrier and interfere with brain 
imaging. Possible metabolism of [123I]-3-I-CO will be verified by analyzing mouse blood and 
brain samples on HPLC.  
Male NMRI (Naval Medical Research Institute) mice were purchased from Charles River 
Laboratories. All test animals were allowed to acclimatise in the lab prior to their use in 
biodistribution studies. All animal experiments were conducted following the principles of 
laboratory animal care and the Belgian law regulations laboratory test animal well-being. Our 
research protocols were pre-approved by the Gent University ethical committee (approval 
number 05/14). 
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5.1.2. Biodistribution study in NMRI mice 
 
5.1.2.1. Methods 
 
A biodistribution study with [123I]-3-I-CO was performed in male NMRI mice. The 
radioligand was dissolved in ethanol/water (10/90 v/v), and the radioactivity concentration 
was adjusted to 200 Ci/ml of injectable tracer solution. Adult male NMRI mice (weight 20 – 
25 g) were injected in the tail vein with [123I]-3-I-CO (20 Ci dissolved in 100 l). At various 
time points post injection (30 sec, 1 min, 2 min, 5 min, 10 min, 30 min, 1 hour, 2 h and 6 h, n 
= 3 per time point) the animals were sacrificed by decapitation. Blood was collected and the 
animals were rapidly dissected. Blood samples and organs of interest were weighed and 
counted for radioactivity in an automated gamma counter. Aliquots of the injected tracer 
solution (n = 3) were weighed and counted for radioactivity to determine the injected 
radioactivity dose received by the animals. Results were corrected for decay and tissue 
radioactivity concentrations were expressed as a percentage of the injected dose per gram of 
tissue (% ID/g tissue, mean ± standard deviation). 
 
 
5.1.2.2. Results and discussion 
 
A summary of the radioactivity concentrations for all organs at all time points studied is 
shown in table 5.1. Radioactivity concentrations were decay corrected and are expressed as a 
percentage of the injected dose per gram of tissue (% ID/g tissue). Mean ± standard deviation 
values are indicated (n = 3 animals per time point).  
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Radioactivity concentrations for [123I]-3-I-CO in blood and brain of NMRI mice are shown in 
figure 5.1. 
 
 
Figure 5.1: Biodistribution of [123I]-3-I-CO in brain and blood of male NMRI mice. Mean ± 
standard deviation (n = 3 per time point). 
 
It is clear from figure 5.1 that the radioactivity concentration of [123I]-3-I-CO in brain is 
higher than the concentration in blood, at all time points studied. This indicates that [123I]-3-I-
CO readily crosses the blood-brain barrier. A maximum concentration of 6.26 % ± 1.36 % 
ID/g tissue was obtained 10 min post injection.. At 1 h post injection, the radioactivity 
concentration of [123I]-3-I-CO in mouse brain was 1.94 % ± 0.37% ID/g tissue. The ratio 
brain-to-blood was always higher than 1 (a ratio of 3 was observed 5 min post injection, 
decreasing to 1.3 at 2 h post injection).  
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The brain uptake of [123I]-3-I-CO was compared with the total brain uptake in mice of a 
clinically used 5-HT2A tracer, [123I]-R91150. For [123I]-R91150, total brain uptake in mice was 
0.73 ± 0.01 % ID/g tissue at 1 h after injection[1]. Compared to these values, the total brain 
uptake of [123I]-3-I-CO is high. When comparing the brain-to-blood ratios, the situation is 
different. Brain-to-blood ratios of 1.5 were obtained at the earliest time points for [123I]-
R91150, increasing to 2 at 2 hours after injection. Brain-to-blood ratios varied between 1.8 
and 3 for the earliest time points in the [123I]-3-I-CO biodistribution study. A ratio of 1.25 was 
obtained for the study at 1 and 2 hours after injection of [123I]-3-I-CO. 
Although the absolute brain uptake of [123I]-3-I-CO in NMRI mice was increased compared to 
the [123I]-R91150 mouse biodistribution study, the blood radioactivity concentration was also 
higher, resulting in a decreased brain-to-blood ratio for the [123I]-3-I-CO study. Also, [123I]-3-
I-CO brain radioactivity uptake decreased quite rapidly over time compared to the results 
obtained with [123I]-R91150, where a slower decrease in brain radioactivity concentration 
could be observed. 
 
The biodistribution pattern of [123I]-3-I-CO in blood, heart and lungs of male NMRI mice is 
shown in figure 5.2. 
 
 
Figure 5.2: Biodistribution of [123I]-3-I-CO in NMRI mice. Mean ± s.d. (n = 3 per time point). 
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Uptake of the tracer [123I]-3-I-CO in heart and lungs of male NMRI mice was high initially 
(lungs: 28.6% ± 1.95% ID/g tissue at 1 min post injection and 18% ± 2.72% % ID/g tissue at 
5 min post injection; heart: 10.9% ± 0.77% % ID/g tissue at 1 min post injection and 4.83% ± 
1.41% % ID/g tissue at 5 min post injection), but there was a rapid wash-out of radioactivity 
from these organs (lungs: 5.40% ± 0.46% % ID/g tissue at 30 min post injection; heart: 2.11% 
± 0.38% ID/g tissue at 30 min post injection), as shown in figure 5.2. The radioactivity 
concentration curves in these organs are probably a reflection of the blood radioactivity 
concentration curve. 
 
A high initial uptake of [123I]-3-I-CO was seen in the liver: a maximum uptake of 21.7% ± 
3.29% ID/g tissue was found at 10 min post injection. The radioactivity gradually decreased 
to 4.47% ± 0.96% ID/g tissue at 6 h post injection. Approximately the same washout pattern 
could be found in the kidneys: a maximum uptake of radioactivity was seen at 2 min post 
injection (19.2% ± 1.01% ID/g tissue), and this decreased to 3.01% ± 0.84% ID/g tissue. 
 
Uptake in the intestines was initially low, but gradually increased over time: 3.29% ± 0.39% 
ID/g tissue at 2 min for the small intestines, 1.45% ± 0.40% ID/g tissue at 2 min for the large 
intestines. This activity increased to 19.0% ± 4.49% ID/g tissue at 2 h post injection for small 
intestines and 4.21% ± 3.16% ID/g tissue at 2 h post injection for the large intestines. The 
relatively high uptake in the intestines suggests that [123I]-3-I-CO is at least partly biliary 
excreted.  
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5.1.3. Metabolite analysis in  NMRI mice 
  
5.1.3.1. Methods 
 
Male NMRI mice (weighing 20 - 25g, n = 3) were injected in the tail vein with [123I]-3-I-CO 
(100 Ci dissolved in ethanol/water 10/90 v/v). At 30 min post injection, the animals were 
sacrificed by decapitation. Blood was collected and the animals were rapidly dissected. Blood 
samples were centrifuged for 3 min at 3000g and the pellet was discarded. Mouse plasma 
(200 l) was mixed with acetonitrile (800 l) and the mixture was vortexed for 30 s, followed 
by centrifugation for 3 min at 3000g. The supernatant (500 l) was analysed on HPLC. 
The brain was transferred to a tube and acetonitrile (2 ml) was added. The mixture was cooled 
on ice, homogenized for 30 sec using a mixer (Ultra Turrax T18 basic, IKA Works Inc, USA, 
setting 5) and finally centrifuged at 3000g for 3 min. The supernatant (500 l) was analysed 
on HPLC. An Alltech Econosil C18 column (250 mm x 10 mm; 10 m particle size) was used. 
The mobile phase was a mixture of ethanol and buffer (60/40 v/v, 0.02 M phosphate buffer 
pH 7.4) at a flow rate of 5 ml/min. A fraction collector was placed at the end of the HPLC 
column, and the eluate was collected in fractions of 5 ml (= 1 min). The fractions were then 
counted for radioactivity with an automated gamma counter (Packard Canberra, five 1”x1” 
NaI(Tl) crystals). The retention time (tR) of the tracer was 25 min. 
The above extraction method was validated by repeating the procedure with animals not 
treated with the tracer [123I]-3-I-CO. Blood and brain from non-treated mice were collected in 
heparinised tubes. The blood was centrifuged at 3000g for 3 min, and [123I]-3-I-CO (1 Ci) 
was added to 200 l of plasma (= ‘spiking’ of the plasma). Acetonitrile (800 l) was added, 
and the mixture was vortexed for 30 sec and centrifuged for 3 min at 3000g. Pellet and 
supernatant were separated and counted for radioactivity. To the brain samples acetonitrile (2 
ml) and [123I]-3-I-CO (1 Ci) were added, the mixture was mixed for 30 sec and centrifuged 
for 3 min at 3000g. Pellet and supernatant were separated and counted for radioactivity in an 
automated gamma counter.  
The extraction efficiency (extraction yield) was expressed as percentage of total activity 
found in the supernatant compared to the total amount of radioactivity present in the tissue or 
blood sample.  
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To exclude the formation of possible [123I]-3-I-CO metabolites by the extraction method, 
aliquots of the above supernatants of brain and blood were also injected on the same HPLC 
system. An aliquot of authentic [123I]-3-I-CO tracer solution was first injected to determine 
the retention time of unmetabolised [123I]-3-I-CO. 
 
 
5.1.3.2. Results 
 
Extraction yield results were always > 90%, indicating that the followed extraction 
methodology was adequate for determination of [123I]-3-I-CO and possible metabolites. 
An aliquot of authentic [123I]-3-I-CO tracer solution was first injected onto the same HPLC 
system to determine the retention time of unmetabolised [123I]-3-I-CO (TR = 25 min). 
 
 
Figure 5.3: [123I]-3-I-CO metabolism pattern in NRMI mouse blood (left) and brain (right) at 
30 min post injection 
 
It is clear from figure 5.3 that two major radioactivity peaks are present in the NRMI mouse 
blood sample at 30 min post injection of [123I]-3-I-CO: a small part is under the form of a 
polar metabolite, which was identified as being free radioiodide 123I- by comparing retention 
times of authentic [123I]-NaI (in 0.05M NaOH solution) on the HPLC system used for 
metabolite determination. The remainder of the radioactivity in the blood was identified as 
[123I]-3-I-CO by comparison of the retention times on the HPLC system. This partial 
dehalogenation of [123I]-3-I-CO should present no problems with later brain imaging, since 
[123I-] radioiodide does not penetrate the blood-brain barrier. 
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Figure 5.3 also shows the presence of only one radioactive compound in the NMRI mouse 
brain samples at 30 min post injection of [123I]-3-I-CO. Comparison of its retention time with 
the retention time of authentic [123I]-3-I-CO revealed that only unmetabolised [123I]-3-I-CO 
was present in the brain samples. All the radioactivity in the different parts of the brain is due 
to the presence of [123I]-3-I-CO, and no radioactive metabolites are present in the brain. 
We can conclude that no radiolabelled metabolites could be detected in blood or brain of 
NRMI mice that could interfere with later imaging and receptor binding studies. 
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5.1.4. Blocking study with ketanserin in NMRI mice 
 
5.1.4.1. Methods 
 
For the blocking study, male NMRI mice (n = 3 per time point) were treated with ketanserin 
tartrate (dissolved in ethanol/water for injection 10/90 v/v). A dosage of 1 mg/kg was 
administered intravenously half an hour before injection of [123I]-3-I-CO. The tracer was 
dissolved in ethanol/water for injection (10/90 v/v) in a concentration of 200 Ci/ml. [123I]-3-
I-CO (20 Ci) was administered 30 minutes after ketanserin injection. At various time points 
post injection (2 min, 10 min, 30 min, 60 min, 120 min and 240 min) the animals were 
sacrificed by decapitation. Blood was collected and the animals were rapidly dissected. Blood 
samples and organs of interest were weighed and counted for radioactivity in an automated 
gamma counter (Cobra, Packard Canberra). Aliquots of the injected tracer solution (n = 3) 
were weighed and counted for radioactivity to determine the injected radioactivity dose 
received by the animals. Results were corrected for decay and tissue radioactivity 
concentrations were expressed as a percentage of the injected dose per gram of tissue (% ID/g 
tissue, mean ± standard deviation, n = 3). Data were analysed and the different groups were 
compared using non-parametric statistical analysis (Mann-Whitney U-test). Results were 
considered statistically significant when p < 0.05. 
 
 
5.1.4.2. Results and discussion 
 
The results of the biodistribution study with [123I]-3-I-CO in male NMRI mice after ketanserin 
blocking are shown in table 5.2 for all organs. Radioactivity concentrations were corrected for 
decay and are expressed as a percentage of the injected dose per gram of tissue (n = 3, mean ± 
standard deviation).
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Radioactivity concentration values for blood and brain after blocking with ketanserin are 
shown in figure 5.4. For reasons of clarity, the results of the normal biodistribution for blood 
and brain are also indicated. 
 
 
Figure 5.4: Blocking study results of [123I]-3-I-CO in male NMRI mice. Mean ± standard 
deviation values (n = 3 per time point). 
 
A maximum uptake of [123I]-3-I-CO in mouse brain of 3.74 ± 0.14 % ID/g was obtained 2 min 
post injection after displacement with ketanserin. Radioactivity concentration in brain rapidly 
declined to reach a value of 1.40 ± 0.019 % ID/g at 60 min post tracer injection. 
When comparing the results of the ketanserin blocking study with the normal [123I]-3-I-CO 
mouse biodistribution study (figure 5.4), it is clear that part of the radioactivity in the brain 
was blocked by ketanserin, resulting in reduced [123I]-3-I-CO brain concentrations. The 
remaining activity after ketanserin blocking is probably due to aspecific binding of the tracer 
to brain tissue. 
Blood radioactivity concentration after ketanserin blocking is also lower compared to the 
normal group. This could be a direct pharmacological effect of ketanserin administration, 
since ketanserin is known to interact with the -adrenergic receptor and is also used for its 
hypotensive effect[2, 3, 4]. 
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The obtained radioactivity concentration data for the other organs were comparable to the data 
obtained in the normal biodistribution study with [123I]-3-I-CO in NMRI mice. 
 
The uptake of the radioligand in NMRI mouse brain was compared to the brain radioactivity 
concentration of [123I]-R91150 in mice. For [123I]-R91150, a maximum brain radioactivity 
concentration of 0.95 ± 0.02 % ID/g tissue was observed at 10 min post injection, at 1 h post 
injection a radioactivity concentration of 0.73 ± 0.01 % ID/g tissue was observed. Brain 
radioactivity concentration values for [123I]-3-I-CO were 3.29 ± 0.18 % ID/g tissue at 10 min 
post injection and 1.41 ± 0.02 % ID/g tissue at 1 h post injection. Compared to [123I]-R91150, 
our newly developed radioligand [123I]-3-I-CO shows a markedly increased uptake in mouse 
brain. Starting 120 min after radioligand injection, no significant difference could be observed 
between the displacement and the control group, indicating that all specifically bound tracer 
was displaced by ketanserin. 
 
The ketanserin blocking study demonstrated specific binding of [123I]-3-I-CO to the 5-HT2A 
receptor in male NMRI mouse brain. A regional brain biodistribution study in larger animals 
(for example Sprague-Dawley rats) could indicate whether the distribution of [123I]-3-I-CO 
overlaps with the currently known distribution of 5-HT2A receptors in the brain. These results 
warrant further evaluation of [123I]-3-I-CO  as a potential 5-HT2A brain tracer in rats.  
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5.2. Evaluation of [123I]-3-I-CO in Sprague-Dawley rats 
 
5.2.1. Introduction 
 
The aim of this research is to evaluate the possible use of [123I]-3-I-CO as a tracer for 
visualizing the 5-HT2A receptor in the brain. The tracer must be able to cross the blood-brain 
barrier and reach the target in the brain. Secondly, it needs to bind to the 5-HT2A receptor with 
good affinity, specificity and selectivity. 
The potential of [123I]-3-I-CO for crossing the blood-brain barrier has been studied in the 
biodistribution study in male NMRI mice, from which we can conclude that [123I]-3-I-CO 
does indeed cross the blood-brain barrier. Specific binding to the 5-HT2A receptor was also 
demonstrated by the ketanserin blocking experiment. 
Pharmacokinetics of the tracer (distribution over time in the different organs) have also been 
studied in the [123I]-3-I-CO mouse biodistribution experiment. However, mouse brains are too 
small to dissect further in their different brain parts. A regional brain biodistribution study 
will be performed in male Sprague-Dawley rats to determine if the brain distribution of [123I]-
3-I-CO radioactivity is in accordance with the distribution of 5-HT2A receptors in the brain, 
obtained from the literature. The expression pattern of the serotonin 5-HT2A receptor depends 
on the localisation in the brain. High concentrations of 5-HT2A receptors have been found in 
many forebrain regions, such as the cortical areas, caudate nucleus, nucleus accumbens, 
olfactory tubercle and hippocampus[5]. Practically no 5-HT2A receptors have been found in 
the cerebellum[6]. 
To demonstrate specific binding of [123I]-3-I-CO to the 5-HT2A receptor, a displacement 
experiment will be performed with a ligand with known affinity for the 5-HT2A receptor. If 
[123I]-3-I-CO can be displaced from the receptor by a selective 5-HT2A antagonist, we can 
conclude that [123I]-3-I-CO does indeed bind to the 5-HT2A receptor in vivo. In all 
displacement studies, ketanserin will be used as the 5-HT2A antagonist.  
Because it is possible that rats show a different tracer metabolism pattern than mice, a 
metabolism study in Sprague-Dawley rat blood and brain will be performed to exclude the 
presence of radiolabelled metabolites of [123I]-3-I-CO in the brain. 
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5.2.2. Regional brain biodistribution of [123I]-3-I-CO in male Sprague-
Dawley rats 
 
5.2.2.1. Methods 
 
Male Sprague-Dawley rats (n = 3) were anesthetized with isoflurane and injected in the penile 
vein with [123I]-3-I-CO (100 - 150 Ci dissolved in ethanol/water 10/90 v/v). At different time 
points after injection of [123I]-3-I-CO (20 min, 40 min, 60 min, 2 hours and 4 hours) the 
animals were sacrificed by decapitation under isoflurane anaesthesia. Blood was collected and 
the brain was rapidly removed and dissected into different regions: the cortex (which was 
further dissected into the frontal cortex, parietal cortex, occipital cortex and temporal cortex), 
cerebellum and a subcortical region. The brain and blood samples were weighed and counted 
for radioactivity in an automated gamma counter (Cobra, Packard Canberra). Aliquots of the 
injected tracer solution (n = 3) were weighed and counted for radioactivity to determine the 
injected radioactivity dose received by the animals. Results were corrected for decay and 
tissue radioactivity concentrations were expressed as a percentage of the injected dose per 
gram of tissue (% ID/g tissue, mean ± standard deviation values, n = 3). 
 
 
5.2.2.2. Results and discussion 
 
The results of the regional brain biodistribution study with [123I]-3-I-CO in male Sprague-
Dawley rats are shown in figure 5.5. Brain radioactivity concentration values are shown in 
table 5.3. Initial brain uptake of [123I]-3-I-CO was the highest in the occipital cortex (0.942 ± 
0.034 % ID/g tissue at 20 min post injection) and frontal cortex (0.674 ± 0.074 % ID/g tissue 
at 20 min post injection).  
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Uptake of [123I]-3-I-CO activity in the blood was consistently low (maximum value was 0.062 
± 0.014 % ID/g tissue at 20 min post injection). At one hour after tracer injection, brain 
uptake of [123I]-3-I-CO was the highest in the frontal cortex (0.349 ± 0.131 % ID/g tissue at 1 
hour post injection).  
Radioactivity concentration values for the frontal cortex lay above the radioactivity 
concentrations in cerebellum until 2 hours after tracer injection. Starting from 2 hours after 
injection, radioactivity concentrations in all cortical regions and cerebellum are more or less 
the same (figure 5.5). Radioactivity concentrations for the other parts of the cortical tissue 
were also high at the earliest time points, and slowly decreased in function of time. Highest 
relative uptake in cortical tissue was observed in the occipital cortex (except for the 1 h time 
point, where highest relative tracer uptake was observed in the frontal cortex). Lowest relative 
brain uptake was observed in the cerebellum throughout the study.  
The binding index was calculated as (% ID/g)cortex/(% ID/g)cerebellum, and is shown in table 5.4. 
 
                 Time (min)     
  20 40 60 120 240 
Temp/CER 1,32 1,25 1,43 0,97 1,01 
Frontal/CER 1,77 1,45 1,66 1,05 1,13 
Occipital/CER 2,48 2,23 1,31 1,21 1,63 
Parietal/CER 0,99 1,06 1,1 0,63 0,59 
Table 5.4: Binding index values for the [123I]-3-I-CO brain biodistribution study in male 
Sprague-Dawley rats. 
 
The highest cortex-to-cerebellum ratio was achieved in the occipital cortex: a maximum ratio 
of 2.48 was obtained at 20 min post injection. Starting at 1 h after radioligand injection, the 
ratio occipital cortex-to-cerebellum is stabilised, varying between 1.3 and 1.2. For the frontal 
cortex, a maximal frontal cortex-to-cerebellum ratio of 1.77 was reached at 20 min post 
injection, decreasing to 1.66 at 1 h after radioligand injection. The ratio stabilised around 1.1 
at the later time points. This indicates that specific binding was minimal at 120 and 240 min 
after radioligand injection. 
Cortical tissue-to-cerebellum ratios for temporal and parietal cortex were significantly lower 
than the ratios observed in frontal and occipital cortical tissues: at the later time points, ratios 
were even lower than 1, indicating that the concentration of radioligand was higher in 
cerebellum compared to these cortical regions.   
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When comparing these results with the data obtained with [123I]-R91150, it is obvious that the 
cortex-to-cerebellum ratios were much lower in the [123I]-3-I-CO study, although the absolute 
radioactivity concentration values in brain were higher. Also, blood radioactivity 
concentration values approached the radioactivity levels of the cerebellum in the [123I]-
R91150 study; in the [123I]-3-I-CO study, cerebellar radioactivity concentration levels were 
much higher than the blood levels. This could possibly indicate an increased aspecific binding 
of [123I]-3-I-CO to brain tissue, which would also explain the lower cortex-to-cerebellum 
ratios obtained with [123I]-3-I-CO. Also, cortical radioactivity concentration data for the [123I]-
3-I-CO study showed a more rapid washout of radioligand out of the brain compared to the 
[123I]-R91150 data in rats.  
When comparing our results with the results obtained by other authors with [18F]-altanserin 
[7], [123I]-3-I-CO showed a higher absolute radioactivity concentration in the brain (0.5 % 
ID/g tissue for [18F]-altanserin), but a much lower cortex-to-cerebellum ratio was observed for 
[123I]-3-I-CO (cortex-to-cerebellum ratios of 11 were obtained in the [18F]-altanserin study). 
Also, [18F]-altanserin radioactivity concentration values in cerebellum averaged around 0.1 % 
ID/g tissue, comparable with the results obtained with [123I]-R91150. The increased 
radioactivity concentration values in cerebellum for the [123I]-3-I-CO study could indicate that 
the radioligand shows considerable aspecific binding to brain tissue. 
 
It can be concluded from these results that [123I]-3-I-CO readily enters the brain, with a 
maximum uptake in frontal cortex of 0.674 ± 0.074 % ID/g tissue at 20 min post injection. 
Highest absolute uptake of the radioligand was seen in the occipital cortex (0.942 ± 0.034 % 
ID/g tissue at 20 minutes after injection).  
Specificity of [123I]-3-I-CO binding to the 5-HT2A receptor in the brain of male Sprague-
Dawley rats remains to be demonstrated with a displacement study, using a well known 
specific 5-HT2A antagonist. A metabolite study will also be performed to exclude the 
unwanted effect of possible radiolabelled metabolites of [123I]-3-I-CO. 
 
 
 
 
 
 
 
 
In vivo evaluation of [123I]-3-I-CO  183 
5.2.3. Metabolite determination in male Sprague-Dawley rats 
 
5.2.3.1. Methods 
 
Male Sprague-Dawley rats (n = 3) were injected in the penile vein with [123I]-3-I-CO (200 
Ci dissolved in ethanol/water 10/90 v/v). At 30 min post injection, the animals were 
sacrificed by decapitation under isoflurane anaesthesia. Blood was collected in heparinised 
tubes and the animals were rapidly dissected. Blood samples were centrifuged for 3 min at 
3000g and the tracer extraction yield was calculated. The plasma (200 l) was mixed with 
acetonitrile (800 l) and the mixture was vortexed for 30 s, followed by centrifugation for 3 
min at 3000g. The supernatant (500 l) was analysed on HPLC after filtration through a 0.22 
m filter. 
The brain was cut into pieces and transferred to a tube and acetonitrile (2 ml) was added. The 
mixture was cooled on ice, homogenized for 30 sec and finally centrifuged at 3000g for 3 
min. The supernatant (500 l) was analysed on HPLC, using an Alltech Econosil C18 column 
(250 mm x 10 mm; 10 m particle size) at a flow rate of 5 ml/min (60/40 ethanol/0.02 M 
phosphate buffer pH 7.4). The HPLC eluate was collected with an automated fraction 
collector in fractions of 5 ml (= 1 min). The fractions were then counted for radioactivity with 
an automated gamma counter (Cobra, Packard Canberra). 
The extraction efficiency (extraction yield) was expressed as percentage of total activity 
found in the supernatant compared to the total amount of radioactivity present in the tissue or 
blood sample. Retention times of the possible radiometabolites were compared with the 
retention times of authentic [123I]-3-I-CO and free radioiodide. 
 
 
5.2.3.2. Results 
 
Values for extraction yields were always > 90 %. The metabolism pattern of [123I]-3-I-CO in 
Sprague-Dawley rats was roughly the same as the metabolism pattern obtained in NMRI mice 
at 30 min after radioligand injection. In blood, only two radiolabelled components were 
present: one component (± 90 %) had the same retention time as authentic [123I]-3-I-CO, and 
the other component (5-10 %) was identified as free radioiodide (figure 5.6 - left). In the 
brain, only unchanged [123I]-3-I-CO was present (figure 5.6 – right). 
 
In vivo evaluation of [123I]-3-I-CO  184 
It is safe to conclude that no lipophilic radiolabelled metabolites were found that could 
possibly interfere with later brain imaging with [123I]-3-I-CO. A small amount of radioiodide 
in the blood should also have no effect in imaging studies. 
 
 
Figure 5.6: Metabolisation pattern of [123I]-3-I-CO in Sprague-Dawley rats 30 min after 
injection of [123I]-3-I-CO. Patterns in blood (left) and brain (right) are shown. 
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5.2.4. Displacement study with [123I]-3-I-CO in male Sprague-Dawley rats 
 
5.2.4.1. Methods 
 
Ketanserin tartrate was used to displace [123I]-3-I-CO in rats. The ketanserin tartrate salt was 
obtained from Tocris (Tocris Bioscience, Bristol, UK) and dissolved in a mixture of 
ethanol/water (5/95 v/v) in a concentration of 1 mg/ml. The dosage used to displace [123I]-3-I-
CO in rats was 1 mg ketanserin tartrate per kg of bodyweight. This resulted in an average 
displacement dose of 0.25 mg per animal. 
Male Sprague-Dawley rats (n = 3) were anesthetized with isoflurane and injected in the penile 
vein with [123I]-3-I-CO (100 - 150 Ci). Thirty minutes after administration of the tracer, the 
animals were injected in the penile vein with ketanserin solution under isoflurane anaesthesia. 
The animals were sacrificed by decapitation under isoflurane anaesthesia one hour after tracer 
injection (30 min after ketanserin injection). Blood was collected and the brain was rapidly 
removed and dissected into different regions: the cortex (which was further dissected into the 
frontal cortex, parietal cortex, occipital cortex and temporal cortex), cerebellum and a 
subcortical region. The different brain and blood samples were weighed and counted for 
radioactivity with an automated gamma counter (Cobra, Packard Canberra). Aliquots of the 
injected tracer solution (n = 3) were weighed and counted for radioactivity to determine the 
injected radioactivity dose received by the animals. Results were corrected for decay and 
tissue radioactivity concentrations were expressed as a percentage of the injected dose per 
gram of tissue (% ID/g tissue, mean ± standard deviation values). The results were compared 
with the normal brain biodistribution results. Differences between groups were calculated 
using non-parametrical statistical analysis (Mann-Whitney). Results were considered 
statistically significant when p < 0.05. 
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5.2.4.2. Results and discussion 
 
The effect of displacement with ketanserin on the biodistribution of [123I]-3-I-CO in male 
Sprague-Dawley rat brain can be clearly seen in figure 5.7. For reasons of clarity, the normal 
biodistribution data of [123I]-3-I-CO at the 1h time point are also shown in figure 5.7. 
 
 
Figure 5.7: Results of the ketanserin blocking study with [123I]-3-I-CO in male Sprague-
Dawley rats. Results were expressed as % ID/g tissue, mean ± standard deviation values are 
shown (n = 3 animals per group, * indicates a p-value < 0.05). 
 
It can be seen in figure 5.7 that [123I]-3-I-CO radioactivity was displaced by ketanserin in the 
cortical areas of the brain. No significant difference in [123I]-3-I-CO radioactivity 
concentration could be observed in blood or cerebellum. In the frontal cortex, radioactivity 
concentration decreased from 0.349 ± 0.131 % ID/g tissue at 1h post injection to 0.17 ± 0.036 
% ID/g tissue after displacement with ketanserin. 
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[123I]-3-I-CO activity also decreased in other parts of the cortex (temporal, occipital and 
parietal cortex), although the relative decrease in radioactivity concentration was the highest 
in frontal cortex (50% decrease in radioactivity concentration after displacement with 
ketanserin).  
Radioactivity concentration in blood and cerebellum did not change significantly after 
ketanserin displacement (0.211 ± 0.086 % ID/g tissue at 1h post injection in cerebellum and 
0.184 ± 0.02 % ID/g tissue after ketanserin displacement. Values for blood were 0.045 ± 
0.018 % ID/g tissue and 0.042 ± 0.008 % ID/g tissue respectively). This is in accordance with 
the use of the cerebellum as a reference region when performing PET or SPECT brain scans 
with 5-HT2A tracers. 
Radioactivity concentration values for the other brain regions are shown in table 5.5.  
 
 Normal BI Ketanserin BI 
Blood 0,045 ± 0,018  0,042 ± 0,008  
Subcortical 0,281 ± 0,122  0,163 ± 0,052  
Temporal 0,303 ± 0,119 1,43 0,165 ± 0,032 0,89 
Frontal 0,349 ± 0,131 1,65 0,17 ± 0,036 0,92 
Occipital 0,276 ± 0,096 1,31 0,167 ± 0,043 0,91 
Parietal 0,231 ± 0,013 1,09 0,161 ± 0,042 0,88 
Cerebellum 0,211 ± 0,085  0,184 ± 0,02  
Table 5.5: Influence of ketanserin displacement on regional brain biodistribution with [123I]-3-
I-CO in Sprague-Dawley rats. Results are expressed as % ID/g tissue (mean ± standard 
deviation, n = 3). The cortex/cerebellum ratios (BI) are displayed in the table. 
 
As can be seen in table 5.5, highest absolute uptake of [123I]-3-I-CO could be seen in the 
frontal cortex. After displacement with ketanserin, the highest radioactivity concentration was 
found in the cerebellum. Radioactivity concentration values were comparable for the different 
brain regions after displacement with ketanserin. This could indicate that the amount of [123I]-
3-I-CO aspecific binding is comparable throughout the brain. 
 
The binding index (BI) was defined as the ratio of cortical region to cerebellum. It was 
calculated as (% ID/g)cortex/(% ID/g)cerebellum for all areas in the cortex. Results are also 
indicated in table 5.5. The highest ratio was observed in frontal cortex for the normal group. 
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In contrast with the results obtained in the [123I]-R91150 displacement study, radioactivity 
levels in the cortex in the [123I]-3-I-CO study did decrease to the levels observed in 
cerebellum.  
Nevertheless, the residual radioactivity levels in cerebellum after ketanserin displacement 
remained significantly higher in the [123I]-3-I-CO study, and could be caused by aspecific 
binding of the radioligand to brain tissue. 
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5.3. Influence of P-glycoprotein modulation on the biodistribution 
of [123I]-3-I-CO in rodents 
 
5.3.1. Introduction 
 
Considering the importance of cyclosporin A modulation on the biodistribution in rodents of 
[123I]-R91150, we decided to also investigate the influence of cyclosporin A administration on 
the biodistribution and brain uptake in rodents of [123I]-3-I-CO, our in-house developed 
potential SPECT tracer for the serotonin 5-HT2A receptor. 
A regional brain biodistribution will be performed in male Sprague-Dawley rats after 
treatment of the animals with cyclosporin A. Also, a displacement study with ketanserin will 
investigate possible effects of P-glycoprotein modulation on specific binding of [123I]-3-I-CO 
to the 5-HT2A receptor. 
To exclude possible altered metabolism of [123I]-3-I-CO after administration of cyclosporin A, 
a metabolite assay will be performed in Sprague-Dawley rats after treatment of the animals 
with cyclosporin A. 
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5.3.2. Influence of cyclosporin A administration on brain uptake of [123I]-3-
I-CO in Sprague-Dawley rats 
 
5.3.2.1. Methods 
 
Male Sprague-Dawley rats (n = 3 per group) were anesthetized with isoflurane and injected in 
the penile vein with cyclosporin A (a dosage of 50 mg/kg was used). Thirty minutes after 
cyclosporin A administration, the rats were anesthetized with isoflurane and injected in the 
penile vein with [123I]-3-I-CO (100 - 150 Ci in ethanol/water 10/90 v/v). The animals were 
sacrificed by decapitation under isoflurane anaesthesia at selected time points after tracer 
injection (2 min, 5 min, 30 min, 60 min, 2 hours and 4 hours). Blood was collected and the 
brain was rapidly removed and dissected into different regions: the cortex (which was further 
dissected into the frontal cortex, parietal cortex, occipital cortex and temporal cortex), 
cerebellum and a subcortical region. The different brain and blood samples were weighed and 
counted for radioactivity with an automated gamma counter (Cobra, Packard Canberra). 
Aliquots of the injected tracer solution (n = 3) were weighed and counted for radioactivity to 
determine the injected radioactivity dose received by the animals. Results were corrected for 
decay and tissue radioactivity concentrations were expressed as a percentage of the injected 
dose per gram of tissue (% ID/g tissue, mean ± standard deviation values, n = 3). The results 
were compared with the normal brain biodistribution results, without pre-treatment of the 
animals with cyclosporin A using non-parametric statistical analysis (Mann-Whitney). 
Differences were considered statistically significant when p-values < 0.05 were obtained. 
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5.3.2.2. Results and discussion 
 
The influence of cyclosporin A pre-treatment (50 mg/kg intravenously, administered one hour 
before injection of [123I]-3-I-CO) on the regional brain biodistribution results with [123I]-3-I-
CO in Sprague-Dawley rats can be seen in table 5.6. Brain radioactivity concentration values 
are expressed as % ID/g tissue (mean ± standard deviation, n = 3 per time point). 
 
    Time (min)     
 20 40 60 120 240 
Blood 0,07 ± 0,01 0,041 ± 0,006 0,056 ± 0,014 0,037 ± 0,01 0,034 ± 0,003 
Subcortical 0,65 ± 0,12 0,67 ± 0,06 0,35 ± 0,085 0,18 ± 0,12 0,075 ± 0,01 
Temporal 0,56 ± 0,25 0,81 ± 0,23 0,32 ± 0,065 0,14 ± 0,09 0,063 ± 0,003 
Frontal 0,61 ± 0,17 0,91 ± 0,11 0,58 ± 0,084 0,22 ± 0,08 0,07 ± 0,005 
Occipital 0,91 ± 0,26 0,85 ± 0,18 0,58 ± 0,065 0,18 ± 0,07 0,071 ± 0,01 
Parietal 0,60 ± 0,15 0,72 ± 0,12 0,357 ± 0,07 0,17 ± 0,07 0,055 ± 0,009 
Cerebellum 0,63 ± 0,1 0,65 ± 0,093 0,34 ± 0,09 0,15 ± 0,06 0,072 ± 0,008 
Table 5.6: Influence of cyclosporin A (50 mg/kg 1 h before radioligand injection) on the 
regional brain biodistribution with [123I]-3-I-CO in Sprague-Dawley rats. Results are 
expressed as % ID/g tissue (mean ± standard deviation, n = 3 animals per time point). 
 
A maximum uptake value of 0.905 ± 0.114 % ID/g tissue was obtained in the frontal cortex at 
40 min post injection after treatment with cyclosporin A. At 1 hour after injection, 
radioactivity concentration in frontal cortex was 0.582 ± 0.084 % ID/g tissue. The occipital 
cortex followed about the same radioactivity uptake and clearance pattern as the frontal 
cortex. The radioactivity concentration in the reference region, the cerebellum,  was 0.355 ± 
0.094 % ID/g tissue at 1 h after injection of [123I]-3-I-CO for the cyclosporin group. The 
highest concentration of [123I]-3-I-CO in blood (0.070 ± 0.012 % ID/g tissue) was found at 20 
min post injection. Activity concentration in blood remained low and was fairly constant over 
time (0.037 ± 0.010 % ID/g tissue at 2h after injection, 0.034 ± 0.003% ID/g tissue at 4h after 
injection). Radioactivity concentration values in temporal and parietal cortex were 
comparable throughout the study, but were significantly lower than the values obtained in 
frontal and occipital cortex. 
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The results obtained after the regional brain biodistribution with cyclosporin A treatment were 
compared with the results obtained from the normal regional brain biodistribution study with 
[123I]-3-I-CO. Radioactivity concentration values for frontal cortex and cerebellum are shown 
for both groups in figure 5.8. 
 
 
Figure 5.8: [123I]-3-I-CO biodistribution results for frontal cortex and cerebellum (with and 
without cyclosporin A pre-treatment). Results are expressed as % ID/g tissue (mean ± 
standard deviation, n = 3 animals per time point). 
 
It is evident from figure 5.8 that both the target region (frontal cortex) and the reference 
region (cerebellum) of Sprague-Dawley rats show an increased uptake of [123I]-3-I-CO 
radioactivity after pre-treatment of the animals with cyclosporin A.  
For example, at 1 hour after injection of [123I]-3-I-CO, radioactivity concentration in frontal 
cortex increased from 0.349 ± 0.131 % ID/g tissue for the normal group to 0.582 ± 0.084 % 
ID/g tissue after treatment of the animals with cyclosporin A (or an increase in radioactivity 
concentration of 67 % after cyclosporin A administration).  
A similar pattern was observed in the cerebellum: radioactivity concentration increased from 
0.211 ± 0.086 % ID/g tissue at 1 hour after injection for the normal group to 0.355 ± 0.094 % 
ID/g tissue at 1 hour after injection for the cyclosporin A group (figure 5.8). 
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The relative increase in [123I]-3-I-CO radioactivity concentration was the same for the 
cerebellum as for the frontal cortex (or an increase in radioactivity concentration of 67 % after 
cyclosporin A administration). All other brain regions followed more or less the same pattern: 
radioactivity concentration values increased markedly after pre-treatment of the rats with 
cyclosporin A. 
On the contrary, no significant difference in radioactivity concentration in blood could be 
found between the two treatment groups. For example, the radioactivity concentration in 
blood was 0.045 ± 0.018 % ID/g tissue at 1 hour after injection of [123I]-3-I-CO for the normal 
group. In the cyclosporin A treated group, radioactivity concentration in blood at 1 hour after 
injection was 0.056 ± 0.014 % ID/g tissue. The other time points showed the same behaviour: 
no significant difference could be observed between the two groups, at all time points. 
This could indicate that the increase in brain [123I]-3-I-CO radioactivity concentration after 
treatment with cyclosporin A is not the result of an increased influx of tracer to the brain, but 
rather the consequence of a decreased tracer efflux out of the brain as a result of the P-
glycoprotein blocking effect of cyclosporin A.  
It should be noted however that the increase in brain radioactivity concentration after 
treatment of the animals with cyclosporin A was not as marked as in the cyclosporin A study 
with [123I]-R91150: in the [123I]-3-I-CO study, brain radioactivity concentrations doubled after 
cyclosporin A treatment, whereas in the [123I]-R91150 study, brain tracer concentrations 
increased up to seven-fold after animal treatment with cyclosporin A. This could indicate that 
[123I]-R91150 is a stronger substrate for P-glycoprotein efflux than [123I]-3-I-CO. 
 
The binding index was calculated as the ratio of cortical tissue-to-cerebellum (% ID/g 
tissue)cortex/(% ID/g tissue)cerebellum. The results are shown in table 5.7.  
 
        Time (min)       
  20 40 60 120 240 
Temp/CER 0,89 1,25 0,94 0,94 0,86 
Frontal/CER 0,97 1,4 1,71 1,47 0,97 
Occipital/CER 1,45 1,31 1,71 1,2 0,99 
Parietal/CER 0,95 1,11 1,05 1,14 0,77 
Table 5.7: [123I]-3-I-CO binding index calculations in Sprague-Dawley rats after treatment of 
the animals with cyclosporin A (50 mg/kg). 
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Binding index data from the cyclosporin A regional brain biodistribution with [123I]-3-I-CO 
(table 5.7) were compared with the data obtained from the normal regional brain 
biodistribution study (table 5.4) with [123I]-3-I-CO. 
In frontal cortex, no significant difference in binding index could be observed between the 
control group and the cyclosporin-treated group at 40 min, 1 hour and 4 hours after injection 
of [123I]-3-I-CO.  
 
Frontal cortex binding indices were significantly different for the control group and the 
cyclosporin-treated group at 20 min post tracer injection (BIcontrol = 1.77; BIcyclo = 0.97) and at 
2 hours after injection of the tracer (BIcontrol = 1.05; BIcyclo = 1.47). In the other cortical 
tissues, binding index values for the cyclosporin A group versus the control group were 
comparable. 
When comparing the binding index data with the results obtained from the regional brain 
biodistribution study with [123I]-R91150 in Sprague-Dawley rats with and without cyclosporin 
A pre-treatment, it is obvious that the values obtained for [123I]-3-I-CO are well below the 
values obtained with [123I]-R91150. Binding index values for [123I]-3-I-CO averaged around 
1.2 both with and without cyclosporin A pre-treatment, whereas the values for [123I]-R91150 
were around 7 for the control and around 4 for the cyclosporin A pre-treated group. These 
results could indicate that [123I]-3-I-CO demonstrates an increased aspecific binding to brain 
tissues (cerebellum) compared to [123I]-R91150. 
Contrary to the results obtained in the [123I]-R91150 cyclosporin A study, binding index 
values did not decrease after animal pre-treatment with cyclosporin A in the biodistribution 
study with [123I]-3-I-CO, but remained at the same level. Also, no influence of cyclosporin A 
was observed on the pharmacokinetics of [123I]-3-I-CO in blood, since blood radioactivity 
levels were comparable before and after cyclosporin A pre-treatment. 
 
We can conclude from this study that modulation of P-glycoprotein by pre-treatment of the 
animals with cyclosporin A resulted in an increased concentration of [123I]-3-I-CO in the 
brain. However, the increase in brain radioactivity concentration was not as large as the 
increase observed in research with other brain tracers, for example [123I]-R91150 (chapter 3) 
and [11C]-(R)-(-)-RWAY [8]. 
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5.3.3. [123I]-3-I-CO displacement study after cyclosporin A treatment in 
Sprague-Dawley rats 
 
5.3.3.1. Methods 
 
Ketanserin tartrate was used to displace [123I]-3-I-CO in rats. The ketanserin tartrate salt was 
obtained from Tocris (Tocris Bioscience, Bristol, UK) and dissolved in a mixture of 
ethanol/water (5/95 v/v) in a concentration of 1 mg/ml. The dosage used to displace [123I]-3-I-
CO in rats was 1mg/kg bodyweight.  
Male Sprague-Dawley rats were pre-treated with cyclosporin A (50 mg/kg) via the penile vein 
30 min before injection of the radioligand. The animals (n = 3) were anesthetized with 
isoflurane and injected in the penile vein with [123I]-3-I-CO (100 - 150 Ci dissolved in 
ethanol/water 10/90 v/v). Thirty minutes after administration of the tracer, the animals were 
injected in the penile vein with ketanserin solution under isoflurane anaesthesia. The animals 
were sacrificed by decapitation under isoflurane anaesthesia one hour after tracer injection (30 
min after ketanserin injection). Blood was collected and the brain was rapidly removed and 
dissected into different regions: the cortex (which was further dissected into the frontal cortex, 
parietal cortex, occipital cortex and temporal cortex), cerebellum and a subcortical region. 
The different brain and blood samples were weighed and counted for radioactivity with an 
automated gamma counter (Cobra, Packard Canberra). Aliquots of the injected tracer solution 
(n = 3) were weighed and counted for radioactivity to determine the injected radioactivity 
dose received by the animals. Results were corrected for decay and tissue radioactivity 
concentrations were expressed as a percentage of the injected dose per gram of tissue (% ID/g 
tissue, mean ± standard deviation values, n = 3). The results were compared with the normal 
brain biodistribution results. Results were compared with a non-parametric method (Mann-
Whitney). P-values < 0.05 were considered as significant. 
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5.3.3.2. Results and discussion 
 
The results of the ketanserin displacement study with [123I]-3-I-CO in male Sprague-Dawley 
rats after treatment of the animals with cyclosporin A can be seen in figure 5.9. Radioactivity 
concentration values are indicated in table 5.8 as % ID/g tissue (mean ± standard deviation, n 
= 3 animals per treatment group). For reasons of clarity, the results for the normal regional 
brain biodistribution study are also shown in figure 5.9.  
 
 
Figure 5.9: Brain biodistribution displacement results with [123I]-3-I-CO after treatment with 
cyclosporin A. Values are expressed as % ID/g (mean ± standard deviation, n = 3). 
 
[123I]-3-I-CO radioactivity concentration was significantly reduced in the brain after 
displacement with ketanserin. An average decrease in radioactivity concentration of 55 to 60 
% was observed throughout the cortex after displacement of [123I]-3-I-CO with ketanserin.  
The relative reduction in [123I]-3-I-CO radioactivity concentration obtained after displacement 
in the cyclosporin pre-treated animals was about the same as the reduction obtained after 
ketanserin displacement in the normal groups (= animals not treated with cyclosporin).  
Nevertheless, absolute radioactivity concentration after displacement was higher in the 
cyclosporin group than in the normal control group. 
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This might indicate an increase in aspecific binding in the brain, since the increased 
radioactivity concentration after cyclosporin A administration could not be fully displaced by 
ketanserin. No significant differences were observed between the cyclosporin-only and the 
displacement group in the blood and in cerebellum. 
 
 Cyclosporin ratio Cyclo-ketanserin ratio 
Blood 0,05 ± 0,01  0,05 ± 0,01  
Subcortical 0,35 ± 0,08  0,22 ± 0,11  
Temporal  0,31 ± 0,06 0,89 0,19 ± 0,09 0,6 
Frontal 0,58 ± 0,08 1,66 0,32 ± 0,09 1 
Occipital 0,36 ± 0,07 1,03 0,23 ± 0,04 0,72 
Parietal 0,58 ± 0,08 1,66 0,36 ± 0,03 1,1 
Cerebellum 0,35 ± 0,09  0,32 ± 0,06  
Table 5.8: Ketanserin displacement results with [123I]-3-I-CO after animal treatment with 
cyclosporin A. Results are expressed as % ID/g tissue (mean ± standard deviation, n = 3). 
 
Cortex-to-cerebellum ratios after treatment of the animals with cyclosporin were comparable 
to the ratios obtained in the normal group. After displacement of the radioligand with 
ketanserin, binding index ratios decreased with about 30 %. This value is comparable with the 
decrease in binding index obtained after displacement of [123I]-R91150 with ketanserin in rats. 
 
We can conclude from these results that modulation of P-glycoprotein by animal pre-
treatment with cyclosporin A results in an increased radioactivity concentration of [123I]-3-I-
CO throughout the brain, resulting in an increase of both specific and aspecific radioligand 
binding. Also, since no change was observed in binding index after cyclosporin A pre-
treatment, it is safe to conclude that the increased radioligand radioactivity concentration did 
not result in saturation of the 5-HT2A receptors. 
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5.3.4. Influence of cyclosporin A on pinhole SPECT imaging with [123I]-3-
I-CO in Sprague-Dawley rats 
 
5.3.4.1. Materials and methods 
 
Male Sprague-Dawley rats (250 – 266 g) were anesthetized with isoflurane and injected with 
cyclosporin A (50 mg/kg). 30 minutes later [123I]-3-I-CO (800 Ci) was injected into the tail 
vein. A U-SPECT-II scan was performed 10 minutes after radioligand injection using the rat 
collimator (75 pinholes of 1.0 mm) for a continuous 90 minutes (18 frames of 5 minutes) with 
list mode output enabled.  
As a reference, animals were also scanned in a similar protocol with [123I]-3-I-CO but without 
administration of cyclosporin A.  For all datasets a 20 % photopeak was selected around 159 
keV while background correction was performed using two additional 10 % windows around 
133 and 188 keV. The selected time frames ranged from 20 to 50 min post-injection. Each 
time the data were reconstructed on 0.75 mm voxels by 3 iterations of 16 OSEM subsets.  The 
images were 3D postfiltered by a 15 pixel Gaussian kernel with a width of 1.5 mm.  Two 
ROI’s were drawn around the frontal cortex and the cerebellum using Amide (OpenSource) 
with 3D Freehand on the coronal slices.  The mean value and standard deviation over all 
voxels in the respective ROI’s were calculated for post-analysis.   
All experiments were conducted following the principles of laboratory animal care and the 
Belgian law on the protection of animals. Our research protocol was approved by the Ghent 
University Hospital ethical committee (ECP 05-14). 
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5.3.4.2. Results and discussion 
 
A pinhole SPECT imaging study was performed with [123I]-3-I-CO in Sprague-Dawley rats. 
Both the normal group and the animals pre-treated with cyclosporin A were scanned. 
The results of the scans are presented in figure 5.10. Increased levels of [123I]-3-I-CO 
radioactivity were present in the cortical tissues, but compared to the imaging results with 
[123I]-R91150, an increased aspecific binding of radioligand throughout the cerebellum and 
the rest of the brain was observed. 
 
 
Figure 5.10: Pinhole SPECT imaging with [123I]-3-I-CO (800 Ci) in Sprague-Dawley rats. 
Panel a: control group; panel b: pre-treatment with cyclosporin A (50 mg/kg). Regions-of-
interest were drawn around cortical tissues and cerebellum. 
 
Regions-of-interest (ROI) were drawn around the frontal region of the cortical tissue and the 
cerebellum. Radioligand uptake in cerebellum was used as a reference for non-specific 
binding.  
 
For semi-quantification, the cortex-to-cerebellum ratio (mean counts in cortex)/(mean counts 
in cerebellum/ was determined using the ROI’s. 
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In the control group (figure 5.10 part a), a cortex-to-cerebellum ratio of 1.57 was found. As 
comparison, in the regional brain biodistribution study with [123I]-3-I-CO in Sprague-Dawley 
rats, a frontal cortex-to-cerebellum ratio between 1.45 and 1.66 was observed 40 and 60 
minutes after injection of the radioligand. 
 
In the cyclosporin A treated group (figure 5.10 part b), a cortex-to-cerebellum ratio of 1.2 was 
obtained. The regional brain biodistribution study with [123I]-3-I-CO after cyclosporin A 
treatment in rodents revealed a cortex-to-cerebellum ratio of 1.4. 
 
When comparing cortex-to-cerebellum binding index values obtained from the biodistribution 
study with the values obtained from the SPECT scans, a good correlation was observed. 
Administration of cyclosporin A did not result in drastically changed [123I]-3-I-CO cortex-to-
cerebellum ratios. Also, P-glycoprotein blocking with cyclosporin A did not have the same 
effect on [123I]-3-I-CO imaging, compared to [123I]-R91150. This is also in accordance with 
the biodistribution studies with [123I]-3-I-CO in rodents, where only a small increase in 
radioligand brain uptake was found after cyclosporin A treatment. 
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5.3.5. Metabolite analysis in Sprague-Dawley rats of [123I]-3-I-CO after 
cyclosporin A treatment 
 
5.3.5.1. Methods 
 
Cyclosporin A (50 mg/kg) was injected into the penile vein of Sprague-Dawley rats 30 
minutes before injection of the radioligand. The animals (n = 3) were injected in the penile 
vein with [123I]-3-I-CO (100 – 150 Ci dissolved in ethanol/water 10/90 v/v) 30 minutes after 
cyclosporin A administration. At 30 min post radioligand injection, the animals were 
sacrificed by decapitation under isoflurane anaesthesia. Blood was collected in heparinised 
tubes and the animals were rapidly dissected. Blood samples were centrifuged for 3 min at 
3000g and the pellet was discarded after calculation of tracer extraction yield. The plasma 
(200 l) was mixed with acetonitrile (800 l) and the mixture was vortexed for 30 s, followed 
by centrifugation for 3 min at 3000g. The supernatant (500 l) was analysed on HPLC after 
filtration through a 0.22 m filter. 
The brain was cut into pieces and transferred to a tube and acetonitrile (2 ml) was added. The 
mixture was cooled on ice, homogenized for 30 sec and finally centrifuged at 3000g for 3 
min. The supernatant (500 l) was analysed on HPLC, using an Alltech Econosil C18 column 
(250 mm x 10 mm; 10 m particle size) at a flow rate of 5 ml/min (60/40 ethanol/0.02 M 
phosphate buffer pH 7.4). The HPLC eluate was collected with an automated fraction 
collector in fractions of 5 ml (= 1 min). The fractions were then counted for radioactivity with 
an automated gamma counter (Cobra, Packard Canberra). 
The extraction efficiency (extraction yield) was expressed as percentage of total activity 
found in the supernatant compared to the total amount of radioactivity present in the tissue or 
blood sample. Retention times of the possible radiometabolites were compared with the 
retention times of authentic [123I]-3-I-CO and free radioiodide. 
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5.3.5.2. Results 
 
The only radiolabelled compounds present in the blood and brain samples of Sprague-Dawley 
rats after cyclosporin A treatment were free radioiodide and the unchanged tracer [123I]-3-I-
CO. No difference in metabolism pattern could be observed between the normal and the 
cyclosporin A pre-treated group. 
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5.4. Conclusion 
 
 
[123I]-3-I-CO was evaluated in vivo in biodistribution studies in NMRI mice and Sprague-
Dawley rats. The mouse biodistribution study revealed high initial uptake of the radioligand 
in the brain (a maximum concentration of 6.26 ± 1.36 % ID/g tissue was obtained at 10 min 
post injection) but also a rapid washout of the radioligand from the brain (radioactivity 
concentration decreased to 0.98 ± 0.30 % ID/g tissue at 2 h post injection). Specific binding to 
the 5-HT2A receptor in the brain of NMRI mice was demonstrated by a displacement study 
with ketanserin. A metabolite assay revealed that no radiolabelled metabolites were present in 
the blood or brain of NMRI mice. 
 
The regional brain biodistribution study with [123I]-3-I-CO in Sprague-Dawley rats also 
revealed high initial uptake of the radioligand in cortical tissues (maximum concentrations of 
0.94 ± 0.03 % ID/g tissue and 0.67 ± 0.07 % ID/g tissue in occipital and frontal cortex 
respectively at 20 min post injection). A rapid washout of radioactivity from the brain was 
observed: radioactivity concentrations decreased to 0.085 ± 0.03 % ID/g tissue at 2 h post 
injection. Also, radioactivity uptake in cerebellum was quite high (0.211 ± 0.086 % ID/g 
tissue at 1 h post injection) compared to other 5-HT2A tracers. Radioactivity concentration 
levels in cortical tissues decreased to the level observed in cerebellum after displacement of 
[123I]-3-I-CO with ketanserin. Also, no radiolabelled metabolites could be detected in the 
blood or brain of Sprague-Dawley rats. For the regional brain biodistribution study, cortex-to-
cerebellum ratios of 1.5 were obtained throughout the study. When comparing these results 
with other 5-HT2A tracers, it becomes evident that the specific ‘signal’ of [123I]-3-I-CO in the 
brain was limited. Other clinically used tracers have cortex-to-cerebellum binding index ratios 
that are much higher (for [123I]-R91150 a BI of 7 was obtained 1 h post injection, for [18F]-
altanserin a BI of 11 was obtained [9]). This could limit the clinical usefulness of [123I]-3-I-
CO as a radioligand for the 5-HT2A receptor. Aspecific binding of [123I]-3-I-CO to brain 
tissues could probably be responsible for the low binding index ratios observed.  
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The influence of P-glycoprotein modulation (by pre-treatment of the animals with cyclosporin 
A) on the regional brain biodistribution and metabolism of [123I]-3-I-CO in Sprague-Dawley 
rats was investigated. Pre-treatment of the animals with cyclosporin A (50 mg/kg) resulted in 
a marked increase of radioactivity concentration throughout the brain: a maximal radioactivity 
concentration of 0.91 ± 0.11 % ID/g tissue was obtained in frontal cortex at 40 min post 
injection. Radioactivity concentration in cerebellum was also markedly increased after 
cyclosporin A treatment, but no influence was observed on radioactivity concentrations in 
blood. Nevertheless, it should be pointed out that the increase in brain radioactivity 
concentration after treatment of the animals with cyclosporin A was not as marked as in the 
cyclosporin A study with [123I]-R91150: in the [123I]-3-I-CO study, brain radioactivity 
concentrations doubled after cyclosporin A treatment, whereas in the [123I]-R91150 study, 
brain tracer concentrations increased up to seven-fold after animal treatment with cyclosporin 
A. From these results we can conclude that [123I]-3-I-CO is a substrate for P-glycoprotein 
efflux in vivo in rodents. However, our data indicate that [123I]-R91150 is a stronger substrate 
for P-glycoprotein efflux in rodents than [123I]-3-I-CO. 
 
When comparing the in vivo evaluation of [123I]-3-I-CO with the data obtained from the [123I]-
R91150 studies in rodents, several conclusions can be drawn. Although the absolute uptake of 
radioligand in the brain was much higher for [123I]-3-I-CO, resulting cortex-to-cerebellum 
binding index ratios were never higher than 1.5. Compared to the mean value of 7 for the 
[123I]-R91150 studies, this indicates that the specific ‘signal’ in cortical tissue is a lot higher 
for [123I]-R91150 compared to [123I]-3-I-CO. This could severely limit the clinical usefulness 
of [123I]-3-I-CO as a 5-HT2A receptor tracer in vivo, and is probably caused by aspecific 
binding of the radioligand to brain tissues. Also, compared to [123I]-R91150, [123I]-3-I-CO 
showed a more rapid washout out of the brain. 
 
A possible solution to the aspecific binding problems observed with [123I]-3-I-CO could be the 
development of the corresponding [18F]-fluorinated derivative. Lipophilicity should be 
reduced, resulting in lower aspecific binding to brain tissues. Of course, affinities of this [18F]-
compound for the 5-HT2A receptor and other receptor systems should be evaluated first. It 
should also be taken into account that a lowered lipophilicity might result in a lower total 
brain uptake of the radioligand. 
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SUMMARY 
 
 
 
The aim of this doctoral dissertation was the precursor synthesis, radiosynthesis and in vivo 
evaluation of [123I]-3-I-CO as a possible new tracer for imaging of the central serotonin 5-
HT2A receptor with SPECT. [123I]-(4-fluorophenyl)[1-(3-iodophenethyl)piperidin-4-yl] 
methanone ([123I]-3-I-CO) demonstrates good affinity for the 5-HT2A receptor (Ki = 0.51 nM) 
and good selectivity ratios over other receptor types and was therefore selected as the ligand.  
 
First, the in vivo behaviour of a currently used 5-HT2A SPECT tracer, [123I]-R91150, was 
evaluated (chapter 3), and brain uptake of the tracer was assessed in rodents, as a standard for 
comparison. The influence of P-glycoprotein blocking (with cyclosporin A) on the 
biodistribution and brain uptake of [123I]-R91150 was also evaluated in rodents, and these 
results were compared with the data obtained from the normal biodistribution studies with 
[123I]-R91150. Also, the influence of P-glycoprotein blocking on pinhole SPECT imaging 
with [123I]-R91150 in rodents was investigated. 
 
In NMRI mice, a dose-dependent influence of cyclosporin A on the brain uptake of [123I]-
R91150 was observed, indicating that the increased brain uptake is the result of a decreased 
efflux of tracer out of the brain after blocking of the P-glycoprotein efflux transporter with 
cyclosporin A. Pre-treatment of Sprague-Dawley rats with cyclosporin A resulted in a 
drastically increased brain uptake of [123I]-R91150 (brain uptake increased seven-fold after P-
glycoprotein blocking) and a vastly improved pinhole SPECT imaging quality. From these 
results it can be concluded that [123I]-R91150 is a substrate for P-glycoprotein efflux in vivo, 
and that it’s brain efflux can be blocked by administration of cyclosporin A. 
 
Organic synthesis of the tributylstannyl precursor for the radiosynthesis of [123I]-3-I-CO was 
performed in adequate yield. An average yield of about 85 % was obtained in the 
radiosynthesis reaction. The radioligand was purified with semi-preparative HPLC, and 
radiochemical purities of > 95 % were obtained consistently. The radioligand was stable at 
room temperature until 48 h after synthesis. A logP value of 3.10 ± 0.10 was obtained for 
[123I]-3-I-CO (chapter 4). 
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In vivo evaluation of [123I]-3-I-CO in NMRI mice revealed high initial brain uptake (6.26 ± 
1.36 % ID/g tissue at 10 min post injection), but radioactivity concentrations in brain 
decreased rapidly over time. No radiolabelled metabolites were observed in blood or brain of 
NMRI mice. Brain uptake of [123I]-3-I-CO was also investigated in Sprague-Dawley rats 
(chapter 5): highest brain radioactivity concentrations were obtained in the occipital (0.942 ± 
0.034 % ID/g tissue at 20 min post injection) and frontal cortex (0.674 ± 0.074 % ID/g tissue 
at 20 min post injection). Blood radioactivity concentrations were consistently low (a 
maximum value of 0.062 ± 0.014 % ID/g tissue was obtained at 20 min post injection).  
 
An average frontal cortex-to-cerebellum ratio of about 1.7 was obtained. In the Sprague-
Dawley rat biodistribution studies, a rapid washout of radioactivity from the brain was 
observed. [123I]-3-I-CO was displaced from the 5-HT2A receptor by ketanserin: radioactivity 
concentration in the 5-HT2A rich areas of the brain decreased by 50 % after ketanserin 
displacement. Nevertheless, the residual radioactivity levels in cerebellum after ketanserin 
displacement remained high, especially compared to the results obtained with [123I]-R91150, 
and are probably caused by aspecific binding of the radioligand to brain tissues. No 
radiolabelled metabolites could be detected in the blood or brain of Sprague-Dawley rats. 
  
The influence of P-glycoprotein modulation with cyclosporin A on the brain uptake of [123I]-
3-I-CO was also investigated. On average, a 67 % increase in [123I]-3-I-CO radioactivity 
concentration was observed throughout the brain after treatment of the animals with 
cyclosporin A. We can conclude from these results that [123I]-3-I-CO is at least a partial 
substrate for P-glycoprotein efflux, but the increase in brain radioactivity concentration after 
cyclosporin A treatment was not as large as the increase observed with [123I]-R91150 (chapter 
3). 
 
Although cortical tissues could be visualized using pinhole SPECT imaging with [123I]-3-I-
CO, aspecific binding of the radioligand was observed in the cerebellum, probably limiting its 
application as a serotonin 5-HT2A receptor tracer in humans. SPECT imaging quality also 
did not improve after cyclosporin A pre-treatment of the animals. 
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Although the initial rodent studies demonstrated promising brain uptake of the radioligand, it 
can be concluded that [123I]-3-I-CO probably has very limited potential as a 5-HT2A tracer for 
SPECT, due to high aspecific binding and rapid washout of the radioligand out of the brain. 
Also, compared to other clinically used brain tracers (for example [123I]-R91150), the specific 
‘signal’ of [123I]-3-I-CO in brain is too limited for application as a tracer in brain receptor 
imaging studies. 
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SAMENVATTING 
 
 
 
Deze doctoraatsthesis had tot doel de precursorsynthese, radiosynthese en de in vivo evaluatie 
van [123I]-3-I-CO als een mogelijke nieuwe SPECT tracer voor het in beeld brengen van de 
serotonine 5-HT2A receptoren in de hersenen. [123I]-(4-fluorophenyl)[1-(3-iodophenethyl) 
piperidin-4-yl]methanone ([123I]-3-I-CO), een molecule met hoge affiniteit voor de serotonine 
5-HT2A receptor (Ki = 0.51 nM) en een goede selectiviteit ten opzichte van andere receptor 
types, werd gekozen als ligand. 
 
Ook werd het in vivo gedrag bestudeerd van [123I]-R91150 (hoofdstuk 3), een serotonine 5-
HT2A tracer die momenteel in kliniek bij patiënten gebruikt wordt. De hersenopname van deze 
tracer werd onderzocht in knaagdieren en zal later als referentie gebruikt worden. De invloed 
van blokkering van de P-glycoproteine efflux pompen in de bloed-hersenbarrière met 
cyclosporine A op de biodistributie en de hersenopname van [123I]-R91150 werd onderzocht, 
en vergeleken met de normale hersenopname. De invloed van cyclosporine A toediening op 
de beeldvorming met een pinhole SPECT camera werd ook nagegaan. 
 
Toediening van cyclosporine A had een dosisafhankelijke invloed op de hersenopname van 
[123I]-R91150 in NMRI muizen. Dit toont aan dat de verhoogde hersenopname het gevolg is 
van een verlaagde efflux van tracer uit de hersenen (wegens blokkering van P-glycoproteine). 
Behandeling van de Sprague-Dawley ratten met cyclosporine A resulteerde in een drastisch 
verhoogde hersenopname van [123I]-R91150 (de hersenopname verhoogde met een factor 7 na 
toediening van cyclosporine A). De kwaliteit van de beeldvorming met de pinhole SPECT 
camera verbeterde ook merkelijk na toediening van cyclosporine A. Uit deze resultaten 
kunnen we besluiten dat [123I]-R91150 een substraat is voor de P-glycoproteine efflux 
transporter, en dat de efflux van tracer uit de hersenen geblokkeerd kan worden door 
toediening van cyclosporine A. 
 
 
 
 
 
Summary - Samenvatting   
 
212
De precursor voor radiosynthese (het tributyltinderivaat) werd gesynthetiseerd in voldoende 
rendement. Een radiochemisch rendement van 85 % werd bekomen tijdens de radiosynthese-
reactie. De tracer werd opgezuiverd met behulp van semi-preparatieve HPLC chromatografie. 
De radiochemische zuiverheid bedroeg meer dan 95 %. Het radioligand was stabiel gedurende 
minstens 48 uur op kamertemperatuur. De logP waarde van [123I]-3-I-CO bedroeg 3.10 ± 0.10 
(hoofdstuk 4). 
 
Een hoge initiële hersenopname van [123I]-3-I-CO werd gezien in NMRI muizen (6.26 ± 1.36 
% ID/g 10 min na injectie), maar de concentratie aan radioactiviteit in de hersenen daalde snel 
in functie van de tijd. Er werden geen radioactieve metabolieten gevonden in bloed of 
hersenen. De hersenopname van [123I]-3-I-CO werd ook onderzocht in Sprague-Dawley ratten 
(hoofdstuk 5): de hoogste concentratie werd gezien in de occipitale (0.942 ± 0.034 % ID/g 20 
min na injectie) en frontale cortex (0.674 ± 0.074 % ID/g 20 min na injectie). De concentratie 
in het bloed was laag (maximum waarde: 0.062 ± 0.014 % ID/g 20 min na injectie). 
 
De ratio frontale cortex/cerebellum was maximaal 1.7. In de biodistributiestudies met ratten 
werd een snel wegwassen van de tracer uit de hersenen vastgesteld. [123I]-3-I-CO werd 
verdrongen van de 5-HT2A receptor door ketanserine: de tracer concentraties in de 5-HT2A 
rijke zones in de hersenen daalden met gemiddeld 50 % na verdringing. Toch bleef de 
concentratie aan [123I]-3-I-CO in het cerebellum hoog na verdringing, vooral vergeleken met 
de resultaten met [123I]-R91150. Deze hoge activiteitsniveaus werden waarschijnlijk 
veroorzaakt door aspecifieke binding van de tracer aan hersenweefsel. Er werden geen 
radioactieve metabolieten gevonden in de proeven met ratten. 
 
De invloed van cyclosporine A toediening op de hersenopname van [123I]-3-I-CO werd 
eveneens onderzocht. Gemiddeld werd een 67 % hogere opname van [123I]-3-I-CO gezien in 
de hersenen na toediening van cyclosporine A. Hieruit kunnen we besluiten dat [123I]-3-I-CO 
minstens een partieel substraat is voor de P-glycoproteine efflux transporter. Het verschil 
tussen beide groepen was echter niet zo groot als in de studies met [123I]-R91150 en 
cyclosporine A (hoofdstuk 3). 
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Hoewel de corticale weefsels gevisualiseerd konden worden met behulp van [123I]-3-I-CO en 
pinhole SPECT, werd toch binding van het radioligand gezien in het cerebellum. Hierdoor is 
het toepassingsgebied van [123I]-3-I-CO bij mensen waarschijnlijk vrij klein. In tegenstelling 
tot de studies met [123I]-R91150, verbeterde de beeldvorming met [123I]-3-I-CO ook niet na 
toediening van cyclosporine A. 
 
Hoewel in de initiële muizenstudies een veelbelovende hersenopname aangetoond werd van 
[123I]-3-I-CO, kunnen we besluiten dat [123I]-3-I-CO waarschijnlijk geen geschikte kandidaat 
is als tracer voor de serotonine 5-HT2A receptor. Hoofdredenen hiervoor zijn een hoge 
aspecifieke binding in de hersenen en een snel wegwassen van het radioligand uit de 
hersenen. Vergeleken met andere bij mensen gebruikte tracers (bijvoorbeeld [123I]-R91150) is 
het specifieke ‘signaal’ van [123I]-3-I-CO té gelimiteerd om bruikbaar te zijn in 
hersenbeeldvorming bij patiënten. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
